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Preface
This Ph.D. thesis is based on the results published or being published in international
scientific journals. It is presented in four chapters corresponding to the papers in as much an
unchanged form of the respective manuscripts as possible. Therefore, compounds and
references are numbered independently in each chapter. An overview of the entire work is
given in the following summary.
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1. Summary
1.1. Introduction
Peptides that contain α,α-disubstituted α-amino acids are restricted in their conformational
freedom. As a consequence of the rigidity of the peptide backbone, secondary structures such
as β-turns and helices are stabilized or even favored. The synthesis of such conformationally
restricted peptides is a basic approach when searching for the biologically active
conformation. Furthermore, these highly organized structures are responsible for the
interesting biological activities of the peptaibols, a class of linear antimicrobial peptides,
which contain a high number of α ,α-disubstituted α-amino acids, above all, α -
aminoisobutyric acid (Aib).
A useful protocol for the introduction of α,α-disubstituted α-amino acids into peptides is
the ‘azirine/oxazolone method’, in which 2H-azirin-3-amines 1 are used as amino acid
synthons (Scheme 1). Thus, the reaction of 2H-azirin-3-amines, e.g., the Aib synthon 2, with
an amino or peptide acid 3 proceeds smoothly and in high yield. The terminal amide bond of
the resulting peptide amide 4 can be hydrolyzed selectively to give the extended peptide acid
5. In solution-phase chemistry, the ‘azirine/oxazolone method’ has proven to be successful for
the introduction of a variety of sterically demanding α,α-disubstituted α-amino acids into
peptides, and it has found application in the synthesis of some antibiotic peptaibols or
segments thereof.
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Solid-phase synthesis offers rapid access to peptides without the need for the isolation of
the sometimes cumbersome peptide acid intermediates. We were interested if it might be
possible to combine these two features, the solid-phase synthesis and the ‘azirine/oxazolone
method’, and apply the ‘azirine/oxazolone method’ to solid-phase conditions.
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1.2. The ‘Azirine/Oxazolone Method’ on Solid Phase (CHAPTER 4)
The first questions concerned chemical reactivity: do 2H-azirin-3-amines react in a similar
way on a solid support as in solution? For that purpose, we added 2H-azirin-3-amine 2 to a
carboxy-polystyrene resin, which, after washing, was treated with 3M HCl. This two steps
were repeated. Attenuated total reflectance (ATR) FT-IR measurements showed an alternating
disappearance and appearance of the carboxy absorption band, confirming our assumptions.
In all variations of solid-phase synthesis, the linker is of crucial importance. For our purpose,
the linker has to be stable during hydrolysis of the terminal amide with 3M HCl and
deprotection of the tBu ester with trifluoroacetic acid (TFA), but finally should be cleavable
under conditions, not affecting the peptide. Finally, it was shown that the carbamate linker
formed from PAM-resin fulfills these requirements best (Scheme 2).
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Scheme 2
A solution of phosgene in toluene was added to PAM-resin 6 to generate a chloroformate
intermediate, which was reacted with H-Ala-OtBu to afford resin 7. Deprotection of the tBu
ester 7 with TFA led to resin 8, which was treated with a solution of N,2,2-trimethyl-N-
phenyl-2H-azirin-3-amine (2). Unconsumed 2 could easily be recovered and re-used.
Selective hydrolysis of the terminal amide with 3M HCl in THF/H2O afforded peptide acid
resin 10. Further extension of the peptide chain could be achieved either with a tBu protected
Summary
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amino acid and a coupling reagent, e.g., PyBOP, or with 2. Cleavage from the resin was
achieved with HBr (33%) in acetic acid to give the tripeptide 11. By this method, several
model peptides and short segments of peptaibols were synthesized.
1.3. Introduction of Various α,α-Disubstituted α-Amino Acids (CHAPTER 5)
It was of interest to ascertain if this method is restricted to the α-aminoisobutyric acid
(Aib) synthon 2, or if it can be extended to other 2H-azirin-3-amines. It was shown that the
method is not limited to the Aib synthon 2, and it was extended successfully to the 1-
aminocyclopentane-1-carboxylic acid synthon 12, the 4-aminotetrahydro-2H-pyran-4-
carboxylic acid synthon 13 and the α-methylphenylalanine synthon 14 (Figure 1). Peptides
with up to seven residues, of which three are α,α-disubstituted α-amino acids, have been
prepared.
In contrast, the synthesis of peptides containing the poly-Aib motif was not successful,
most probably due to aggregation.
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Figure 1
1.4. Introduction of the Aib-Pro Unit (CHAPTERS 6 AND 7)
Since many peptaibols contain the Aib-Pro motif, it would be of great interest to introduce
this unit by a dipeptide synthon. In solution-phase synthesis, this was indeed possible by using
the dipeptide synthon 15 (Figure 1). However, when using 15 on solid phase, the experiments
failed. The reason for this failure is the acid sensitivity of the Aib-Pro amide bond to strong
acids such as HBr, we used to cleave the peptide from the resin.
While a Pd0-labile allyl linker led not to the desired results, the use of the photolabile
nitroveratryl linker 16  allowed the successful preparation of the model peptide
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H-Ala-Aib-Phe-OtBu (21) (Scheme 3). But when the dipeptide synthon 15 was used to
incorporate the Aib-Pro unit, the experiment failed again (Scheme 3). During saponification of
resin 22, we observed a considerable darkening of the resin. Hence, quenching prevented
photocleavage of the peptide from the resin. This issue was addressed by the synthesis of new
2H-azirin-3-amines, which contain easily removable carboxy-protecting groups. Finally, we
were able to prepare the phenacyl ester and the allyl ester (25) protected dipeptide synthons.
The latter one was successfully introduced into H-Ala-Aib-Pro-Phe-OtBu (24) using the
previously described photolinker 16 and a Pd0-promoted procedure for the deprotection of
allyl ester 26 (Scheme 4).
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1.5. Applications (CHAPTER 7)
To evaluate the use of the ‘azirine/oxazolone method’ on solid phase, we attempted to
synthesize some Aib-Pro containing peptaibol segments. H-Val-Aib-Gly-Aib-Aib-Pro-Leu-
OtBu (27; A8 – A14 of Trichovirin Ia), H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (28; A1 –
A6 of Trichovirin I 1B) and H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (29; A7 – A14 of
Trichovirin I 1B) were prepared by using the photolinker 16, the Aib synthon 2 and the Aib-
Pro synthon 25.
In contrast to the ‘PAM/HBr-strategy’ (Scheme 2), the use of the photolinker allows the
isolation of tBu-protected peptides, which, in turn, offers the possibility of segment
condensations. The N-terminus of hexapeptide 28 was protected as benzyl carbamate and the
corresponding tBu ester was hydrolyzed. The resulting N-protected peptide and octapeptide
29 were coupled with TBTU/HOBt to give protected Trichovirin I 1B (Z-Aib-Asn-Leu-Aib-
Pro-Ser(OBn)-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu).
Zusammenfassung
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2. Zusammenfassung
2.1. Einleitung
Peptide, welche α,α-disubstituierte α -Aminosäuren enthalten, sind in ihren
konformationellen Freiheiten stark eingeschränkt. Als Folge des starren Peptidrückgrates
werden Sekundärstrukturen, wie z. B. β-turns und Helices stabilisiert oder sogar begünstigt.
Bei der Suche nach der biologisch aktiven Konformation eines Peptids ist die Herstellung
solcher konformationell eingeschränkter Peptide (‘conformationally restricted peptides’) ein
wichtiger Ansatz. Peptaibole sind eine Klasse linearer, antibiotisch wirkender Peptide, die
einen hohen Anteil von α,α-disubstituierten α-Aminosäuren, vor allem α-Aminoisobutter-
säure (Aib), enthalten. Die interessanten biologischen Eigenschaften der Peptaibole werden
durch die hochgeordneten Strukturen, welche diese speziellen Peptide ausbilden, erklärt.
Zur Einführung von α ,α-disubstituierten α-Aminosäuren in Peptide hat sich die
‘Azirin/Oxazolon Methode’ als eine äusserst nützliche Methode erwiesen. Dabei werden 2H-
Azirin-3-amine 1 als Aminosäure-Synthone eingesetzt (Schema 1). Die Reaktion von 2H-
Azirin-3-aminen, wie z.B. dem Aib-Synthon 2, mit einer Aminosäure oder einer Peptidsäure 3
verläuft in hoher Ausbeute zum Peptid-Amid 4. Die um eine Aminosäure verlängerte Peptid-
Säure 5 wird schliesslich durch die selektive Hydrolyse der terminalen Amid-Gruppe von 4
erhalten. Mit Hilfe der ‘Azirin/Oxazolon Methode’ konnte in der ‘solution-phase chemistry’
eine Vielzahl von sterisch anspruchsvollen α,α-disubstituierten α-Aminosäuren in Peptide
eingeführt werden. Mit der Synthese von Peptaibolen und Segmenten davon, hat die
‘Azirin/Oxazolon Methode’ eine erfolgreiche Anwendung gefunden.
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Die Festphasen-Synthese ermöglicht einen schnellen Zugang zu Peptiden ohne die
teilweise umständliche Isolation der Peptid-Säure Zwischenprodukte. Das Ziel dieser
Dissertation war, nach Möglichkeiten zu suchen, die ‘Azirin/Oxazolon Methode’ an der
Festphase durchzuführen, und damit zusätzlich von deren Eigenschaften zu profitieren.
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2.2. Die ‘Azirin/Oxazolon Methode’ an der Festphase (CHAPTER 4)
Die erste, grundlegende Frage stellte sich bezüglich der Reaktivität: Reagieren denn 2H-
Azirin-3-amine an der Festphase überhaupt in analoger Weise wie in der Lösung? Um diese
Frage zu beantworten, wurde Carboxy-Polystyren-Harz erst mit einer Lösung von 2H-Azirin-
3-amin 2 und anschliessend, nach ausführlichem Waschen des Harzes, mit einer 3M HCl-
Lösung behandelt. Diese beiden Schritte wurden wiederholt. Attenuated total reflectance
(ATR) FT-IR Messungen zeigten abwechselnd ein Verschwinden und Erscheinen der
Carboxy-Absorptions Bande, womit die gestellte Frage positiv beantwortet werden konnte.
In allen Festphasen-Synthesen ist der Linker von entscheidender Bedeutung. Für unsere
Verwendung sollte der Linker während der Hydrolyse der terminalen Amidbindung mit 3M
HCl und der Entschützung des tBu Esters mit Trifluoressigsäure (TFA) stabil, jedoch am Ende
der Synthese unter Bedingungen, welche das Peptid nicht beeinträchtigen spaltbar sein. Zur
Erfüllung dieser Voraussetzungen hat sich der Carbamat Linker des ‘PAM-Resins’ als am
geeignetsten erwiesen (Schema 2).
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Das Harz 6 wurde mit einer Lösung von Phosgen in Toluol behandelt. Das dabei
entstandene Chloroformat-Harz wurde mit H-Ala-OtBu zu 7 umgesetzt, dessen tBu ester mit
TFA hydrolysiert wurde. Das Harz 8 wurde anschliessend mit einer Lösung von N,2,2-
Zusammenfassung
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Trimethyl-N-phenyl-2H-azirin-3-amin (2) zum Peptid-Amid 9 umgesetzt, welches wiederum
mit 3M HCl in THF/H2O zur Peptid-Säure 10 hydrolysiert wurde. Überschüssiges 2 konnte
zurückgewonnen und wieder verwendet werden. Zur weiteren Kettenverlängerung wurden
entweder tBu geschützte Aminosäuren und ein Kupplungsreagenz, wie z. B. PyBOP, oder 2
eingesetzt. Die Abspaltung vom Harz erfolgte mit HBr (33%) in Essigsäure, wobei das
Tripeptid 11 erhalten wurde. Mit dieser Methode konnten mehrere Modell-Peptide und einige
Peptaibol-Segmente hergestellt werden.
2.3. Einführung Verschiedener α,α-Disubstituierter α-Aminosäuren (CHAPTER 5)
Im nächsten Schritt wurde abgeklärt, ob die an die Festphase angepasste ‘Azirin/Oxazolon
Methode’ auf das Aib-Synthon 2 beschränkt ist, oder ob eine Erweiterung auf andere 2H-
Azirin-3-amine möglich ist. Es wurde gezeigt, dass die Methode auf das 1-
Aminocyclopentan-1-carbonsäure-Synthon 12, das 4-Aminotetrahydro-2H-pyran-4-
carbonsäure-Synthon 13 und das α-Methylphenylalanin-Synthon 14 ausgedehnt werden kann
(Abbildung 1).
Die Synthesen von Peptiden, welche ein poly-Aib Motif enthielten, verliefen aufgrund von
Aggregationseffekten nicht erfolgreich.
N
N
13
Ph
N
N
12
Ph
Ph
N
N
14
Ph
O
N
15
N
O OMe
Space
Abbildung 1
2.4. Einführung der Aib-Pro Einheit (CHAPTERS 6 AND 7)
Da der grösste Teil der Peptaibole eine Aib-Pro Sequenz enthält, war es von grossem
Interesse, diese Einheit mit einem Dipeptid-Synthon einzuführen. Als jedoch das Dipeptid-
Synthon 15 (Abbildung 1) eingesetzt wurde, scheiterte das Experiment an der Empfindlichkeit
der Aib-Pro Amidbindung gegenüber starken Säuren wie HBr, die zur Spaltung des Linkers
eingesetzt wurde.
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Während ein Pd0-labiler Linker nicht zu den gewünschten Resultaten führte, gelang mit
dem photolabilen Nitroveratryl-Linker 16 die Synthese des Modell-Peptides H-Ala-Aib-Phe-
OtBu (21) (Schema 3). Als jedoch zur Einführung der Aib-Pro Einheit das Dipeptid-Synthon
15 verwendet wurde, scheiterte das Experiment erneut (Schema 3). Während der Verseifung
von 22, wurde eine deutliche Verdunkelung des Harzes beobachtet, was wiederum die
Photolyse des Linkers verunmöglichte. Um dieses Problem zu lösen, wurde versucht 2H-
Azirin-3-amine vom Typ 15 mit leicht entfernbaren Carboxy-Schutzgruppen herzustellen.
Schliesslich gelangen die Synthesen des Phenacyl-Ester und des Allyl-Ester (25) geschützten
Dipeptid-Synthons. Letzteres konnte erfolgreich zur Synthese von H-Ala-Aib-Pro-Phe-OtBu
(24) benutzt werden, indem der oben beschriebene Photolinker und ein auf Pd0 basierendes
Verfahren zur Entschützung des Allyl-Esters 26 verwendet wurden (Schema 4).
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2.5. Anwendungen (CHAPTER 7)
Zur Evaluation der ‘Azirin/Oxazolon Methode’ an der Festphase, wurde versucht, Aib-Pro
enthaltende Peptaibol-Segmente zu synthetisieren. H-Val-Aib-Gly-Aib-Aib-Pro-Leu-OtBu
(27; A8 – A14 von Trichovirin Ia), H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (28; A1 – A6
von Trichovirin I 1B) und H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (29; A7 – A14 von
Trichovirin I 1B) wurden mit Hilfe des Photolinkers 16, dem Aib-Synthon 2 und dem Aib-
Pro-Synthon 25 hergestellt.
Im Gegensatz zur ‘PAM/HBr’-Strategie (Schema 2), erlaubt die Verwendung des
Photolinkers die Herstellung von tBu-geschützten Peptiden, welche wiederum die Möglichkeit
zu Segmentkondensationen eröffnet. Der N-Terminus des Hexapeptides 28 wurde als Benzyl
Carbamat geschützt und der tBu Ester des entstandenen Peptids hydrolysiert. Das N-
geschützte Hexapeptid konnte erfolgreich mit dem Octapeptid 29 und TBTU/HOBt als
Kupplungsreagenz zu geschütztem Trichovirin I 1B (Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-Val-
Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu) gekoppelt werden.
General Introduction
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3. General Introduction
3.1. Properties and Structure of Peptides and Proteins
3.1.1. General
Proteins are one of the classes of biopolymers, along with nucleic acids, polysaccharides,
and lipids, that make up the fundamental constituents of living cells. The name ‘protein’ is
derived from the Greek ‘προτειοσ’ (proteios), meaning ‘of primary importance’.
Proteins are essential to the structure and function of a cell. As enzymes they are able to
catalyze complex biochemical reactions. They serve as transport and storage molecules
(hemoglobin, ferritin), as molecular motors (myosin, kinesin, dynein), as biological scaffolds
for the mechanical integrity and tissue (keratin, collagens), as hormones (follitropin (FSH),
thyrotropin), as receptors for hormones and neurotransmitters, as regulators (enzyme
inhibitors, transcription factors), and are present in the immune system (immunglobulins,
complement). Furthermore, they play an important role in vision (rhodopsin), and in the
exceedingly compact organization of the DNA (histones). Besides carbohydrates and lipids,
they act as the third large group of nutrition and storage compounds.
Peptides and proteins are assembled from 20 different L-α-amino acids, which are linked
by peptide bonds. Alongside these 20 proteinogenic amino acids, others (e.g., α -
aminoisobutyric acid, vide infra) are rare in nature. Peptides are oligomers, while proteins are
built from 100 and more (up to many thousands) amino acids [1].
3.1.2. The Structure of Peptides and Proteins
Proteins are folded into unique three-dimensional structures. The sequence of the amino
acids determines the shape into which the protein naturally folds (native state). The structure
of a protein can be assigned to its primary-, secondary-, tertiary-, and quaternary-structure.
The primary structure refers to the amino acid sequence of the polypeptide chain of a protein,
while the secondary structure is the locally defined arrangement of the polypeptide chain.
These segments are highly organized elements such as α-helices, β-sheets, and turns. The
folding of the whole polypeptide chain determines the overall shape of a single protein
molecule and is known as the tertiary structure. Finally, the assembly of several polypeptide
chains, called protein subunits, results in the overall shape of the protein, and is defined as the
quaternary structure of a protein [1].
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Figure 1. The Torsion Angles Φ and Ψ of the Peptide Backbone.
Due to mesomeric stabilization, the amide bond is nearly planar and usually prefers a s-
trans-configuration. In order to describe the local shape of the amino acids, and therefore to
classify secondary structures, the torsion angels Φ and Ψ were introduced (Figure 1). Φ is
defined as the torsion angle of the N–C(α) bond, and Ψ as the torsion angle of the C(α)–CO
bond, respectively. Viewing from the C(α) atom, clockwise rotation results in a plus sign (et
vice versa). A Ramachandran-Plot (or diagram) is the plot of Φ  against Ψ  and shows
favorable combinations of Φ and Ψ, which result from minimizing Pitzer-, Newman-, and
1,3-allylic-strain, as well as from an conformation that enables optimal H-bonding (Figure 2)
[2]. The more restricted the conformational freedom of an amino acid is, the smaller is the
area of favored (or ‘allowed’) conformations in the Ramachandran-Plot (chapter 3.1.4).
Figure 2. Ramachandran-Plot for Poly-L-Alanine (αR/αL: Right/Left Handed α-Helix; P:
Parallel β-Sheet; AP: Antiparallel β-Sheet).
Ψ (N–C(α)) [°]
Ψ
 (C
( α
)–C
)
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The most important secondary structures are the α- and the 310-helix, the parallel and the
antiparallel β-sheet, as well as β- and γ-turns (Table 1) [3–5].
Table 1. Torsion Angles Φ and Ψ of Common Secondary Structures.
Structure Φi+1 [°] Ψi+1 [°] Φi+2 [°] Ψi+2 [°]
α-helix (right/left handed) –(+)58 –(+)47 –(+)58 –(+)47
310-helix (right/left handed) –(+)60 –(+)30 –(+)60 –(+)30
parallel β-sheet –119 +113 –119 +113
antiparallel β-sheet –139 +135 –139 +135
β-turn type I and I’ –(+)60 –(+)30 –(+)90 0
β-turn type II and II’ –(+)60 +(–)120 +(–)80 0
β-turn type III and III’ –(+)60 –(+)30 –(+)60 –(+)30
γ-turn +70 to +85 –60 to –70
inverse γ-turn –70 to –85 +60 to +70
3.1.3. Peptide Design
Often, only a small peptide segment gives rise to the biological activity of a protein. When
searching for peptide mimetics, this segment is determined and its biologically active
conformation has to be found. A basic approach when searching for the biologically active
conformation of a peptide segment is the synthesis of conformationally restricted peptides
[6–9]. Furthermore, medicinal chemists commonly also turn to unnatural analogues in search
of metabolic stability.
By introducing local constraints, modifications are performed, which stabilize or even
favor secondary structures such as α-helices or β-turns. The most commonly used method to
restrict the conformational freedom of a peptide is the alkylation of the amide N-atom or the
C(α)-atom of the peptide backbone, or the formation of cyclic structures. In N-alkylated
amino acids, the ability of the NH-group for H-bonding is lost, and a bulky alkyl group is
inserted into the backbone. Consequently, N-alkylated amino acids are strong helix-disrupters
[10]. In contrast to primary amides, the preference for trans-amide bonds is strongly reduced
in N-alkylated amino acids. In fact, the cis- and trans-amide conformations are nearly
isoenthalpic, and N-methyl amino acids often adopt, like proline, cis- as well as trans-amide
conformations in peptides. Further characteristics of N-alkylated amino acids are their
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enhanced hydrophobicity and an improved stability towards proteolytic degradation
increasing their bioavailability and therapeutical potential [6 and refs. cited therein, 11]. Since
C(α)-alkylated (α,α-disubstituted α-amino acids) are of great importance, they are discussed
in chapter 3.1.4. Further possibilities to modify the peptide chain are the introduction of β-
amino acids [12–14], the introduction of unnatural D-amino acids [6, 15], or the exchange of
the amide group by one of the following groups: CO–O (depsipeptides) [16], CS–NH
(endothiopeptides) [17], NH–CO (retropeptides) [18], CH2–NH (reduced) [19], CH2–S [20],
CH2–SO [20], CO–CH2 [21], CH=CH [22], and CH2–CH2 [23].
In order to introduce global constraints, covalent bonds between distant parts in the
sequence are formed. This affects drastically the overall conformation of the peptide as well
as segments within the formed cycle adopt more defined conformations than in the linear
form. The formation of lactames, lactones, (thio)ethers, and disulfidebridges are the most
common possibilities to achieve cyclization, and it can be performed by linking the backbone
termini or by using functional groups of the side chains.
3.1.4. α,α-Disubstituted α-Amino Acids in Peptides
The fourfold substitution of the C(α )-atom causes a drastic restriction of the
conformational freedom of an amino acid. In the corresponding Ramachandran-Plots, 50% of
the area are accessible to glycine, 16% to alanine, while only a few percent remains accessible
to α-aminoisobutyric acid (Aib) (Figure 3). The region allowed for the Aib-residue includes
both the left- and right-handed α- and 310-helices. Thus, the introduction of Aib or other α,α-
disubstituted α-amino acids into peptides is particularly useful, since it promotes or favors
turns or helical conformations [6, 24].
     
A     B         C
Figure 3. Ramachandran-Plots for Gly (A), L-Ala (B), and Aib (C).
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Examples of α,α-disubstituted α-amino acids are the strongly helix-inducing, and probably
best examined representative, α-aminoisobutyric acid (Aib), the most simple chiral α,α-
disubstituted α-amino acid isovaline (Iva), 1-aminocyclpentanecarboxylic acid (Acp) which
behaves, in terms of conformational characteristics, very similar to Aib, and α-
methylphenylalanine (Phe(2Me)) (Figure 4).
H3N COO H3N COO H3N COO H3N COO
Ph
Aib Iva Acp Phe(2Me)
+ – + – + – + –
Figure 4. Examples of α,α-Disubstituted α-Amino Acids.
A class of α ,α-disubstituted α-amino acids containing peptides, the peptaibols, have
attracted great interest, due to their biological activities. Peptaibols are linear, amphiphilic
oligopeptides from fungal sources with a high proportion of α,α-disubstituted α-amino acids,
above all, Aib, and containing a C-terminal alcohol [25, 26]. Peptaibols show antibiotic
properties due to self association in lipid membranes forming ion channels [27]. Prominent
representatives among the so far 309 known different peptaibol sequences are Alamethicin,
Antiamöbin, Hypomurocin, Trichovirin, and Zervamicin sequences [28].
General Introduction
16
3.2. Peptide Synthesis
3.2.1. The Formation of the Peptide Bond
Since carboxylic acids and amines form at moderate temperatures only salts, an activation
of the carboxyl- or amino-component is necessary to form a peptide bond. Most often, the
activation of the carboxyl-component is realized by turning the OH group into a good leaving
group. The reactive acylating agent can be prepared in a separate step in advance to the
nucleophilic attack of the amino-component, or in presence of it by using coupling reagents.
The probably most popular coupling method is the use of coupling reagents. The first
member of this class, N,N’-dicyclohexylcarbodiimide (DCC), was introduced by Sheehan in
1955 (Figure 5) [29]. DCC remains one of the most popular and widespread coupling
reagents. Its principal limitation is the dehydration of asparagine and glutamine residues,
although this can largely be prevented by adding 1-hydroxy-1H-benzotriazole (HOBt). In
solid-phase peptide synthesis the principal drawback to the use of DCC is the formation of
dicyclohexylurea which is insoluble in CH2Cl2. To overcome this issue, other carbodiimides
such as N -ethyl-N’-(3-dimethylaminopropyl)carbodiimide (EDC) [30], N,N’-diiso-
propylcarbodiimide [31, 32], N-tert-butyl-N’-methylcarbodiimide [33, 34], N-tert-butyl-N’-
ethylcarbodiimide [33] were developed, which form ureas being more soluble in CH2Cl2 than
dicyclohexylurea.
Other widely used coupling reagents are based on phosphonium or amidinium (or
uronium) salts which, in the presence of a tertiary base (e.g., ethyldiisopropylamine, N-
methylmorpholine, collidine), smoothly convert protected amino acids to a variety of
activated species.  The most commonly employed, (1H-benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) [35], (1H-benzotriazol-
1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) [36], 2-(3-oxido-1H-
benzotriazol-1-yl)-1,1,3,3-tetramethylamidinium hexafluorophosphate (HBTU) [37], 2-(3-
oxido-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylamidinium tetrafluoroborate (TBTU) [37],
generate OBt esters, which have found wide application in solution- and solid-phase peptide
synthesis (Figure 5). BOP can be substituted by PyBOP without loss of performance. The
substitution of BOP is highly recommended since when using it, the highly carcinogenic by-
product HMPA is formed. Other coupling reagents such as 2-(3-oxido-7-aza-1H-benzotriazol-
1-yl)-1,1,3,3-tetramethylamidinium hexafluorophosphate (HATU) [38, 39] or 2-(6-chloro-3-
oxido-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylamidinium hexafluorophosphate (HCTU)
[40] generate esters that are more reactive than OBt esters (Figure 5). When using coupling
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reagents for peptide bond formation, HOBt or 1-hydroxy-7-aza-1H-benzotriazole (HOAt),
respectively, are added to improve performance and to reduce epimerization/racemization.
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N N
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N
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P Cl
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Figure 5. Common Coupling Reagents.
The formation of the peptide bond using TBTU as the coupling reagent is outlined in
Scheme 1. The base, most often a sterically demanding tertiary amine such as EtN(iPr)2,
deprotonates the N-protected amino acid or the N-protected peptide acid (1). Then, the
resulting carboxylate anion attacks the electrophilic amidinium C-atom of TBTU and –OBt is
expelled. After a nucleophilic attack of –OBt and elimination of tetramethylurea, the activated
OBt ester 3 is formed. The attack of the C-protected amino acid or the C-protected peptide
affords the corresponding peptide 4 by expelling HOBt.
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Scheme 1. TBTU as the Coupling Reagent for Peptide Bond Formation.
For the coupling of N-methyl amino acids, the use of PyBrOP, PyClOP, or PyClU provides
a significant improvement over the HOBt-based reagents (Figure 5) [41, 42]. For the
introduction of the sterically demanding α,α-disubstituted α-amino acids, coupling reagents
were applied with various levels of success [42, 43]. In general, the introduction of α,α-
disubstituted α -amino acids into peptides is complicated by inefficient coupling,
racemization, and cyclization to give diketopiperazines (attributed to the gem. dialkyl effect)
[42]. The ‘azirine/oxazolone method’ (chapter 3.2.2) and the use of N-protected amino acid
fluorides (vide infra) have proven to be valuable protocols for the introduction of the bulky
α,α-disubstituted α-amino acids.
Preformed active esters such as pentafluorophenyl esters [44–46], urethane-protected
amino acid N-carboxyanhydrides (UNCA’s) [47], and preformed symmetrical anhydrides
(PSA) [48, 49] are also efficient acylating agents. PSA have been used in many research
groups, mainly in Boc solid-phase peptide chemistry, because of their high reactivity. They
are generated using two equivalents of protected amino acid and one equivalent of DCC in
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CH2Cl2. Some N-protected amino acids are not soluble in CH2Cl2 and require significant
amounts of N,N-dimethylformamide (DMF) for solubilization, but DMF slows down the rate
of the formation of the activated derivative. Another drawback is that the preparation and use
of PSA is quite wasteful, since two equivalents of the amino acid are required to form one
equivalent of the activated species.
Although known since the beginning of the last century [50], N-protected amino acid
chlorides have been rarely used in peptide synthesis. Several decades later, [(9H-fluoren-9-
yl)methyloxy]carbonyl (Fmoc) amino acid chlorides were successfully applied to synthesize
short peptide segments [51–55]. Due to their high reactivity and sensitivity to hydrolysis, the
amino acid chlorides have to be prepared immediately before use. Moreover, in amino acid
chlorides the carboxy group is somewhat ‘overactivated’, which may lead to
racemization/epimerization and to the formation of a multitude of side products. Another
drawback is the impossibility of obtaining stable Fmoc amino acid chlorides from
trifunctional amino acids bearing side chain protection incorporating the tert-butyl moiety.
On the other hand, amino acid fluorides are of greater stability than the corresponding
chlorides, but appear to be of nearly equal reactivity toward amines. N-protected amino acid
fluorides can be prepared by the reaction of the corresponding N-protected amino acids with
cyanuryl fluoride, and have been used successfully in solution- and solid-phase peptide
synthesis [56–60]. In regarding the incorporation of the bulky α,α-disubstituted α-amino acid
Aib into peptides, the use of Fmoc-protected amino acid fluorides has been shown to be
superior in comparison with PSA’s, UNCA’s, and PyBroP activation.
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3.2.2. The ‘Azirine/Oxazolone Method’
As already mentioned in the previous chapter, the introduction of α,α-disubstituted α-
amino acids into peptides is complicated by inefficient coupling, racemization/epimerization,
and diketopiperazine formation when using coupling reagents.
One useful, and very efficient method for the introduction of the sterically demanding α,α-
disubstituted α-amino acids is the ‘azirine/oxazolone method’ [61–63]. Thus, the reaction of
2H-azirin-3-amines 5, which represent the amino acid synthons, with amino or peptide acids
leads to peptide amides, the terminal amide bonds of which can be hydrolyzed selectively to
give the extended peptide acids (Schemes 2 and 3). Due to considerable ring strain, the 2H-
azirin-3-amine represents the activated amino component. Therefore, an activation of the
carboxyl component is no longer necessary, and no further reagents are required, which
avoids, in turn, the formation of side products, and finally facilitates the work up.
In a first step, the protected amino acid or peptide acid 6 protonates the 2H-azirin-3-amine
5, which is then attacked by the carboxylate anion at its C(3)-atom. A ring enlargement of
aziridine 7 leads to the zwitterion 8, which provides the extended peptide amide 9 in a ring
opening reaction.
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Scheme 2. Mechanism of the ‘Azirine/Oxazolone Method’. Reaction of the 2H-Azirin-3-amine
with an Amino or Peptide Acid.
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Under acidic conditions (3M HCl, H2O/THF), peptide amide 9 can be hydrolyzed via the
formation of an 1,3-oxazol-5(4H )-on intermediate 11  to give the peptide acid 12 . In
comparison with N,N-dimethylamides, the hydrolysis of N-methylanilides (R3 = Me, R4 = Ph)
is faster, and therefore, the danger for racemization of the penultimate amino acid is smaller
(Scheme 4).
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Scheme 3. Mechanism of the ‘Azirine/Oxazolone Method’. Hydrolysis of the Terminal Amide
Bond.
The ‘azirine/oxazolone method’ has proven to be successful for the introduction of a
variety of sterically demanding α,α-disubstituted α-amino acids into oligopeptides [64–73],
endothiopeptides [74–76], cyclic peptides [77–78], and cyclic depsipeptides [79–82].
Moreover, the ‘azirine/oxazolone method’ has found application in the synthesis of several
peptaibols, or segments thereof [64, 68–73].
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Scheme 4. Racemization of the Penultimate Amino Acid.
General Introduction
22
3.3. 2H-Azirin-3-amines
3.3.1. Synthesis and Properties of 2H-Azirin-3-amines
2H-Azirin-3-amines 5 are three-membered, cyclic amidines with an endocyclic CN-double
bond, and are derivatives of the 2H-azirines 13 (Figure 6). The structure of several 2H-azirin-
3-amines have been determined by X-ray crystal-structure determination. The structures show
a short C(2)–C(3)- and a long N(1)–C(2)-single bond, alongside with a lengthened
N(1)–C(3)-double bond and a shortened C(3)–N(4)-single bond in common, indicating
delocalization of the N(4) lone-pair with the π-system of the CN-double bond [61, and Refs.
cited therein].
N
N
R4
R3
R1 N
R3
R1
1
2 3 4
5 13
R2 R2
Figure 6. 2H-Azirin-3-amines and 2H-Azirines.
The disubstituted N(1)-atom is, as usual in amidines, the most nucleophilic and most
probably also the most basic atom. In comparison with acyclic amidines, the basicity of the
2H-azirin-3-amines is lower, due to a different hybridization of the N-atom. While the acyclic
system allows a sp2-hybridization of the N-atom with interorbital-angles of 120°, a non-
hybridizied N-atom is favored in three-membered rings (interorbital angles of 90°).
Consequently, the lone-pair is located in a s-orbital, and therefore, less basic (Figure 7) [61].
N
CR3
CR2
CR2
CR
120°
sp2
60°
s N
Figure 7. Hybridization of the N-Atom in a 3-Membered Ring and in an Acyclic Structure.
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The first syntheses of 2H-azirin-3-amines were carried out by Rens and Ghosez in 1970
[83]. N,N-Disubstituted amides 14, containing at least one α-H-atom, were treated with
phosgene to give chloroiminium chlorides 15, which, after base-promoted HCl-abstraction,
afforded the α-chloroenamins 16 (Scheme 5). By addition of NaN3, the α-chloroenamines 16
react via their corresponding keteniminiumsalts 17 to α-azidoenamines 18, which, in turn,
afford under N2-loss the 2H-azirin-3-amines 5. For less reactive amides (R1 and/or R3 = aryl)
modified procedures are used. Thus, the addition of catalytic amounts of N ,N -
dimethylformamide during the reaction of the amide and phosgene leads to a spontaneous
formation of the α-chloroenamine [62]. Another modification is proceeding via the
corresponding thioamides [84], which are, in general, easily accessible by thionation of the
amides with Lawesson-reagent [85, 86].
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Scheme 5. Synthesis of 2H-Azirin-3-amines According to Rens and Ghosez.
N-Methyl-N-phenyl-2H-azirin-3-amines 19 can alternatively be obtained by the method of
Villalgordo and Heimgartner which avoids the use of toxic phosgene [87, 88]. Thus, amide
20 is deprotonated with LDA and the resulting amide enolate 21 is converted into the α-
chloroenamine 22 by treatment with diphenylphosphorylchloride (DPPCl). In turn, 22 reacts
analogously to the method of Rens and Ghosez with NaN3 to give the N-methyl-N-phenyl-2H-
azirin-3-amine 19 (Scheme 6).
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Scheme 6. Synthesis of N-Methyl-N-phenyl-2H-azirin-3-amines According to Villalgordo and
Heimgartner.
Optically active C(2)-monosubstituted 2H-azirin-3-amines are obtained via a modified
Neber-rearrangement from the corresponding amino acid [89]. Other access to 2H-azirin-3-
amines is reported in the literature [90–92].
3.3.2. Reactions of 2H-azirin-3-amines
The versatile reactivity of 2H-azirin-3-amines 5 is caused by the nucleophilic amidine
function, which is part of the highly strained azirine structure (200 KJ/mol). Depending on the
reaction conditions, each of the three ring bonds can be opened selectively, leading to reactive
intermediates (Scheme 7) [61].
A: Cleavage of the C(2)–C(3)-single bond. Irradiation leads to nitrile ylides 24. If the
irradiation is performed in the presence of a dipolarophil, five-membered heterocycles are
formed. Pyrolysis at 300–400°C results in the formation of 2-azabuta-1,3-dienes 25, which
can be used in Diels-Alder reactions for the synthesis of pyridines.
B: Cleavage of the N(1)–C(2)-single bond. In the presence of strong proton-acids and
under non-nucleophilic conditions, reactive 1-azallyl-cations 26 are formed.
C: Cleavage of the N(1)–C(3)-double bond. 2H-Azirin-3-amines 5 react with carboxylic
acids, thiocarboxylic acids, sulfinic acids, activated phenols and thiophenols, and with cyclic,
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enolizable 1,3-diketones forming amino acid derivatives 27. In general, the reactions proceed
smoothly and already at 0°C. This reaction path starts with the protonation of the 2H-azirin-3-
amine 5, and therefore a pka < 8 of the substrate is required.
For Peptide synthesis, path C is of interest, which was already discussed in more detail
(chapter 3.2.2).
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Scheme 7. General Reactions of 2H-Azirin-3-amines.
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3.3.3. Optically Pure 2H-Azirin-3-amines
For peptide synthesis by means of the ‘azirine/oxazolone method’, optically pure 2H-
azirin-3-amines were desired. Since the above described syntheses only led to racemic
mixtures when different substituents were present at C(2), chiral auxiliaries were introduced
with the aim of obtaining separable diastereoisomers. Although no selectivity in the syntheses
was achieved, the diastereoisomeric mixtures of 28 and 29 could be separated by means of
preparative HPLC (Figure 8) [93, 94].
N
N
Ph
MeH N
N
Ph
28 29
Figure 8. The First Separable Mixtures of Diastereoisomers of 2H-Azirin-3-amines.
The preparation of gram-quantities of optically pure 2H-azirin-3-amines was achieved with
the syntheses of the α-methylphenylalanine synthon 31, and the isovaline synthon 32, the
diastereoisomeric mixtures of which could be separated by means of MPLC. In the case of the
isovaline synthon, a phenylsulfonyl group had to be introduced to enable separation. Prior to
the use of the synthon in peptide synthesis, the phenylsulfonyl group had to be removed
(Figure 9) [70, 95, 96].
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Figure 9. Optically Pure 2H-Azirin-3-amines Prepared in Gram Quantities.
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Recently, the series of optically pure synthons was significantly extended by the N-(1-
naphtylethyl)-N-methyl-2H-azirin-3-amines 33 (Figure 9) [97, 98]. Although the naphtylethyl
auxiliary group can be applied for a variety of optically pure synthons, the acidic hydrolysis
of the terminal amide proceeds in some cases only in low yields.
3.3.4. Dipeptide Synthons
The Aib-Pro motif is widespread in peptaibols – in fact, 266 out of the 309 so far known
peptaibol sequences contain the Aib-Pro motif [99]. However, the Aib-Pro amide bond is
relative acid-labile, and therefore, it was of great interest to introduce this unit directly with a
dipeptide synthon. Hence, the Aib-Pro dipeptide synthon 34 was synthesized (Figure 10)
[69], and it has found application in the syntheses of model-peptides and the peptaibol
Trichovirin I 1B [72]. In the meantime, further dipeptide synthons have become available
such as, Thp-Pro (35) [66], Thf-Pro (36) [67], Aib-Hyp (37) [100], Aib-(Me)Ala (38) [101],
Aib-(Me)Val (39) [101], Aib-HomoPro (40) [101], and Iva-Pro (41) [101] (Figure 10).
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Figure 10. Dipeptide Synthons.
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3.4. Solid-Phase Peptide Synthesis
3.4.1. General
Construction of organic molecules, and in particular, peptides, on an insoluble solid
support has obvious benefits. The separation of intermediates from soluble reagents and
solvents can be achieved simply by filtration and washing the solid support. Therefore, also
excess of reagents can be employed to drive the reactions to completion. Moreover, physical
losses of material can be minimized as the molecule remains attached to the solid support
throughout the synthesis. In particular in solid-phase peptide synthesis (SPPS), many
reactions are simple, and therefore, can be automated. Solid-phase organic synthesis (SPOS)
follows the principles of SPPS, although a broader range of reactions and linkers is applied.
However, the solid-phase approach also has its limitations. By-products arising from
incomplete reactions, side reactions, or impure reagents will accumulate on the resin during
the assembly of the molecule and contaminate the final product. The effect of incomplete
reactions is dramatically illustrated in Table 2. Hence, product purification often is a
challenge, and pure products can only be obtained by means of HPLC.
Table 2. Yields of Final Product as a Function of Yield per Step and Number of Steps.
Number of Steps
Yield per Step 2 5 10 20
99% 98% 95% 90% 82%
95% 90% 77% 60% 36%
90% 81% 59% 35% 12%
85% 72% 44% 20% < 1%
80% 64% 33% 11% < 1%
Another drawback of solid-phase synthesis are the scanty possibilities of monitoring
reactions or analyzing resin-bound intermediates. Although efforts were made in using NMR-
and mass-spectroscopy, most often IR-spectroscopy and simple color-tests such as the Kaiser-
(ninhydrin), the chloranil-, or the 2,4,6-trinitrosulfonic acid-test, are the sole tools for on-bead
analysis. This may not imperatively affect routine and well documented syntheses, but can
heavily complicate the development of new procedures.
In chapters 3.4.1 to 3.4.6 the basic principles of SPPS are discussed, and therefore, no
specific literature is given. Instead, the reader is referred to some comprehensive books
[102–106].
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3.4.2. The Solid-Phase Principle
In standard SPPS the C-terminal amino acid of the target peptide is attached to an insoluble
support via its carboxyl group (Scheme 8). The permanent protecting groups (Y) are used to
mask the functional groups in the amino acid side chains. These permanent protecting groups
may not be affected by any of the reaction conditions used to assemble the peptide chain. In
contrast, the temporary protecting groups (X), masking the amino group of the amino acids to
be introduced, have to be removed prior to the next coupling step.
O
O
H
N
R1
LinkerX
Y1
O
O
H2N
R1
Linker
Y1
O
O
H
N
R1
Linker
Y1
O
R2
N
H
Y2
X
A
O
H
N
R2
X
Y2
Deprotection
Coupling
Repeat
OH
O
H
N
R1O
R2
H2N
Deprotection
and cleavage
from the resin
Scheme 8. The Principle of Solid-Phase Peptide Synthesis (SPPS).
After having attached the first amino acid to the resin, the amino group of the first amino
acid has to be deprotected. Excess of reagents and the released protecting group are removed
by extensive washing of the resin. After coupling with the next amino acid (activated amino
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acid or use of coupling reagents), excess of reagents can be removed again simply by washing
the resin. Cleavage of the temporary protecting group introduces the next extension cycle.
After having assembled the desired sequence, the peptide is released from the support and the
side chain protecting groups are removed as well if desired.
3.4.3. Merrifield Solid-Phase Peptide Synthesis
Solid-phase peptide synthesis was introduced by R. B. Merrifield (Nobel Prize in
Chemistry, 1984) in 1963: ‘A novel approach to peptide synthesis has been the use of a
chloromethylated polystyrene polymer as an insoluble but porous solid phase on which the
coupling reactions are carried out. Attachment to the polymer constitutes protection of the
carboxyl group (as a modified benzyl ester), and the peptide is lengthened from its amino-end
by successive carbodiimide couplings. The method has been applied to the synthesis of a
tetrapeptide, but incomplete reactions lead to the accumulation of by-products. Further
development of this interesting method is awaited [107].’ To many organic chemists this was
both the beginning but also the end of an interesting new technique, since the difficulties in
bringing heterogeneous reactions to completion would always result in impure products.
Furthermore, the purification problems were expected to worsen as the chain length was
increased beyond the described tetrapeptide.
But the situation changed dramatically when R. B. Merrifield published a second paper
[108] reporting the successful synthesis of bradykinin. The nonapeptide was synthesized in
four days and was isolated, purified and fully characterized in a further five. These results
greatly exceeded any which could be achieved by contemporary solution-chemistry methods
and set off high activity in SPPS.
Due to limited acid stability of the peptide-benzyl ester linkage, the original support
(chloromethyl polystyrene) is rarely used now, and the C-terminal amino acid is attached to
hydroxymethylphenylacetamidomethyl polystyrene (PAM resin) instead. In the Merrifield-
approach the tert-butoxycarbonyl (Boc) group is used for temporary protection, while benzyl-
based protecting groups are employed for side-chain protection. Removal of the Boc
protecting group is usually performed with trifluoroacetic acid. Coupling is carried out with
symmetrical anhydrides (PSA’s) or benzotriazolyl esters of the incoming amino acids in N-
methylpyrrolidone (NMP). Originally, the incoming amino acids were activated with N,N’-
dicyclohexylcarbodiimide (DCC). Cleavage of the peptide from the resin and removal of the
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side-chain protecting groups is effected with anhydrous hydrogen fluoride, which places
special demands on the equipment.
3.4.4. Fmoc/tBu Solid-Phase Peptide Synthesis
Unlike the Merrifield-approach which achieves selectivity in the removal of temporary-
protection, permanent-protection, and release of the peptide from the resin by graduated
acidolysis, the Fmoc/tBu method is based on an orthogonal protecting group strategy. For
temporary protection the base-labile [(9H-fluoren-9-yl)methyloxy]carbonyl (Fmoc) group is
used, which can be removed by treatment with 20% piperidine in N,N-dimethylformamide
(DMF). The removal, a β-elimination, proceeds usually fast (τ1/2 = 6 s), and can easily be
monitored by UV-spectroscopy. In contrast, the side-chain protecting groups and the resin-
linkage are acid-labile. For side-chain protection tert-butyl- and trityl-based protection groups
were usually employed. Coupling is typically carried out in NMP with pre-formed active
esters or with coupling reagents (chapter 3.2.1.).
3.4.5. Resins
In batchwise synthesis, the peptide containing resin is kept within a fritted reaction vessel.
Reagents and solvents are added through the top of the vessel, and were removed by adding
nitrogen pressure on the top, or applying vacuum to the bottom of the vessel. In general, the
base matrix consists of divinylbenzene (typically 1%) cross-linked polystyrene, and can be
functionalized by the Friedel-Crafts reaction with chloromethyl, aminomethyl, and
benzhydrylamino groups. Because polystyrene is a hydrophobic, polarizable material,
swelling is generally strong in dipolar aprotic solvents such as CH2Cl2, DMF, and NMP used
for SPPS, but is poor in alkanes, protic solvents or water. Poly(ethyleneglycol)-polystyrene
polymers (e.g., Tentagel) on the other hand are more hydrophilic than pure polystyrene, and
therefore, swell in a broad variety of solvents. The loading of commercially available
Tentagel range between 0.15–0.30 mmol/g, which is considerably lower to that of pure
polystyrene resins (ca. 0.4–1.5 mmol/g). Along with the low loading, the major disadvantage
of Tentagel resins is the release of polyethyleneglycol (PEG) upon treatment with TFA or
upon heating.
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3.4.6. Linkers
In all variations of SPPS, the linker is of crucial importance, since it has to provide a
reversible linkage between the synthetic molecule and the solid support. The linker should be
stable to all reaction conditions used for the synthesis of the molecule, but finally should be
cleavable not affecting the target molecule. In Figure 11, the linker resins most frequently
used in Merrifield- and Fmoc/tBu-SPPS are listed. The chloromethyl and PAM resins are used
for the Merrifield-approach, and cleavage is achieved with anhydrous hydrogen fluoride. The
Wang resin is used in Fmoc/tBu SPPS, and peptide release is effected with trifluoroacetic acid
(TFA) (90–95%) leading to unprotected peptide acids (apart from the N-terminus). Hyperacid
labile linkers, e.g., the Rink acid resin, the SASRIN resin, and the 2-chlorotrityl chloride resin,
are able to be cleaved with a mild acidic solution (ca. 1% TFA in CH2Cl2) yielding protected
peptide acids. For the preparation of peptide amides, the Rink amide resin  and the hyperacid
labile Sieber amide resin were developed. Photolabile linkers are discussed in more detail in
the next chapter.
N
H
O OH
Cl O
OH
O
OH
OMe
MeO
O
OH
OMe
Cl
Cl
O
N
H
OMe
MeO
Fmoc
O O
HN
Fmoc
Chloromethyl resin PAM resin Wang resin
Rink acid resin SASRIN resin 2-Chlorotrityl chloride resin
Rink amide resin Sieber amide resin
Figure 11. Linker Resins Commonly Used for the Synthesis of Peptide Acids and Peptide
Amides.
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3.4.7. Photolabile Linkers
Photolabile linkers and protecting groups are orthogonal to acid-, base-, and transition
metal-labile systems, and offer mild conditions for their cleavage [109–111]. The first
photolabile linker to bind peptides to a solid support was introduced in 1973 [112], and was
based on o-nitrobenzyl alcohol derivatives [113]. This photolabile resin was prepared by
nitration of the already available chloromethyl resin (42) (Scheme 9). Heating the resulting
nitrated resin 43  with an amino acid (or a peptide fragment) and a base led to the
immobilization of the substrate. Photolysis at 350 nm gave the tripeptide in 62% yield, but the
yield dropped significantly when releasing a tetrapeptide from the resin.
42 (Chloromethyl resin)
Cl Cl
O
O
N Tyr Ser Boc
OBn OBn
H
OHGlyTyrSerBoc
OBnOBn
Et3N, EtOAc
hν, 350 nm H
O
NO
NO2
NO2
OHGlyTyrSerBoc
OBnOBn
+
43
44
45 46
Scheme 9. The First Photolabile Resin; Prepared by Nitration of Chloromethyl Resin.
This problem was rationalized to poor swelling properties of the resin, which, in turn, were
attributed to an increase in polarity by the numerous nitro groups. This issue was overcome by
not nitrating the resin itself, but by introducing a proper linker, thus ensuring that only the
required number of nitro groups were present. Hence, 4-bromomethyl-2-nitrobenzoic acid
was attached to aminomethyl polystyrene resin (47), and the first amino acid was reacted with
the benzylic bromide of resin 48 (Scheme 10) [114].
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47 (Aminomethyl resin)
NH2
HO2C
Br
CH2
NO2
48
N
H
O
NO2
BrDCC
Boc-Xaa-OH
base
CH2
49
N
H
O
NO2
O
O
R
NHBoc
Scheme 10. Introduction of a ‘Proper’ Linker.
Although resin 48 provided a suitable support for longer peptides, it suffered from slow
cleavage kinetics (12–24 h), and therefore undesired photo-oxidations occurred (e.g.,
methionine to methionine  sulfoxide). Incorporation of two alkoxy groups in the benzene ring
to generate the veratryl-based linker 50a increased the cleavage-rate dramatically (Figure 12)
[115, 116]. An additional benzylic methyl group (50b) and the introduction of two additional
methylene groups (51) further increased the rate. These nitroveratryl-based linkers are among
the most effective photolinkers ever described, and they are stable to various chemical
conditions. The half lives of these nitroveratryl-based linkers are in the range of a few
minutes, while that of 52 (linker of original support 49) was 362 minutes (in MeOH, 10
mW/cm2 at 365 nm) [116].
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Figure 12. Photolabile Linkers.
The corresponding photocleavable resins (e.g., 53) are meanwhile commercially available.
Cleavage is effected with UV-light at 365 nm in H2O, DMSO, MeOH, or in a phosphate
buffer (PBS)/dithiothreitol system for biological assays. For reasons of light scattering,
shielding and shadowing effects of the resin, the photolysis of the supported linker is much
slower than in the solution-phase. The addition of a scavenger (e.g., ethanolamine, hydrazine,
semicarbazide hydrochloride) during photolysis was found to be of crucial importance,
otherwise the remaining nitrosoaldehyde resin may re-capture the amino group of the released
molecule/peptide forming an imine [113, 117–119].
Nitroveratryl-based linkers have found successful application in the synthesis of peptides
[115], small molecules such as thiazolidinones [120] and β -lactams [121], and
oligonucleotides [122].
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4. The ‘Azirine/Oxazolone Method’ under Solid-Phase Conditions1
Aib-containing peptides are synthesized by means of the ‘azirine/oxazolone method’ on
solid-phase from the N- to the C-terminus. In this new and convenient method for the
synthesis of sterically demanding peptides on solid-phase, 2H-azirin-3-amines are used to
introduce α-aminoisobutyric acid, an α,α-disubstituted α-amino acid into the peptide without
the need for further reagents. Using this method, segments of naturally occuring peptaibols
have been prepared.
1. Introduction
Solid-phase peptide synthesis (SPPS) allows rapid access to peptides and peptide
conjugates.[1-3] In particular, its importance appears in combinatorial chemistry, where it made
the synthesis of compound libraries possible. SPPS is exclusively carried out from the C- to
the N-terminus. Attempts to reverse the strategy failed mainly due to incomplete couplings
and significant epimerization during the coupling steps. Therefore, the synthesis of C-terminal
modified peptides and peptide libraries is not routine. Nevertheless, methods for the synthesis
of peptides from the N- to the C-terminus were investigated.[4-9] Moreover, the introduction of
sterically demanding α,α-disubstituted α-amino acids into peptides on solid-phase still
remains a challenge, although progress has been made in the case of aminoisobutyric acid
(Aib) and isovaline (Iva).[10-12]
Peptides containing α,α-disubstituted α-amino acids are restricted in their conformational
freedom.[13-16] As a consequence of the rigidity of the peptide backbone, secondary structures
such as β-turns and helices are stabilized or even promoted.[17-20] The synthesis of such
conformationally restricted peptides is a basic approach when searching for the biologically
active conformation of a peptide. A useful method for introducing α,α-disubstituted α-amino
acids into peptides is the ‘azirine/oxazolone method’, in which 2H-azirin-3-amines 1 are used
as amino acid synthons (Scheme 1).[21-23] Thus, the reaction of 2H-azirin-3-amines, e.g., the
Aib synthon 2, with amino or peptide acids 3 leads to peptide amides 4, the terminal amide
                                                 
1 S. Stamm, H. Heimgartner, Eur. J. Org. Chem. 2004, 3820.
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bond of which can be hydrolyzed selectively to give extended peptide acids 5. In solution-
phase chemistry, the ‘azirine/oxazolone method’ was successful at introducing a multiplicity
of sterically demanding α,α-disubstituted α-amino acids into peptides and found successful
application in the synthesis of some antibiotic active peptaibols or segments of it.[24-28] A
drawback of this method was that it was not yet applicable to solid-phase synthesis.
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R1 = R2 = Me: 2
Scheme 1. a) 1, CH2Cl2; b) HCl (3M), THF/H2O.
Here we report the successful attempt to synthesize peptides by means of the
‘azirine/oxazolone method’ on solid-phase – a synthesis from the N- to the C-terminus, where
2H-azirin-3-amines are used to introduce α,α-disubstituted α-amino acids into peptides
without the need for further reagents.
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2. Results and Discussion
The first questions we asked concerned chemical reactivity: Do 2H-azirin-3-amines react
in a similar way on a solid support as in solution, i.e. is a terminal amide formed by the
reaction of a 2H-azirin-3-amine with a solid-phase bound carboxylic acid? Is the selective
hydrolysis of the terminal amide possible? Attenuated total reflectance (ATR) FT-IR
measurements of the corresponding intermediates 7, 8, 9 and 10 (Scheme 2), as well as the
synthesis of a resin-bound tripeptide and its hydrolysis[29] confirmed our assumptions.
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Scheme 2. a) 2, CH2Cl2; b) HCl (3M), THF/H2O.
In all variations of solid-phase synthesis, the linker is of crucial importance. Therefore, this
was the second problem we dealt with. The 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl
(Dde)-linker, developed by Bycroft et al.,[30] is stable in trifluoroacetic acid (TFA), but can be
cleaved with 2% N2H4 in DMF. Its use led to the successful synthesis of H-Ala-Aib-N(Me)Ph
(15, Scheme 3). However, the selective hydrolysis of the terminal amide group of 14 was not
possible, since the Dde-linker was not stable in aqueous, acidic medium.
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Scheme 3. a) H-Ala-OtBu · HCl, CH2Cl2, DIPEA; b) TFA/CH2Cl2 (1:1), TIPS; c) 2, CH2Cl2;
d) N2H4 (2%), DMF. DIPEA = N,N-diisopropylethylamine, TFA = trifluoroacetic acid, TIPS
= triisopropylsilane, DMF = N,N-dimethylformamide.
A wide variety of amines were immoblizied on solid supports using carbamate linkers,
which were synthesized either with phosgene,[31-34] 1,1’-carbonyldiimidazole (CDI)[35] or 4-
nitrophenylchloroformate.[36-39] The use of a carbamate linker to attach amino acids via their
N-terminus was first reported by Letsinger.[5, 31] Therefore, we also planned to use a carbamate
linker, but the stability of the carbamate had to be tuned carefully. The carbamate has to be
stable during hydrolysis of the terminal amide with 3M HCl and deprotection of the tBu ester
with TFA, but finally should be cleavable under conditions not affecting the peptide. It was
shown that the carbamate linker formed from [4-(hydroxymethyl)phenyl]acetamidomethyl
(PAM) resin 16 fulfilled these requirements the best (Scheme 4).[40]
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Scheme 4. a) COCl2 (1.9M in PhMe), THF; b) H-Ala-OtBu · HCl, DIPEA, CH2Cl2; c) TFA,
CH2Cl2, TIPS; d) 2, CH2Cl2; e) HCl (3M), THF/H2O; f) H-Phe-OtBu · HCl, PyBOP, DIPEA,
CH2Cl2; g) HBr (33%) in acetic acid. PyBOP = (1H-benzotriazol-1-yloxy)tripyrrolidino-
phosphonium hexafluorophosphate.
Phosgene in toluene (1.9M) was added to PAM resin 16 to generate a chloroformate
intermediate. Reaction with H-Ala-OtBu afforded resin 17. Amino acid tBu esters proved to
be useful building blocks for inverse peptide synthesis,[4] because their chemistry is well
known and they are readily available from commercial suppliers. Deprotection with TFA
afforded resin 18, which was treated with a solution of N,2,2-trimethyl-N-phenyl-2H-azirin-3-
amine (2, 4 equiv.) in DCM (conc. of 2 = 0.2M). Unconsumed 2 can easily be recovered and
used in further coupling steps. Hydrolysis of resin 19 with 3M HCl in H2O/THF afforded resin
20, which was conventionally coupled to H-Phe-OtBu using PyBOP as coupling reagent.
Cleavage from the solid support was achieved with HBr (33%) in acetic acid. After
purification by means of HPLC and lyophilization, model peptide 21 was isolated in 50%
yield. A second model peptide (H-Ala-Aib-Val-Aib-Phe-OH (22)) containing two Aib
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residues was synthesized in an analogues manner (Table 1) with 33% yield after HPLC and
lyophilization.
Table 1. General procedures.
Description Reagents[a] Duration andrepetition
General procedure for the attachment of the first amino acid
Chloroformate
formation 10 eq. COCl2 (1.9M) in toluene, THF 1 × 2 h
Washes THF, CH2Cl2 2 ×, each
Coupling 4 eq. H-AA-OtBu · HCl, 8 eq. DIPEA, CH2Cl2 1 ×
Washes CH2Cl2, DMF, CH2Cl2 3 ×, each
General procedure for removing the tBu protecting group
Hydrolysis TFA/CH2Cl2, TIPS (5 %) 1 × 5 s (25 %), 1× 30 min (50 %)
Washes CH2Cl2, DMF, CH2Cl2 3 ×, each
General procedure for peptide synthesis using 2H-azirin-3-amine 2
Coupling 4 eq. 2, CH2Cl2 1 ×
Washes CH2Cl2 3 ×
Hydrolysis HCl (3M) in THF/H2O 1 ×
Washes THF, DMF, CH2Cl2 3 ×, each
General procedure for peptide synthesis using coupling reagents method A, (removing
tBu see above)
Coupling 4 eq. PyBOP, 4 eq. H-AA-O
tBu · HCl, 12 eq.
DIPEA, CH2Cl2 1 ×
Washes CH2Cl2, DMF, CH2Cl2 2 ×, each
General procedure for peptide synthesis using coupling reagents method B,[47]
(removing tBu see above)
Coupling 6 eq. HOBt, 4 eq. PyBOP, 4 eq. H-AA-O
tBu ·
HCl, 11 eq. NMM, DMF 1 ×
Washes CH2Cl2, DMF, CH2Cl2 2 ×, each
General procedure for cleavage from the support
Cleavage HBr (33 %) in acetic acid, 2 drops of H2O 1 × 6 h
Washes Acetic acid/CH2Cl2 (1:1), CH3CN/CH2Cl2 (1:1) 3 ×, each
[a] DIPEA = N,N-diisopropylethylamine, HOAt = 1-hydroxy-7-azabenzotriazole, HOBt = 1-
hydroxybenzotriazole, NMM = N-methylmorpholine, PyBOP = (1H-benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate, TIPS = triisopropylsilane.
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A crucial point in the context of this strategy was the question of epimerization of the C(α)
center(s). In order to determine the extent of racemization/epimerization, the tripeptide 21 was
hydrolyzed and the amino acids were analyzed by means of capillary gas chromatography
with enantiomer labeling.[41] As a result, alanine and phenylalanine have racemized by 0.6%
and 2.8%, respectively. It was not possible to achieve resolution of the epimers by means of
HPLC[42] on the crude product, the derivatized crude product[43] or the purified product.
Therefore, we assume that the extent of racemization/epimerization in the crude product is
similar to that of the purified product, i.e. the synthesis has been carried out with an
acceptable degree of racemization, comparable to that seen in classical SPPS.
To examine the use of the ‘azirine/oxazolone method’ on solid-phase, we attempted to
synthesize a Peptaibolin derivative and two segments of other peptaibols.[44] The hexapeptide
H-Ala-Aib-Ala-Gln-Aib-Val-OH (A4–9) (23) of the peptaibol antibiotic Alamethicin[45, 46] was
synthesized using the procedures listed in Table 1 in 25% yield (Table 2). Both Aib residues
were introduced by means of the ‘azirine/oxazolone method’, Ala (A3) by method A (Table
1) and Gln as well as Val according to method B.[47] Method B was applied to prevent nitrile
formation as the side chain of Gln was not protected.[48] The pentapeptide H-Leu-Aib-Leu-
Aib-Phe-OH (24) is a derivative of Peptaibolin[49] (Ac-Leu-Aib-Leu-Aib-Pheol), and it was
synthesized according to the procedures listed in Table 1. Both Aib residues were introduced
by means of the ‚azirine/oxazolone method’, while method A was used for the coupling of the
other amino acids. The lower yield (20%) is the result of incomplete coupling of
phenylalanine, but a repeated coupling with additional pentafluorophenol did not increase the
yield. The segment H-Val-Aib-Gly-Aib-Ala-OH (A9–13) (25) of Stilboflavin A3[50] was
prepared in 30% yield using the ‘azirine/oxazolone method’ and method A.
Table 2. Synthesized peptides.
Description Sequence Yield [%][a]
Modelltripeptide H-Ala-Aib-Phe-OH (21) 50
Modellpentapeptide H-Ala-Aib-Val-Aib-Phe-OH (22) 33
A4–9 of Alamethicin H-Ala-Aib-Ala-Gln-Aib-Val-OH (23) 25
Peptaibolin derivative H-Leu-Aib-Leu-Aib-Phe-OH (24) 20
A9–13 of Stilboflavin A3 H-Val-Aib-Gly-Aib-Ala-OH (25) 30
[a] Yield of product isolated after HPLC purification.
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3. Conclusions
In conclusion, we were able to adapt the ‘azirine/oxazolone method’ on solid-phase, and
consequently developed a new and convenient method for the synthesis of sterically
demanding peptides on solid-phase. The simple procedure can possibly be automated. It has
been shown that this approach for the synthesis of Aib-containing peptides from the N- to the
C-terminus can be combined with conventional coupling methods. The method found a
successful application in the synthesis of different peptaibol segments.
4. Experimental Part
4.1. General Remarks
Unless otherwise noted, materials were obtained from commercial suppliers and were used
without further purification. Hydroxymethylpolystyrene, 1% divinylbenzene, 100-200 mesh,
loading 0.98 mmol/g from Novabiochem (Calbiochem-Novabiochem, Läufelfingen,
Switzerland).  [4-(Hydroxymethyl)phenyl]acetamidomethylpolystyrene (4-
(oxomethyl)phenylacetamidomethylpolystyrene), 1% divinylbenzene, 100-200 mesh, loading
0.62 mmol/g from Acros Organics (Acros Organics, Geel, Belgium). Carboxylpolystyrene,
1% divinylbenzene, 200-400 mesh, loading 4.0 mmol/g from Lipal Biochemicals (Lipal
Biochemicals, Gundetswil, Switzerland). Aminomethylpolystyrene, 1% divinylbenzene, 100-
200 mesh, loading 1.14 mmol/g, hydroxyethylpolystyrene, 1% divinylpolystyrene, 100-200
mesh, loading 1.30 mmol/g, and carboxylpolystyrene, 1% divinylbenzene, 100-200 mesh,
loading 1.96 mmol/g from Rapp Polymere (Rapp Polymere, Tübingen, Germany). N,2,2-
Trimethyl-N-phenyl-2H-azirin-3-amine was synthesized according to the method of
Villalgordo and Heimgartner.[51, 52] Reaction vessels for solid phase synthesis: Single fritted
(20 µm) PE reservoir (15 mL) (Separtis, Grenzach-Wyhlen, Germany) were used on an
Advanced ChemTech PLS 4 × 6 Shaker (Advanced ChemTech, Inc., Louisville, KY, USA)
with a selfmade adapter. The original Advanced ChemTech reaction vessels were used for
reactions under N2. High-performance liquid chromatography (HPLC): instrument: Waters
600E multisolvent delivery system equipped with a Waters 996 PDA (Waters, Milford, CA,
USA); column: Interchim Uptisphere ODB C18, 300 Å, 10 µm, 250 × 4.6 mm (Interchim,
Montluçon, France), Interchim Uptisphere WOD C18, 300 Å, 10 µm, 250 × 21.2 mm (prep.
HPLC) or Vydac 218TP C18, 300 Å, 10 µm, 250 × 22 mm (prep. HPLC) (Vydac, Hesperia,
CA, USA). Column chromatography (CC): Silica gel C-560 (0.04-0.063 mm, 230-400 mesh)
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from Chemie Uetikon (CU Chemie Uetikon GmbH, Uetikon, Switzerland). Prep. TLC: Merck
TLC plates (glass), silica gel 60 F254, 0.25 mm (Merck KGaA, Darmstadt, Germany). IR
Spectra: Perkin-Elmer, Spectrum one FT-IR spectrophotometer (Perkin-Elmer, Wellesley,
MA, USA); ATR-FT-IR on a Bio-Rad FTS-45 (Bio-Rad, Hercules, CA, USA) instrument
equipped with a MKII Golden Gate single reflection ATR system from Specac (Specac Inc.,
Smyrna, GA, USA). NMR Spectra: Bruker ARX-300, Bruker DRX-500 or Bruker DRX-600
(Bruker Biospin, Karlsruhe, Germany). Chemical shifts are given in ppm relative to
tetramethylsilane (TMS) as internal standard. 2D-NMR experiments were performed for
assignment of the signals. Some spin systems were simulated with NMR-Sim from Bruker.
HPLC-MS: instrument: Hewlett-Packard HP 1100 HPLC system (Hewlett-Packard, Palo
Alto, CA, USA) equipped with a HTS PAL autosampler (CTC Analytics, Zwingen,
Switzerland), connected to a Bruker ESQUIRE-LC quadrupole ion trap instrument (Bruker
Daltonik GmbH, Bremen, Germany) equipped with a combined Hewlett-Packard
Atmospheric Pressure Ion (API) source (Hewlett-Packard Co., Palo Alto, CA, USA); column:
Interchim Uptisphere HDO C18, 120 Å, 3 µm, 200 × 2.0 mm column (Interchim, Montluçon,
France); eluents: A = H2O/HCOOH (99.95/0.05), B = CH3CN/HCOOH (99.95/0.05); flow
rate: 0.18 mL/min, gradient (A:B): 0-10 min: 95:5-50:50, 10-20 min: 50:50-0:100, 20-30:
0:100. MS: Bruker ESQUIRE-LC quadrupole instrument (Bruker Daltonik GmbH, Bremen,
Germany) or Finnigan TSQ-700 triple quadrupole instrument (Finnigan MAT, San Jose, CA,
USA). Direct infusion ESI-MS were performed with a syringe infusion pump at a flow rate of
5 µL/min.
4.2. Abbreviations
Aib: α-aminoisobutyric acid; ATR-FT-IR: attenuated total reflectance fourier transform
infrared spectroscopy; CC: column chromatography; DCM: dichloromethane; Dde: N-1-(4,4-
dimethyl-2,6-dioxocyclohexylidene)ethyl; DIPCDI: diisopropylcarbodiimid; DIPEA: N,N-
diisopropylethylamine; HM: hydroxymethyl; HOAt: 1-hydroxy-7-azabenzotriazole; HOBt: 1-
hydroxybenzotriazole; NMM: N -methylmorpholine; PAM: [4-(hydroxy-
methyl)phenyl]acetamidomethyl; PfpOH: pentafluorophenol; PyBOP: (1H-benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate; TIPS: triisopropylsilane.
Chapter 4
51
4.3. Synthesis of Resin 10, IR Analysis
Resin 7. Carboxylpolystyrene (50 mg, 0.20 mmol) was swollen in DCM. A solution of
N,2,2-trimethyl-N-phenyl-2H-azirin-3-amine (2, 178 mg, 1.02 mmol) in DCM (1.5 mL) was
added and the resin agitated at r.t. for 15 h. The resin was separated by filtration, washed with
DCM (3×) and Et2O (3×) and dried in vacuum. ATR-FT-IR (beads): ν~ = 1632 cm-1
(carboxylpolystyrene, beads: ν~ = 1692 cm-1). Resin 8. Resin 7 was swollen in THF. A solution
of HCl (2 mL, 3 M in THF/H2O, prepared from conc. HCl and THF) was added and the resin
agitated at r.t. for 16 h. The resin was separated by filtration, washed with THF (3×), DCM
(3×) and Et2O (3×) and dried in vacuum. ATR-FT-IR (beads): ν~ = 1716, 1645 cm-1. Resin 9.
Remaining resin 8 (ca. 5 mg) was swollen in DCM. A solution of 2 (13 mg, 0.08 mmol) in
DCM (1.5 mL) was added and the resin agitated at r.t. for 16 h. The resin was separated by
filtration, washed with DCM (3×) and Et2O (3×) and dried in vacuum. ATR-FT-IR (beads): ν~
= 1636 cm-1. Resin 10. Resin 9 was swollen in THF. A solution of HCl (2 mL, 3 M in
THF/H2O, prepared from conc. HCl and THF) was added and the resin agitated at r.t. for 7 h.
The resin was separated by filtration, washed with THF (3×), DCM (3×) and Et2O (3×) and
dried in vacuum. ATR-FT-IR (beads): ν~ = 1728, 1645 cm-1.
4.4. Synthesis of Resin-bound Ala-Aib-Phe-OtBu and its Hydrolysis
Carboxylpolystyrene (103 mg, 0.20 mmol) was swollen in DCM. A solution of H-Ala-
OtBu · HCl (76 mg, 0.42 mmol) in DCM (1 mL), a solution of PyBOP (208 mg, 0.40 mmol)
in DCM (1 mL), and DIPEA (0.2 mL, 1.17 mmol) were added and the resin agitated at r.t.
over night. The resin was separated by filtration, washed with DMF (4×), DCM (3×) and Et2O
(2× ), and dried in vacuum. ATR-FT-IR (beads): ν~ = 1729, 1663, 1652 cm-1
(carboxylpolystyrene, beads: ν~ = 1685 cm-1). The new resin was swollen in DCM. TFA/DCM
(3 mL, 1:1) and TIPS (0.2 mL) were added and the resin agitated for 2 h. The resin was
separated by filtration, washed with DMF (3×), DCM (3×) and Et2O (2×), and dried in
vacuum. ATR-FT-IR (beads): ν~ = 1733, 1641 cm-1. Half of the obtained resin was swollen in
DCM. A solution of N,2,2-trimethyl-N-phenyl-2H-azirin-3-amine (2, 40 mg, 0.23 mmol) in
DCM (2 mL) was added and the resin agitated at r.t. over night. The resin was separated by
filtration, washed with DCM (3×) and Et2O (2×), and dried in vacuum. ATR-FT-IR (beads): ν~
= 1637 cm-1. The resulted resin was swollen in THF. A solution of HCl (3 mL, 3M in
THF/H2O, prepared from conc. HCl and THF) was added and the resin agitated at r.t. over
night. The resin was separated by filtration, washed with THF (3×), DCM (3×) and Et2O (2×),
and dried in vacuum. ATR-FT-IR (beads): ν~ = 1719, 1636 cm-1. The resin was swollen in
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DCM. A solution of PyBOP (103 mg, 0.20 mmol) in DCM (1 mL), H-Phe-OtBu · HCl (51
mg, 0.20 mmol) in DCM (1 mL) and DIPEA (0.1 mL, 0.58 mmol) were added and the resin
agitated at r.t. over night. The resin was separated by filtration, washed with DMF (3×), DCM
(3×) and Et2O (2×), and dried in vacuum. ATR-FT-IR (beads): ν~ = 1730, 1652, 1646 cm-1.
The resin-bound peptide was hydrolyzed according to Westall et al.[53] (propionic acid/HCl
(1:1) at 130°C, sealed tube). The mixture was filtered, the filtrate was concentrated and dried
in vacuum to yield a colorless powder. MS (ESI): m/z (%): 90 (2) [Ala+H]+, 104 (17)
[Aib+H]+, 120 (60),[54] 166 (100) [Phe+H]+. ATR-FT-IR (beads): ν~ = 1686 cm-1.
4.5. Synthesis of H-Ala-Aib-N(Me)Ph (15) Using the Dde-Linker
The immobilised linker system 11 was synthesized according to Chhabra et al.[55] using
aminomethypolystyrene (500 mg, 0.57 mmol), 5-(4,4-dimethyl-2,6-dioxocyclohexylidene)-5-
hydroxypentanoic acid (291 mg, 1.14 mmol), DIPCDI (177 µL, 1.14 mmol) and HOAt (2.28
mL, 1.14 mmol of a 0.5 M solution in DMF). Resin 12. Resin 11 was swollen in DMF, then
H-Ala-OtBu · HCl (416 mg, 2.29 mmol) and DIPEA (390 µL, 2.28 mmol) in DMF (5 mL)
were added and the resin was agitated at r.t. for 1 d. The resin was separated by filtration and
washed with DMF (3×) and DCM (3×). Resin 13. Resin 12 was swollen in DCM. TFA/DCM
(5 mL, 1:1) and TIPS (230 µL) were added and the resin agitated for 2 h. The resin was
separated by filtration and washed with DCM (3×), DMF (3×) and DCM (2×). Resin 14.
Resin 13 was swollen in DCM. A solution of N,2,2-trimethyl-N-phenyl-2H-azirin-3-amine (2,
204 mg, 0.17 mmol) in DCM (4 mL) was added and the resin agitated at r.t. over night. The
resin was separated by filtration and washed with DCM (3×). H-Ala-Aib-N(Me)Ph (15). Resin
14 was swollen in DMF. A solution of N2H4 · H2O (100 µL) in DMF (5 mL) was added and
the resin agitated for 20 min. The resin was separated by filtration and the cleavage was
repeated. Finally, the resin was washed with DMF (3×), and the filtrate was concentrated. CC
(DCM/MeOH 40:1, 1% Et3N) yielded 15 (91 mg, 61%). 1H NMR (300 MHz, CDCl3, 25°C,
TMS): δ = 1.19 (d, J = 7.0 Hz, 3 H; CH3(Ala)), 1.51, 1.54 (2s, 6 H; 2 CH3(Aib)), 3.13 (q, J =
7.0 Hz, 1 H; CH(α)(Ala)), 3.26 (s, 3 H; CH3 of (N(CH3)Ph)), 7.41-7.23 (m, 5 arom. H). NH
and NH2 could not be detected. MS (ESI): m / z  (%): 157 (46) oxazolone of
[M–HN(CH3)Ph+H]+, 264 (100) [M+H]+, 286 (6) [M+Na]+, 527 (5) [2M+H]+.
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4.6. General Procedures
a) Attachment of the First Amino Acid: All manipulations were carried out under N2. PAM
or HM resin was swollen in THF. After filtration, a solution of COCl2 in toluene (1.9M, 10
equiv.) and THF (ca. 2.5 mL/1 g resin) were added to the resin, which was agitated at r.t. for 2
h, then washed with THF (2×) and DCM (2×). In a separate vial H-AA-OtBu · HCl (4 equiv.)
was dissolved in DIPEA (8 equiv.) and DCM (conc. (AA) = 0.2M). This mixture was added to
the resin, whereas possibly occuring ammonium salt was removed by filtration. The resin was
agitated at r.t. over night, then washed with DMF (3×) and DCM (3×).
b) Removing the tBu Protecting Group: The resin was swollen in DCM. TFA in DCM (1×5
s, 25%; 1×30 min, 50%) and TIPS (5%, in each case) were added and the resin agitated at r.t.
Afterwards, the resin was washed with DCM (3×), DMF (2×) and DCM (3×).
c) Coupling with N,2,2-Trimethyl-N-phenyl-2H-azirin-3-amine (2): The resin was swollen
in DCM. A solution of 2 (4 equiv.) in DCM (conc. of 2 = 0.2M) was added and the resin
agitated at r.t. over night, then washed with DCM (3×). Unconsumed 2 can easily be
recovered.
d) Hydrolysis of the Terminal Amide: The resin was swollen in THF. HCl (ca. 3–4 mL/200
mg resin, 3M in THF/H2O, prepared from conc. HCl and THF) was added and the resin
agitated at r.t. over night, then washed with THF (3×), DMF (3×) and DCM (3×).
e) Coupling with H-AA-OtBu · HCl (method A): The resin was swollen in DCM. PyBOP (4
equiv.) in DCM, then H-AA-OtBu · HCl (4 equiv.) in DCM and DIPEA (12 equiv.) were
added (conc. (AA) = 0.2M) and the resin agitated at r.t. over night, then washed with DCM
(2×), DMF (2×) and DCM (3×).
f) Coupling with H-AA-OtBu · HCl (method B, according to Gausepohl et al.[47]): The
resin was swollen in DMF. HOBt (6 equiv.) in DMF, PyBOP (4 equiv.) in DMF, NMM (2.3
equiv.), then H-AA-OtBu · HCl (4 equiv.) in DMF and NMM (4 equiv.) were added (conc.
(AA) = 0.2M). The resin was agitated at r.t. and, after 10 and 20 min, additional NMM (2.3
equiv., each) was added. The resin was agitated at r.t. for 1 h and 5 h for coupling to Aib,
resp. The resin was washed with DMF (3×) and DCM (3×).
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g) Coupling with H-AA-OtBu · HCl (method C): The resin was swollen in DCM. PfpOH (4
equiv.) in DCM, PyBOP (4 equiv.) in DCM, then H-AA-OtBu · HCl (4 equiv.) in DCM and
DIPEA (12 equiv.) were added (conc. (AA) = 0.2M). The resin was agitated at r.t. over night,
then washed with DCM (2×), DMF (2×) and DCM (3×).
h) Cleavage: The resin was swollen in DCM. HBr in AcOH (33%, 1 mL/100 mg resin) and
two drops of water were addeed and the resin agitated for 5 to 6 h. The resin was separated by
filtration and washed with AcOH/DCM (1:1, 3×) and MeCN/DCM (1:1, 3×). The solvents
were evaporated under reduced pressure and the crude product was purified by means of
HPLC. The purified product was lyophilized.
4.7. H-Ala-Aib-Phe-OH (21)
PAM resin (202 mg, 0.125 mmol) was treated according to general procedures a), b), c),
d), e) and h) to yield, after purification by means of prep. HPLC and lyophylization, 21 (32
mg, 50%) as a colorless powder.
HM resin (201 mg, 0.197 mmol) was treated according to general procedures a), b), c), d),
e) and h) to yield, after precipitation in ether or purification by means of prep. HPLC and
lyophylization, 21 (33 mg, 40%) as a colorless powder. HPLC-MS: tR = 11.6 min, m/z (%):
129 (31), 157 (47) oxazolone of [M–Phe+H]+, 251 (28) [M–Ala+H]+, 322 (100) [M+H]+, 344
(8) [M+Na]+. MS (ESI): m/z (%): 322 (100) [M+H]+, 344 (60) [M+Na]+. IR (KBr): ν~ = 3422s,
3575s, 3237s, 3068s, 3034s, 2992s, 2945s, 2617w, 1724vs, 1671vs, 1534vs, 1500s, 1467m,
1457m, 1443m, 1392m, 1369m, 1332w, 1266s, 1201vs, 1142vs, 1031m, 1003w, 839w, 800m,
723m, 702m, 641m, 518w cm-1. 1H NMR (600 MHz, [D6]DMSO, 25°C, TMS): δ = 1.32 (d, J
= 7.0 Hz, 3 H; CH3(Ala)), 1.34, 1.35 (2s, 6 H; CH3(Aib)), 2.95 (dd, J (CHAHB,CH(α)) = 8.3
Hz, 2J = 13.7 Hz, 1 H; CHAHB(Phe)), 3.08 (dd, J (CHAHB,CH(α)) = 5.3 Hz, 2J = 13.7 Hz, 1 H;
CHAHB(Phe)), 3.82-3.83 (m, 1 H; CH(α)(Ala)), 4.44 (ddd, J (CH(α),CHAHB) = 8.3 Hz, J
(CH(α),NH) = 8.0 Hz, J (CH(α),CHAHB) = 5.3 Hz, 1 H; CH(α)(Phe)), 7.18-7.28 (m, 5 arom.
H), 7.53 (d, J (NH,CH(α)) = 8.0 Hz, 1 H; NH(Phe)), 8.04 (br. s, 3 H; NH3+(Ala)), 8.35 (s, 1
H; NH(Aib)), ca. 12.0-13.5 (br. s, 1 H; COOH). 13C NMR (150 MHz, [D6]DMSO, 25°C,
TMS): δ  = 17.1 (q, CH3(Ala)), 24.4, 25.0 (2q, 2 CH3(Aib)), 36.7 (t, CH2), 48.3 (d,
CH(α)(Ala)), 53.5 (d, CH(α)(Phe)), 56.3 (s, C(α)(Aib)), 126.4 (d, arom. CH(p)), 128.1 (d,
arom. CH(m)), 129.3 (d, arom. CH(o)), 137.5 (s, arom. C), 168.9 (s, CO(Ala)), 172.7 (s,
CO(Phe)), 172.9 (s, CO(Aib)).
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4.8. Ac-Ala-Aib-Phe-OMe (26) (Derivatizing 21)
The crude product 21 of a 0.062 mmol batch was dissolved in (NH4)2CO3 (2.4 mL, 0.1 M),
then Ac2O/MeOH (6 mL, 1:3) was added and the solution stirred at r.t. for 1 h. After
lyophilization, the residue was dissolved in MeOH/H2O (2 mL, 10:1) and a solution of CH2N2
in Et2O (ca. 2 mL, ca. 1 M) was added . The solution was stirred at r.t., then concentrated in
vacuum. HPLC-MS: tR = 14.8 min, m/z (%): 120 (45), 180 (92) [H-Phe-OMe+H]+, 199 (84)
oxazolone of [M–(Phe-OMe)+H]+, 265 (100) [M–(Ac-Ala)+H]+, 378 (52) [M+H]+, 400 (71)
[M+Na]+. Prep. TLC (DCM/MeOH, 20:1) yielded 26 (9 mg, 38%) as a colorless powder.
HPLC-MS: tR = 14.8 min, m/z (%): 120 (37), 180 (100) [H-Phe-OMe+H]+, 199 (63)
oxazolone of [M–(Phe-OMe)+H]+, 265 (82) [M–(Ac-Ala)+H]+, 378 (48) [M+H]+, 400 (89)
[M+Na]+.
4.9. H-Ala-Aib-Val-Aib-Phe-OH (22)
PAM resin (402 mg, 0.249 mmol) was treated according to general procedure a) and dried
in vacuum. The synthesis was continued with half of the resin according to general
procedures b), c), d), e), b), c), d), e) and h) to yield, after purification by means of prep.
HPLC and lyophylization, 22 (25 mg, 33%) as a colorless powder.
HM resin (501 mg, 0.491 mmol) was treated according to general procedure a) and dried in
vacuum. The synthesis was continued with 25% of the resin according to general procedures
b), c), d), e), b), c), d), e) and h) to yield, after purification by means of prep. HPLC and
lyophylization, 22 (16 mg, 21%) as a colorless powder. HPLC-MS: tR = 10.4 min, m/z (%):
256 (11), 341 (48) oxazolone of [M–Phe+H]+, 506 (100) [M+H]+. MS (ESI): m/z (%): 506
(100) [M+H]+, 528 (31) [M+Na]+, 550 (9) [MNa+Na]+. IR (KBr): ν~ = 3428m, 3308s, 3065s,
2976s, 2940s, 2622w, 1722s, 1668vs, 1529vs, 1468m, 1458m, 1389m, 1367m, 1322w, 1263m,
1202vs, 1139s, 1004w, 929w, 837w, 800w, 722m, 701w, 598w cm-1. 1H NMR (500 MHz,
[D6]DMSO, 25°C, TMS): δ = 0.81, 0.85 (2d, J = 6.8 Hz, 6 H; 2 CH3(Val)), 1.34 (d, J = 6.9
Hz, 3 H; CH3(Ala)), 1.29, 1.35, 1.38, 1.41 (4s, 12 H; 4 CH3(Aib)), 2.01 (oct., J = 6.8 Hz, 1 H;
CH(β)(Val)), 2.94 (dd, J (CHAHB,CH(α)) = 8.1 Hz, 2J = 13.8 Hz, 1 H; CHAHB(Phe)), 3.03 (dd,
J (CHAHB,CH(α)) = 5.7 Hz, 2J = 13.8 Hz, 1 H; CHAHB(Phe)), 3.85 (q, J = 6.9 Hz, 1 H;
CH(α)(Ala)), 4.02 (t, J = 7.3 Hz, 1 H; CH(α)(Val)), 4.41 (ddd, J (CH(α),CHAHB) = 8.1 Hz, J
(CH(α),NH) = 7.9 Hz, J (CH(α),CHAHB) = 5.7 Hz, 1 H; CH(α)(Phe)), 7.18-7.27 (m, 5 arom.
H), 7.30 (d, J = 7.7 Hz, 1 H; NH(Val)), 7.48 (d, J (NH,CH(α)) = 7.9 Hz, 1 H; NH(Phe)), 7.5-
8.5 (br. s, 3 H; NH3+(Ala)), 7.91, 8.48 (2s, 2 H; 2 NH(Aib)), ca. 11.0-13.5 (br. s, 1 H; COOH).
13C NMR (125 MHz, [D6]DMSO, 25°C, TMS): δ = 17.0 (q, CH3(Ala)), 18.4, 19.3 (2q, 2
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CH3(Val)), 24.3, 24.9, 25.0, 25.1 (4q, 4 CH3(Aib)), 30.1 (d, CH(β)(Val)), 36.8 (t, CH2(Phe)),
48.4 (d, CH(α)(Ala)), 53.6 (d, CH(α )(Phe)), 56.1, 56.5 (2s, 2 C(α )(Aib)), 58.4 (d,
CH(α)(Val)), 126.4 (d, arom. CH(p)), 128.1 (d, arom. CH(m)), 129.2 (d, arom. CH(o)), 137.5
(s, arom. C), 169.1 (s, CO(Ala)), 170.4 (s, CO(Val)), 172.6 (s, CO(Phe)), 173.3, 173.5 (2s, 2
CO(Aib)).
4.10. H-Ala-Aib-Ala-Gln-Aib-Val-OH (23)
PAM resin (202 mg, 0.125 mmol) was treated according to general procedures a), b), c),
d), e), b), f), b), c), d), f) and h) to yield, after purification by means of prep. HPLC and
lyophylization, 23 (21 mg, 25%) as a colorless powder. HPLC-MS: tR = 8.3 min, m/z (%): 441
(10) oxazolone of [M–Val+H]+, 558 (100) [M+H]+. MS (ESI): m/z (%): 558 (29) [M+H]+, 580
(100) [M+Na]+, 602 (74) [MNa+Na]+. IR (KBr): ν~ = 3315s, 3065m, 2984m, 2942m, 2614w,
1665vs, 1533s, 1467m, 1455m, 1424w, 1390m, 1368w, 1332w, 1267m, 1201s, 1140s, 1042w,
1004w, 930w, 836w, 800w, 722w, 598w, 518w cm-1. 1H NMR (500 MHz, [D6]DMSO, 25°C,
TMS): δ = 0.82, 0.85 (2d, J = 6.8 Hz, 6 H; 2 CH3(Val)), 1.23 (d, J = 7.0 Hz, 3 H; CH3(Ala)),
1.36, 1.38 (2s, 6 H; 2 CH3(Aib)), 1.38 (d, J = 6.9 Hz, 3 H; CH3(Ala)), 1.40 (s, 6 H; 2
CH3(Aib)), 1.84-1.93 (m, 2 H; CH2(Gln)), 2.01-2.08 (m, 1 H; CH(β)(Val)), 2.10-2.14 (m, 2 H;
CH2(Gln)), 3.84 (q, J  = 7.0 Hz, 1 H; CH(α )(Ala)), 4.06-4.10 (m, 2 H; CH(α)(Val),
CH(α)(Gln)), 4.15 (quint., J = 6.9 Hz,1 H; CH(α)(Ala)), 6.89 (s, 1 H; NH2(Gln)), 7.12 (d, J =
8.5 Hz, 1 H; NH(Val)), 7.40 (s, 1 H; NH2(Gln)), 7.66 (d, J = 6.3 Hz, 1 H; NH(Ala)), ca. 7.7-
8.4 (br. s, 3 H; NH3+(Ala)), 7.84 (d, J = 7.1 Hz, 1 H; NH(Gln)), 7.86 (s, 1 H; NH(Aib)), 8.63
(s, 1 H; NH(Aib)), ca. 11.8-13.1 (br. s, 1 H; COOH). 13C NMR (125 MHz, [D6]DMSO, 25°C,
TMS): δ = 17.0, 17.5 (2q, 2 CH3(Ala)), 18.0, 19.1, (2q, 2 CH3(Val)), 24.2, 24.6, 24.9, 25.7
(4q, 4 CH3(Aib)), 27.4 (t, CH2(Gln)), 29.9 (d, CH(β)(Val)), 31.8 (t, CH2(Gln)), 48.3, 48.9 (2d,
2 CH(α)(Ala)), 53.1 (d, CH(α)(Gln)), 56.2, 56.2 (2s, 2 C(α)(Aib)), 57.3 (d, CH(α)(Val)),
169.3 (s, CO(Ala)), 171.0 (s, CO(Gln)), 172.3 (s, CO(Ala)), 172.8 (s, CO(Val)), 173.4, 173.7
(2s, 2 CO(Aib)), 174.2 (s, CONH2).
4.11. H-Leu-Aib-Leu-Aib-Phe-OH (24)
PAM resin (201 mg, 0.125 mmol) was treated according to general procedures a), b), c),
d), e), b), c), d), e)  and dried in vacuum. One part (14%) was cleaved according to general
procedure h) and the crude product analyzed by HPLC-MS. With the other part (86%) a
second coupling was performed according to general procedure g). Cleavage according to
general procedure h) yielded, after purification by means of prep. HPLC and lyophylization,
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24 (15 mg, 20%) as a colorless powder. HPLC-MS: tR = 12.0 min, m/z (%): 397 (15)
oxazolone of [M–Phe+H]+, 562 (100) [M+H]+. IR (KBr): ν~ = 3423m, 3320s, 3064m, 3034m,
2962s, 2939s, 2874m, 1723sh, 1668vs, 1529vs, 1468m, 1441m, 1388m, 1367m, 1269m,
1202vs, 1140s, 1081w, 1031w, 941w, 878w, 837w, 800w, 722w, 700w, 598w, 518w, 490w cm-
1. 1H NMR (600 MHz, [D6]DMSO, 25°C, TMS): δ = 0.83, 0.86, 0.90, 0.92 (4d, J = 6.3 Hz, 12
H; 4 CH3(Leu)), 1.30, 1.36, 1.38, 1.39 (4s, 12 H; 4 CH3(Aib)), 1.40-1.65 (m, 6 H; 2 CH2(Leu),
2 CH(γ)(Leu)), 2.95 (dd, J (CHAHB,CH(α)) = 8.3 Hz, 2J = 13.8 Hz, 1 H; CHAHB(Phe)), 3.04
(dd, J (CHAHB,CH(α)) = 5.4 Hz, 2J  = 13.8 Hz, 1 H; CH AHB(Phe)), 3.77 (br. s, 1 H;
CH(α)(Leu)), 4.15 (m, 1 H; CH(α)(Leu)), 5.41 (ddd, J (CH(α),CHAHB) = 8.3 Hz, J
(CH(α),NH) = 7.8 Hz, J (CH(α),CHAHB) = 5.4 Hz, 1 H; CH(α)(Phe)), 7.18-7.26 (m, 5 arom.
H), 7.51 (d, J (NH,CH(α)) = 7.8 Hz, 1 H; NH(Phe)), 7.59 (d, J = 7.4 Hz, 1 H, NH(Leu)), 7.80
(s, 1 H; NH(Aib)), 8.08 (br. s, 3 H; NH3+(Leu)), 8.58 (s, 1 H, NH(Aib)), ca. 12.4-13.0 (br. s, 1
H; COOH). 13C NMR (150 MHz, [D6]DMSO, 25°C, TMS): δ = 21.5, 21.9, 22.5, 23.1 (4q, 4
CH3(Leu)), 23.6, 24.0 (2d, 2 CH(γ)(Leu)), 24.0, 24.2, 25.0, 25.5 (4q, 4 CH3(Aib)), 36.7 (t,
CH2(Phe)), 39.5, 39.7 (2t, 2 CH2(Leu)), 51.1, 51.8 (2d, 2 CH(α)(Leu)), 53.6 (d, CH(α)(Phe)),
55.9, 56.4 (2s, 2 C(α)(Aib)), 126.3 (d, arom. CH(p)), 128.0 (d, arom. CH(m)), 129.1 (d, arom.
CH(o)), 137.5 (s, arom. C), 168.4, 171.3 (2s, 2 CO(Leu)), 172.6 (s, CO(Phe)), 173.3, 173.8
(2s, 2 CO(Aib)).
4.12. H-Val-Aib-Gly-Aib-Ala-OH (25)
PAM resin (200 mg, 0.124 mmol) was treated according to general procedures a), b), c),
d), e), b), c), d), e) and h) to yield, after purification by means of prep. HPLC and
lyophylization, 25 (20 mg, 31%) as a colorless powder. HPLC-MS: tR = 9.8 min, m/z (%): 327
(51) oxazolone of [M–Ala+H]+, 416 (100) [M+H]+. IR (KBr): ν~ = 3315s, 3066s, 2985s,
2943s, 2642w, 1667vs, 1537vs, 1468m, 1387m, 1367m, 1335w, 1296m, 1248m, 1202vs,
1140s, 1018w, 980w, 946w, 837w, 800w, 722m, 662w, 598w, 562w, 518w cm-1. 1H NMR (500
MHz, [D6]DMSO, 25°C, TMS): δ = 0.94, 0.95 (2d, J = 6.7 Hz, 6 H; 2 CH3(Val)), 1.27 (d, J =
7.3 Hz, 3 H; CH3(Ala)), 1.38, 1.39, 1.41 (3s, 12 H; 4 CH3(Aib)), 2.10 (oct., J = 6.7 Hz, 1 H;
CH(β)(Val)), 3.52 (dd, J (NH,CHAHB) = 5.6 Hz, 2J = –16.3 Hz, 1 H; CHAHB(Gly)), 3.60 (d, J
= 6.2 Hz, 1 H; CH(α)(Val)), 3.65 (dd, J (CHAHB,NH) = 5.7 Hz, 2J = –16.3 Hz, 1 H;
CHAHB(Gly)), 4.16 (quint., J = 7.3 Hz, 1 H; CH(α)(Ala)), 7.47 (d, J = 7.3 Hz, 1 H; NH(Ala)),
ca. 7.6-8.5 (br. s, 3 H; NH3+(Val)), 7.70 (s, 1 H; NH(Aib)), 8.01 (dd, J (NH,CHAHB) = 5.7 Hz,
J (NH,CHAHB) = 5.6 Hz, 1 H; NH(Gly)), 8.70 (s, 1 H; NH(Aib)), ca. 11.8-13.0 (br. s, 1 H;
COOH). 13C NMR (125 MHz, [D6]DMSO, 25°C, TMS): δ = 17.0 (q, CH3(Ala)), 17.6, 18.4,
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(2q, 2 CH3(Val)), 23.7, 23.9, 25.8, 25.8 (4q, 4 CH3(Aib)), 29.6 (d, CH(β)(Val)), 43.4 (t,
CH2(α)(Gly)), 47.7 (d, CH(α)(Ala)), 55.9, 56.3 (2s, 2 C(α)(Aib)), 57.6 (d, CH(α)(Val)),
167.8 (s, CO(Val)), 168.3 (s, CO(Gly)), 173.7 (s, CO(Aib)), 174.0 (s, CO(Ala)), 174.1 (s,
CO(Aib)).
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5. The ‘Azirine/Oxazolone Method’ on Solid-Phase: Introduction of
Various α,α-Disubstituted α-Amino Acids1
Peptides containing various α,α-disubstituted α-amino acids, such as α-aminoisobutyric
acid (Aib), 1-aminocyclopentane-1-carboxylic acid, α-methylphenylalanine, and 4-
aminotetrahydro-2H-pyran-4-carboxylic acid have been synthesized from the N- to the C-
terminus by means of the ‘azirine/oxazolone method’ under solid-phase conditions. In this
convenient method for the synthesis of sterically demanding peptides on solid-phase, 2H-
azirin-3-amines are used to introduce the α,α-disubstituted α-amino acids without the need of
additional reagents. Furthermore, the synthesis of poly-Aib sequences has been explored.
1. Introduction
Due to the restrictions in their conformational freedom, α,α-disubstituted α-amino acid
containing peptides form stabilized secondary structures, such as β-turns and helices [1–4].
One useful method for the introduction of α,α-disubstituted α-amino acids into peptides is the
‘azirine/oxazolone method’ [5–7]. Thus, the reaction of 2H-azirin-3-amines, e.g. the Aib
synthon 1, with an amino or peptide acid proceeds smoothly and in high yield. The terminal
amide bond of the resulting peptide amide can be hydrolyzed selectively to give the extended
peptide acid. In solution-phase chemistry, the ‘azirine/oxazolone method’ has proven to be
successful for the introduction of a multitude of sterically demanding α,α-disubstituted α-
amino acids into peptides, and it has found application in the synthesis of some antibiotic
peptaibols or segments thereof [8–15].
Since solid-phase synthesis offers rapid access to peptides without the need for the
isolation of the sometimes cumbersome peptide acid intermediates, we adapted the
‘azirine/oxazolone method’ to solid-phase conditions (Scheme 1) [16].
                                                 
1 S. Stamm, A. Linden, H. Heimgartner, Helv. Chim. Acta. 2006, 89, 1.
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Scheme 1. DIPEA = ethyldiisopropylamine; HOBt: 1-hydroxybenzotriazole; PyBOP = (1H-
benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate; TFA = trifluoroacetic
acid; TIPS = triisopropylsilane.
In this convenient method for the synthesis of sterically demanding peptides on solid-
phase, the first amino acid was attached through a carbamate linker to a [4-
(hydroxymethyl)phenyl]acetamidomethyl (PAM) polystyrene resin (2). Deprotection of the
tBu ester 3 with TFA afforded resin 4, which was treated with a solution of N,2,2-trimethyl-N-
phenyl-2H-azirin-3-amine (1). Unconsumed 1 could easily be recovered and reused. Selective
hydrolysis of the terminal amide with 3M HCl in THF/H2O afforded peptide acid resin 6.
Further extension of the peptide chain could be achieved either with a tBu ester protected
amino acid and a coupling reagent, e.g. PyBOP, or with 1. Cleavage from the resin was
achieved with HBr (33%) in acetic acid to give the tripeptide 7.
It was of interest to ascertain if this method is restricted to the α-aminoisobutyric acid
(Aib) synthon 1, or if it can be extended to other 2H-azirin-3-amines. Herein we report the use
of the 1-aminocyclopentane-1-carboxylic acid (Acp) synthon 8, the 4-aminotetrahydro-2H-
pyran-4-carboxylic acid (Thp) synthon 9, and the α-methylphenylalanine (Phe(2Me)) synthon
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10 in peptide synthesis using the ‘azirine/oxazolone method’ under solid-phase conditions.
Furthermore, a limitation of the method in the synthesis of poly-Aib sequences is revealed.
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2. Results and Discussion
In analogy to the model peptide H-Ala-Aib-Phe-OH, which had been used to establish the
viability of the ‘azirine/oxazolone method’ under solid-phase conditions, the tripeptides H-
Ala-Acp-Phe-OH (11a) and H-Ala-Thp-Phe-OH (11b) were synthesized on solid-phase in
37% and 38% yield (after prep. HPLC, based on resin loading), respectively (see Scheme 1;
instead of 1, the Acp and Thp synthons 8 and 9 were used; Table 1). Both α,α-disubstituted
residues were introduced by the ‘azirine/oxazolone method’, and Phe with PyBOP as the
coupling reagent.
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O
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11a 11b
When (S)-1-[(S)-2-benzyl-2-methyl-2H-azirin-3-yl]-2-(1-methoxy-1-methylethyl) pyrro-
lidine (12) was used as an optically pure Phe(2Me) synthon, the syntheses of H-Ala-
Phe(2Me)-Phe-OH and H-Ala-Phe(2Me)-Leu-OH failed, although this 2H-azirin-3-amine has
been used successfully in solution-phase chemistry. N-Methyl-N-phenyl-2H-azirin-3-amines
belong to the most reactive 2H-azirin-3-amines. Therefore, the racemic Phe(2Me)-synthon 10
was used in a second, successful attempt to synthesize the tripeptide H-Ala-Phe(2Me)-Leu-
OH (13) as a mixture of two diastereoisomers. The diastereoisomers (S,S,S)-13 and (S,R,S)-13
were separated by means of preparative HPLC, which gave the two isomers in a 1:1 ratio in
49% yield.
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X-ray crystallography would have allowed the configuration of the C(α)-center of the
Phe(2Me) residue to be determined, but all attempts to crystallize at least one of the two
diastereoisomeric tripeptides 13 failed. Therefore, (S,S,S)-13 and (S,R,S)-13 were derivatized
with 4-bromobenzoyl chloride (Scheme 2). Crystals, suitable for an X-ray crystal-structure
determination were obtained from (S,S,S)-14 (Fig. 1) and the absolute configuration of the
molecule was determined independently by the diffraction experiment. This confirmed the
(S)-configurations of the alanine and leucine residues and revealed the (S)-configuration of
the Phe(2Me) residue. The knowledge of the absolute configuration of (S,S,S)-14 allowed the
absolute configurations of the primarily isolated tripeptides (S,S,S)-13 and (S,R,S)-13 to be
assigned.
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Scheme 2
The asymmetric unit in the structure of (S,S,S)-14 contains two symmetry-independent
peptide and two MeOH molecules. The two peptide molecules have very similar
conformations and differ primarily in the orientation of the plane of the bromophenyl ring.
Each peptide molecule is involved in one intramolecular and four intermolecular H-bonds.
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The amide group closest to the carboxy group in each peptide molecule forms an
intramolecular H-bond with the amide O-atom adjacent to the bromophenyl moiety thereby
stabilizing a β-turn. Each of these interactions has a graph set motif [18] of S(10). The OH-
group in each peptide molecule forms an intermolecular H-bond with the O-atom of a
neighbouring MeOH molecule. In turn, each of these MeOH molecules forms an
intermolecular H-bond to one of the symmetry-independent peptide molecules. These
interactions link the peptide and MeOH molecules alternately into extended chains which run
parallel to the [0 1 0] direction in the sequence ···peptideA···MeOH2···peptideB···MeOH1···
peptideA···. The quaternary graph set motif that describes this sequence is C44(26). The amide
group closest to the bromophenyl moiety in peptide molecule A forms an intermolecular H-
bond with the carboxylate carbonyl O-atom of a neighbouring molecule B. In turn, molecule
B interacts in an identical fashion with another molecule A. These interactions link peptide
molecules A and B alternately into extended chains, which run parallel to the [0 -1 1]
direction and can be described by a binary graph set motif of C22(22). The central amide group
in peptide molecule A forms an intermolecular H-bond with the carbonyl O-atom of the
amide group closest to the carboxylic acid end of a neighbouring molecule A. This interaction
links the peptide molecules A into centrosymmetric dimers and can be described by a graph
set motif of R22(10). The peptide molecules B display identical interactions that also link the
molecules into centrosymmetric dimers. The combination of all intermolecular H-bonding
interactions links the peptide and MeOH molecules into extended two-dimensional networks
which lie parallel to the (1 0 0) plane.
Fig. 1. ORTEP Plot [17] of the molecular structure of one of the two symmetry-independent
molecules of (S,S,S)-14 (50% probability ellipsoids; arbitrary numbering of atoms; the MeOH
molecules are not shown).
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Some longer model peptides containing up to three α,α-disubstituted residues were
synthesized successfully on solid-phase (Table 1). The pentapeptides H-Val-Thp-Gly-Acp-
Ala-OH (15) and H-Ala-Thp-Val-Thp-Phe-OH (16) were obtained in 23% and 16% yield,
respectively. All α,α-disubstituted residues were introduced by the ‘azirine/oxazolne
method’, while the couplings of the other amino acids were introduced by using PyBOP as the
coupling reagent. The 1H-NMR spectrum of 15 showed partial doubling of the signals. The
contribution of the minor signals is ca. 20%. Unexpectedly, while increasing the temperature
in the NMR experiment, the chemical shifts of the minor and major NH signals did not
coalesce or converge. The convergence of the NH signals with increasing temperature would
have been strong evidence for the existence of conformers and not diastereoisomers. To rule
out the presence of diastereoisomers, however, an amino acid analysis was performed [19]: in
order to determine the extent of racemization/epimerization of the C(α) center(s), the
pentapeptide was hydrolyzed and the amino acids were analyzed by capillary gas
chromatography with enantiomer labelling. The results showed that alanine and valine had
racemized by 0.4% and 0.8%, respectively. Thus, the doubling of the  signals in the 1H-NMR
was caused by different conformers and not by diastereoisomers. Furthermore, this analysis
shows that, although the peptide was synthesized from the N- to the C-terminus, the product
was obtained with an acceptably low degree of racemization.
Table 1. Synthesized Peptides Containing Aib, Acp, Thp and Phe(2Me) Residues.
Sequence Yield [%] a)
H-Ala-Acp-Phe-OH (11a) 37
H-Ala-Thp-Phe-OH (11b) 38
H-Ala-Phe(2Me)-Leu-OH (13) 49
H-Val-Thp-Gly-Acp-Ala-OH (15) 23
H-Ala-Thp-Val-Thp-Phe-OH (16) 16
H-Ala-Aib-Val-Acp-Gly-Thp-Leu-OH (17) 21
H-Ala-Aib-Val-Acp-Phe-Thp-Leu-OH (18) 13
a) Yield of product isolated after HPLC purification, based on resin loading.
The heptapeptides H-Ala-Aib-Val-Acp-Gly-Thp-Leu-OH (17) and H-Ala-Aib-Val-Acp-
Phe-Thp-Leu-OH (18) were synthesized analogously on solid-phase with yields of 21% and
13%, respectively. The two peptides only differ in one amino acid (Gly(4) → Phe(4)). While
the coupling of the α,α-disubstituted α-amino acid is a difficult step (which has been solved
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by using 2H-azirin-3-amines), the following coupling can be difficult too, so we assume that
this might be the reason for the noticeably lower yield of 18 compared with 17.
Peptides containing α,α-disubstituted α-amino acids stabilize or even promote secondary
structures, such as helices or β-turns.  Therefore, poly-Aib motifs with an accumulation of
helix-stabilizing residues are of some interest. The repeated coupling of 2H-azirin-3-amines in
solution is an efficient method for the preparation of this type of sterically highly congested
oligopeptides [20] [21]. The tripeptide H-(Aib)3-OH (19) was synthesized using the
‘azirine/oxazolone method’ on solid-phase in 33% yield (Table 2), but the preparation of H-
(Aib)4-OH failed. A similar result was obtained in the extension from H-Ala-(Aib)2-OH (20)
to H-Ala-(Aib)3-OH (21). While 20 could be prepared in 41% yield, 21 was obtained in a
conspicuously lower yield (ca. 12%, not pure; additionally, 35% of 20 were obtained). The
introduction of the fourth amino acid in H-Ala-Aib-Aib-Val-OH with conventional coupling
by using PyBOP as the coupling reagent was also in vain. All attempts to improve the
introduction of the fourth amino acid, such as performing the reaction in different solvents
(CH2Cl2, THF, DMF, PhMe, H2O), raising the temperature to 50° or using a Tentagel resin
were not effective. Since the most probable reason for the failure is aggregation, we also
performed the reaction by using the ‘magic mixture’ [22] (DCM/DMF/NMP (1:1:1), triton X-
100, ethylenecarbonate (2M)) and in CHCl3/hexafluoroisopropanol (1:1), but no improvement
could be achieved.
Table 2. Synthesized Peptides Containing Poly-Aib Motifs.
Sequence Yield [%] a)
H-Aib-Aib-Aib-OH (19) 33
H-Ala-Aib-Aib-OH (20) 41
H-Ala-Aib-Aib-Aib-OH (21) 12 b)
H-Ala-Val-Aib-Aib-Aib-OH (22) 16
H-Ala-Val-Phe-Aib-Aib-Leu-OH (23) 6
H-Ala-Val-Phe-Aib-Aib-Aib-Leu-OH (24) 9
a) Yield of product isolated after HPLC purification, based on resin loading.
b) not pure
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A slight improvement was observed if proteinogenic α-amino acids were introduced prior
to the poly-Aib motif, e.g., H-Ala-Val-Aib-Aib-Aib-OH (22) was prepared in 16% yield.
Furthermore, the poly-Aib containing peptides H-Ala-Val-Phe-Aib-Aib-Leu-OH (23) and H-
Ala-Val-Phe-Aib-Aib-Aib-Leu-OH (24) were synthesized, although in low yield (6% and 9%,
respectively). All Aib residues were introduced by the ‘azirine/oxazolone method’, while all
other amino acids were introduced by using PyBOP as the coupling reagent.
3. Conclusions
Peptide synthesis using the ‘azirine/oxazolone method’ on solid-phase was carried out
from the N- to the C-terminus. 2H-Azirin-3-amines were used to introduce α,α-disubstituted
α-amino acids into the peptides without the need for further reagents. It was shown that the
method is not limited to the Aib synthon 1, and it was extended successfully to the 1-
aminocyclopentane-1-carboxylic acid (Acp) synthon 8, the 4-aminotetrahydro-2H-pyran-4-
carboxylic acid (Thp) synthon 9  and the α-methylphenylalanine (Phe(2Me)) synthon 10.
Peptides with up to seven residues, of which three are α,α-disubstituted α-amino acids, have
been prepared. In contrast, the synthesis of peptides containing the poly-Aib motif was not
successful, most probably due to aggregation.
Experimental Part
1. General. See [16], except analytic HPLC-MS: The system consists of a Rheos 2000
pump, a Rheos CPS-LC degasser (Flux Instruments, Basel, Switzerland) and a Thermo
Finnigan Surveyor photo-diode array detector (Thermo Finnigan, San Jose, CA, USA). The
HPLC-system is equipped with a HTS PAL autosampler (CTC Analytics, Zwingen,
Switzerland) and connected to a Thermo Finnigan MSQ linear quadrupole instrument.
Method A: Interchim Uptisphere C18-NEC, 120 Å, 3 µm, 50 × 2.0 mm column (Interchim,
Montluçon, France); eluents: A = H2O, B = MeCN, C = HCOOH (1%) in H2O; flow rate: 0.2
ml/min, gradient (A:B:C): 0.0–10.0 min: 85:5:10–75:15:10. Method B: Interchim Uptisphere
C18-ODB, 120 Å, 3 µm, 50 × 2.0 mm column; eluents: A = H2O, B = MeCN, C = HCOOH
(1%) in H2O; flow rate: 0.2 ml/min, gradient (A:B:C): 0.0–15.0 min: 87:3:10–40:50:10.
N,2,2-Trimethyl-N-phenyl-2H-azirin-3-amine (1), N-methyl-N-phenyl-1-azaspiro[2.4]hept-1-
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en-2-amine (8), N-methyl-N-phenyl-6-oxa-1-azaspiro[2.5]oct-1-en-2-amine (9), and 2-benzyl-
N,2-dimethyl-N-phenyl-2H -azirin-3-amine (10) were synthesized by Villalgordo and
Heimgartner ’s  method [23–25]. (S ) -1-[(S)-2-benzy1-2-methy1-2H-azirin-3-y1]-2-(1-
methoxy-1-methylethyl)pyrrolidine (12) was synthesized according to [26]. In the NMR data,
the integer n in Xaan corresponds to the position of the amino acid within the peptide, but is
only given if the amino acid was present more than once in the peptide and if the NMR signal
could be assigned unambigously. In some 1H-NMR spectra, the broad COOH signal could not
be detected. In the 1H- and 13C-NMR spectra of 15, the descriptor (w) means the weaker, (s)
the stronger signal of the two conformers observed.
2. Abbreviations. Aib: α-aminoisobutyric acid; CC: column chromatography; Acp: 1-
aminocyclopentane-1-carboxylic acid; DCM: dichloromethane; DIPEA: N ,N -
d i i sopropyle thy lamine ;  HOBt :  1 -hydroxybenzo t r i azo le ;  PAM:  [4 -
(hydroxymethyl)phenyl]acetamidomethyl; Phe(2Me): 2-amino-2-methyl-3-phenylpropanoic
acid; PyBOP: (1H -benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate;
Thp: 4-aminotetrahydro-2H-pyran-4-carboxylic acid; TIPS: triisopropylsilane.
3. General Procedures (GP1–GP6). GP1: Attachment of the First Amino Acid. All
manipulations were carried out under N2. PAM resin was swollen in THF. After filtration, a
soln. of COCl2 in toluene (1.9M, 10 equiv.) and THF (ca. 2.5 ml/1 g resin) were added to the
resin, which was agitated at r.t. for 2 h, then washed with THF (2×) and DCM (2×). In a
separate vial, H-Xaa-OtBu · HCl (4 equiv.) was dissolved in DIPEA (8 equiv.) and DCM
(conc. of H-Xaa-OtBu · HCl = 0.2 M). This mixture was added to the resin, and any
ammonium salt that occured was removed by filtration. The resin was agitated at r.t.
overnight, then washed with DMF (3×) and DCM (3×).
GP2: Removing the tBu Protecting Group. The resin was swollen in DCM. TFA in DCM
(1×5 s, 25%; 1×30 min, 50%) and TIPS (5%, in each case) were added and the resin agitated
at r.t. Afterwards, the resin was washed with DCM (3×), DMF (2×) and DCM (3×).
GP3: Coupling with 2H-azirin-3-amines 1, 8, 9, 10. The resin was swollen in DCM. A
soln. of 2H-azirin-3-amine (4 equiv.) in DCM (conc. of 2H-azirin-3-amine = 0.2M) was added
and the resin agitated at r.t. overnight, then washed with DCM (3×). Unconsumed 2H-azirin-
3-amine can easily be recovered.
GP4: Hydrolysis of the Terminal Amide. The resin was swollen in THF. Aq. HCl (ca. 3-4
ml/200 mg resin, 3M in THF/H2O, prepared from conc. HCl and THF) was added and the
resin agitated at r.t. overnight, then washed with THF (3×), DMF (3×) and DCM (3×).
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GP5: Coupling with H-Xaa-OtBu · HCl. The resin was swollen in DMF. HOBt (6 equiv.)
in DMF, PyBOP (4 equiv.) in DMF, H-Xaa-OtBu · HCl (4 equiv.) in DMF and DIPEA (12
equiv.) was added (conc. of H-Xaa-OtBu . HCl = 0.2M), and the resin agitated at r.t. overnight,
then washed with DMF (3×) and DCM (3×).
GP6: Cleavage. The resin was swollen in DCM. HBr in AcOH (33%, 1 ml/100 mg
resin), two drops of H2O were added and the resin agitated for 6 h. The resin was separated by
filtration and washed with AcOH/DCM (1:1, 3×) and MeCN/DCM (1:1, 3×). The solvents
were evaporated under reduced pressure and the crude product was purified by means of
HPLC. The purified product was lyophilized.
4. Synthesis of Peptides. (S)-2-{[({[(S)-2-Amino-1-oxopropyl]amino}cyclopentyl)-
carbonyl]amino}-3-phenylpropanoic Acid (H-Ala-Acp-Phe-OH; 11a). PAM resin (200 mg,
0.124 mmol) was treated as described in GP 1, 2, 3, 4, 5 and 6 to yield 11a (21.0 mg, 37%) as
a colorless powder after prep. HPLC purification and lyophilization. HPLC-MS (method B):
tR = 7.7 min, m/z = 348 (100, [M + H]+), 183 (76, [M – Phe]+), 155 (20, [M – Phe – CO]+). IR
(KBr): 3397m, 3262s, 3076s, 2962m, 2876m, 1731s, 1664sh, 1647vs, 1561m, 1517s, 1490m,
1455m, 1442m, 1382w, 1331w, 1266m, 1238m, 1202vs, 1141s, 1004w, 982w, 845w, 802w,
734w, 724w, 699w. 1H-NMR ((D6)DMSO, 600 MHz): 12.84 (br. s, COOH); 8.53, 8.48 (2s,
NH(Acp)); 8.06 (br. s, NH3(Ala)); 7.36 (d, J = 7.7, NH(Phe)); 7.27–7.17 (m, 5 arom. H); 4.44
(ddd, J = 7.7, 7.7, 5.6, CH(α)(Phe)); 3.82 (br. s, CH(α)(Ala)); 3.07 (dd, 2J = 13.8, J = 5.6, 1 H
of CH2(Phe)); 2.94 (dd, 2J = 13.8, J = 7.7, 1 H of CH2(Phe)); 2.14–2.09 (m , 1 H of 4
CH2(Acp)); 1.89–1.82 (m, 3 H of 4 CH2(Acp)); 1.60–1.59 (m, 4 H of 4 CH2(Acp)); 1.33 (d, J
= 7.0, Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 172.7 (s, CO(Phe)); 172.2 (s, CO(Acp));
169.3 (s, CO(Ala)); 137.4 (s, arom. C); 129.3, 128.1, 126.4 (3d, 5 arom. CH); 66.4 (s,
C(α)(Acp)); 53.4 (d, CH(α)(Phe)); 48.3 (d, CH(α)(Ala)); 36.9 (t, CH2(Phe)); 36.3, 35.3, 23.7
(3t, 4 CH2(Acp)); 16.9 (q, Me(Ala)). ESI-MS: 370 (8, [M + Na]+), 348 (100, [M + H]+), 183
(13, [M – Phe]+), 151 (24).
(S)-2-{[(4-{[(S)-2-Amino-1-oxopropyl]amino}-3,4,5,6-tetrahydro-2H-pyran-4-yl)carbon-
yl]amino}-3-phenylpropanoic Acid (H-Ala-Thp-Phe-OH; 11b).  PAM resin (200 mg, 0.124
mmol) was treated as described in GP 1, 2, 3, 4, 5 and 6 to yield 11b (22.5 mg, 38%) as a
colorless powder after prep. HPLC purification and lyophilization. HPLC-MS (method B): tR
= 6.1 min, m/z = 364 (100, [M + H]+), 199 (58, [M – Phe]+). IR (KBr): 3425s, 3243s, 3061vs,
3033vs, 2875s, 2616w, 1724vs, 1678vs, 1533vs, 1499s, 1455m, 1444m, 1429m, 1394m,
1356m, 1331w, 1302m, 1261s, 1244s, 1202vs, 1141s, 1102s, 1029w, 1019w, 969w, 843w,
800w, 723m, 701m . 1H-NMR ((D6)DMSO, 600 MHz): 12.79 (br. s, COOH); 8.43 (s,
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NH(Thp)); 8.06 (br. s, NH3(Ala)); 7.52 (d, J = 8.0, NH(Phe)); 7.28–7.51 (m, 5 arom. H); 4.46
(ddd, J = 8.3, 8.0, 5.4, CH(α)(Phe)); 3.95 (q, J = 6.7, CH(α)(Ala)); 3.68–3.65, 3.59–3.59,
3.52–3.46 (3m, 2 CH2O(Thp)); 3.08 (dd, 2J = 13.8, J = 5.4, 1 H of CH2(Phe)); 2.95 (dd, 2J =
13.8, J = 8.3, 1 H of CH2(Phe)); 1.99–1.94, 1.87–1.76 (2m, 2 CH2CH2O(Thp)); 1.38 (d, J =
7.0, Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 172.6 (s, CO(Phe)); 171.9 (s, CO(Thp));
169.5 (s, CO(Ala)); 137.4 (s, arom. C); 129.3, 128.1, 126.4 (3d, 5 arom. CH); 62.6, 62.3 (2t, 2
CH2O(Thp)); 57.0 (s, C(α)(Thp)); 53.3 (d, CH(α)(Phe)); 48.4 (d, CH(α)(Ala)); 36.9 (t,
CH2(Phe)); 31.9, 31.3 (2t, 2 CH2CH2O(Thp)); 17.1 (q, Me(Ala)). ESI-MS: 364 (100, [M +
H]+).
(S)-2-[((S)-2-{[(S)-2-Amino-1-oxopropyl]amino}-2-benzyl-1-oxopropyl)amino]-4-meth-
ylpentanoic Acid and (S)-2-[((R)-2-{[(S)-2-Amino-1-oxopropyl]amino}-2-benzyl-1-oxoprop-
yl)amino]-4-methylpentanoic Acid (H-Ala-Phe(2Me)-Leu-OH; (S,S,S)-13 and (S,R ,S)-13).
PAM resin (200 mg, 0.124 mmol) was treated as described in GP 1, 2, 3, 4, 5 and 6 to yield
(S,S,S)-13 and (S,R,S)-13 in a 1:1 ratio  as colorless powders after prep. HPLC purification
and lyophilization (29 mg, 49% altogether).
Data of (S,S,S)-13. HPLC-MS (method B): tR = 8.8 min, m/z = 364 (100, [M + H]+). IR
(KBr): 3045sh, 3281s, 3066s, 3033s, 2960s, 2874s, 2623w, 1672vs, 1528vs, 1454m, 1388m,
1329w, 1268m, 1238m, 1202vs, 1141vs, 1031w, 1004w, 969w, 928w, 879w, 838w, 800w,
740w, 722m, 706m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 9.5–8.0 (br. s, NH3(Ala)); 8.09 (s,
NH(Phe(2Me))); 7.82 (d, J = 8.2, NH(Leu)); 7.27–7.21, 7.12–7.11 (2m, 5 arom. H); 4.36–4.32
(m, CH(α)(Leu)); 3.81–3.80 (m, CH(α)(Ala)); 3.36, 3.18 (AB, J = 13.5, PhCH2); 1.68–1.59
(m, CH(γ)(Leu), 1 H of CH2(Leu)); 1.52–1.41 (m, 1 H of CH2(Leu)); 1.31 (s, Me(Phe(2Me)));
1.30 (d, J = 7.0, Me(Ala)); 0.88, 0.86 (2d, J = 6.5, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150
MHz): 174.3 (s, CO(Leu)); 172.5 (s, CO(Phe(2Me))); 169.4 (s, CO(Ala)); 136.8 (s, arom. C);
130.6, 127.8, 126.4 (3d, 5 arom. CH); 59.6 (s, C(α)(Phe(2Me))); 50.5 (d, CH(α)(Leu)); 48.8
(d, CH(α)(Ala)); 40.1 (t, CH2(Leu)); 38.8 (t, PhCH2); 24.0 (d , CH(γ)(Leu)); 23.7 (q,
Me(Phe(2Me))); 23.0, 21.4 (2q, 2 Me(Leu)); 17.1 (q, Me(Ala)). ESI-MS: 408 (12, [M – H + 2
Na]+), 386 (100, [M + Na]+), 364 (11, [M + H]+), 293 (7, [M – Ala + H]+), 233 (8, [M – Leu]+),
205 (23, [M – Leu – CO]+), 134 (28).
Data of (S,R,S)-13. HPLC-MS (method B): tR = 9.7 min, m/z = 364 (100, [M + H]+). IR
(KBr): 3291s, 3066s, 3034s, 2961s, 2875s, 2618w, 1720s, 1670vs, 1525vs, 1468m, 1454m,
1387m, 1329w, 1269m, 1202vs, 1143vs, 1031w, 1004w, 968w, 927w, 838w, 800w, 742w,
723m, 703m. 1H-NMR ((D6)DMSO, 600 MHz): 8.11 (s, NH3(Ala)); 8.02 (s, NH(Phe(2Me)));
8.00 (d , J = 7.9, NH(Leu)); 7.25–7.19, 7.10–7.09 (2m , 5 arom. H); 4.29–4.25 (m ,
Chapter 5
73
CH(α)(Leu)); 3.93–3.91 (m, CH(α)(Ala)); 3.34 (s, PhCH2); 1.71–1.65 (m, CH(γ)(Leu), 1 H of
CH2(Leu)); 1.55–1.52 (m , 1 H of CH2(Leu)); 1.45 (s, Me(Phe(2Me))); 1.24 (d , J  = 6.9,
Me(Ala)); 0.92, 0.88 (2d, J = 6.4, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 173.9 (s,
CO(Leu)); 172.5 (s, CO(Phe(2Me))); 168.8 (s, CO(Ala)); 136.7 (s, arom. C); 130.1, 127.8,
126.4 (3d , 5 arom. CH); 60.2 (s, C(α)(Phe(2Me))); 50.8 (d , CH(α)(Leu)); 48.4 (d,
CH(α)(Ala)); 39.8 (t, CH2(Leu)); 39.7 (t, PhCH2); 24.3 (d , CH(γ)(Leu)); 23.0 (q,
Me(Phe(2Me))); 23.0, 21.1 (2q, 2 Me(Leu)); 17.2 (q, Me(Ala)). ESI-MS: 408 (5, [M – H + 2
Na]+), 386 (100, [M + Na]+), 364 (96, [M + H]+), 293 (23, [M – Ala + H]+), 233 (24, [M –
Leu]+), 205 (43, [M – Leu – CO]+), 134 (63).
(S)-2-[({[(2-{[(4-{[(S)-2-Amino-3-methyl-1-oxobutyl]amino}-3,4,5,6-tetrahydro-2H-pyr-
an-4-yl)carbonyl]amino}-1-oxoethyl)amino]cyclopentyl}carbonyl)amino]propanoic Acid (H-
Val-Thp-Gly-Acp-Ala-OH; 15). PAM resin (200 mg, 0.124 mmol) was treated as described in
GP 1, 2, 3, 4, 5, 2, 3, 4, 5 and 6 to yield 15 (17.0 mg, 23%) as a colorless powder after prep.
HPLC purification and lyophilization. HPLC-MS (method B): tR = 4.9 min, m/z = 484 (100,
[M + H]+). IR (KBr): 3337s, 3056s, 2971s, 2880m, 2642w, 1720sh, 1670vs, 1534vs, 1455m,
1430w, 1400w, 1379w, 1333w, 1297m, 1240m, 1202vs, 1141s, 1103m, 1027w, 961w, 935w,
840w, 800w, 722m . 1H-NMR ((D6)DMSO, 600 MHz) (2 conformers): ca. 13.0–12.0 (br. s,
COOH); 8.82 (s, NH(Thp)); 8.57 (w) (s, NH(Acp)); 8.11 (s, NH3(Val)); 8.04 (s, NH(Gly));
7.73 (s) (s, NH(Acp)); 7.53 (w), 7.38 (s) (2d, J = 7.3, NH(Ala)); 4.26 (w), 4.14 (s) (2dq, J =
7.3, 7.3, CH(α)(Ala)); 3.77–3.71, 3.66–3.53, 3.47–3.43 (3m, CH(α)(Val), CH2(Gly), 2
CH2O(Thp)); 2.23–2.18, 2.14–2.07 (2m, CH(β)(Val), 1 H of 2 CH2CH2O(Thp), 1 H of 2
CH2CH2C(α)(Acp)); 1.97–1.76 (m, 3 H of 2 CH2CH2O(Thp), 3 H of 2 CH2CH2C(α)(Acp));
1.69–1.56 (m, 2 CH2CH2C(α)(Acp)); 1.27 (s), 1.24 (w) (2d, J = 7.3, Me(Ala)); 0.99 (s), 0.95
(s), 0.94 (w, w) (3d, J = 6.9, Me(Val)). 13C-NMR ((D6)DMSO, 150 MHz) (2 conformers):
173.9 (s, CO(Ala)); 173.3 (s, CO(Thp)); 173.2 (s, CO(Acp)); 168.7 (s, CO(Gly)); 168.5 (s,
CO(Val)); 66.4 (w), 65.9 (s) (2s, C(α)(Acp)); 62.5, 62.4 (2t, 2 CH2O(Thp)); 57.6 (s), 57.6 (w)
(2d, CH(α)(Val)); 56.9 (s , C(α)(Thp)); 47.7 (s), 47.6 (w) (2d, CH(α)(Ala)); 43.2 (t,
CH2(Gly)); 37.1, 35.2 (2t, 2 CH2CH2C(α)(Acp)); 32.8, 30.1 (2t, 2 CH2CH2O(Thp)); 29.6 (s),
29.5 (w) (2d, CH(β)(Val)); 24.1 (s), 24.0 (s), 23.9 (w), 23.8 (w) (4t, 2 CH2CH2C(α)(Acp));
18.6 (s), 18.2 (w), 17.5 (w), 17.2 (s) (4q, 2 Me(Val)); 17.1 (w), 17.0 (s) (2q, Me(Ala)). ESI-
MS: 484 (100, [M + H]+), 300 (20).
(S)-2-[({4-[((S)-2-{[(4-{[(S)-2-Amino-1-oxopropyl]amino}-3,4,5,6-tetrahydro-2H-pyran-
4-yl)carbonyl]amino}-3-methyl-1-oxobutyl)amino]-3,4,5,6-tetrahydro-2H-pyran-4-yl}carbon-
yl)amino]-3-phenylpropanoic Acid (H-Ala-Thp-Val-Thp-Phe-OH; 16). PAM resin (200 mg,
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0.124 mmol) was treated as described in GP 1, 2, 3, 4, 5, 2, 3, 4, 5 and 6 to yield 16 (14.3 mg,
16%) as a colorless powder after prep. HPLC purification and lyophilization. HPLC-MS
(method B): tR = 8.3 min, m/z = 590 (100, [M + H]+), 425 (98, [M – Phe]+), 298 (48, [M –
(Thp–Phe)]+). IR (KBr): 3426s, 3306s, 3061s, 2967s, 2875m, 2620w, 1720s, 1671vs, 1533vs,
1469m, 1444m, 1429m, 1393m, 1356w, 1302m, 1259m, 1245m, 1203vs, 1189sh, 1142s,
1104s, 1029w, 968w, 946w, 917w, 838w, 800w, 722m, 702w. 1H-NMR ((D6)DMSO, 600
MHz): ca. 13.0–12.5 (br. s, COOH); 8.52 (s, NH(Thp1)); 8.07 (s, NH3(Ala)); 8.03 (s,
NH(Thp2)); 7.45 (d, J = 7.9, NH(Phe)); 7.38 (d, J = 7.7, NH(Val)); 7.27–7.16 (m, 5 arom. H));
4.43 (ddd, J = 7.9, 7.9, 5.9, CH(α)(Phe)); 4.17 (dd, J = 7.3, 7.3, CH(α)(Val)); 3.99–3.97 (m,
CH(α)(Ala)); 3.71–3.41 (m, 4 CH2O(Thp)); 3.02 (dd, 2J = 13.8, J = 5.9, 1 H of CH2(Phe));
2.95 (dd, 2J = 13.8, J = 7.5, 1 H of CH2(Phe)); 2.07–2.04 (m, CH(β)(Val)); 2.01–1.84 (m, 4
CH2CH2O(Thp)); 1.39 (d, J = 7.0, Me(Ala)); 0.87, 0.82 (2d, J = 6.7, 2 Me(Val)). 13C-NMR
((D6)DMSO, 150 MHz): 172.5 (s, 2 CO(Thp)); 172.4 (s, CO(Phe)); 171.1 (s, CO(Val)); 169.7
(s, CO(Ala)); 137.2 (s, arom. C); 129.1, 128.1, 126.3 (3d, 5 arom. CH); 62.4, 62.3, 62.3 (3t, 4
CH2O(Thp)); 58.4 (d, CH(α)(Val)); 57.1, 56.9 (2s, 2 C(α)(Thp)); 53.3 (d, CH(α)(Phe)); 48.5
(d, CH(α)(Ala)); 36.9 (t, CH2(Phe)); 31.9, 31.7, 31.3, 31.1 (4t, 4 CH2CH2O(Thp)); 30.0 (d,
CH(β)(Val)); 19.5, 18.2 (2q, 2 Me(Val)); 17.1 (q, Me(Ala)). ESI-MS: 590 (100, [M + H]+),
425 (27, [M – Phe]+).
(S)-2-{[(4-{[(S)-2-({[({(S)-2-[(2-{[(S)-2-Amino-1-oxopropyl]amino}-2-methyl-1-oxo-
propyl)amino]-3-methyl-1-oxobutyl}amino)cyclopentyl]carbonyl}amino)-1-oxoethyl]amino}-
3,4,5,6-tetrahydro-2H-pyran-4-yl)carbonyl]amino}-4-methylpentanoic Acid (H-Ala-Aib-Val-
Acp-Gly-Thp-Leu-OH; 17). PAM resin (200 mg, 0.124 mmol) was treated as described in GP
1, 2, 3, 4, 5, 2, 3, 4, 5, 2, 3, 4, 5 and 6 to yield 17 (20.2 mg, 21%) as a colorless powder after
prep. HPLC purification and lyophilization. For the ‘conventional’ coupling of Gly and Leu,
the coupling was performed two times (1 × 2 h and 1 × overnight). HPLC-MS (method B): tR
= 11.9 min, m/z = 682 (100, [M + H]+). IR (KBr): 3314s, 3054m, 2962s, 2874m, 1722sh,
1662vs, 1536vs, 1470m, 1448m, 1389m, 1368w, 1329w, 1295m, 1267m, 1250sh, 1202s,
1172m, 1141m, 1107w, 1062w, 1029w, 977w, 947w, 929w, 851w, 835w, 800w, 722w. 1H-
NMR ((D6)DMSO, 600 MHz): ca. 12.6–12.1 (br. s, COOH); 8.69 (s, NH(Aib)); 8.49 (s,
NH(Acp)); 8.23 (br. s, NH3(Ala)); 8.10 (t, J = 5.6, NH(Gly)); 7.90 (d, J = 6.1, NH(Val)); 7.47
(s, NH(Thp)); 7.42 (d, J = 8.1, NH(Leu)); 4.23–4.19 (m , CH(α)(Leu)); 3.90–3.88 (m,
CH(α)(Ala)); 3.79 (m, CH(α)(Val)); 3.68–3.64 (m, 3 H of 2 CH2O(Thp)); 3.60 (d, J = 5.6,
CH2(Gly)); 3.57–3.45 (m, 1 H of 2 CH2O(Thp)); 2.30–2.28 (m, 1 H of 2 CH2CH2C(α)(Acp));
2.19–2.16 (m, CH(β)(Val)); 2.09–2.02 (m, 2 H of 2 CH2CH2O(Thp)); 2.00–1.88 (m, 1 H of 2
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CH2CH2O(Thp), 3 H of 2 CH2CH2C(α)(Acp)); 1.84–1.80 (m, 1 H of 2 CH2CH2O(Thp));
1.72–1.60 (m, CH(γ)(Leu), 1 H of CH2(Leu), 4 H of 2 CH2CH2C(α)(Acp)); 1.49–1.46 (m, 1 H
of CH2(Leu)); 1.44, 1.40 (2s, 2 Me(Aib)); 1.37 (d, J = 6.9, Me(Ala)); 0.88, 0.87 (2d, J = 6.7, 2
Me(Val)); 0.86, 0.82 (2d, J = 6.4, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 175.0 (s,
CO(Acp)); 174.7 (s, CO(Aib)); 173.8 (s, CO(Leu)); 173.1 (s, CO(Thp)); 172.4 (s, CO(Val));
169.5 (s, CO(Ala)); 168.9 (s, CO(Gly)); 66.1 (s, C(α)(Acp)); 62.4, 62.3 (2t, 2 CH2O(Thp));
60.1 (d, CH(α)(Val)); 57.1 (s, C(α)(Thp)); 56.4 (s, C(α)(Aib)); 50.3 (d, CH(α)(Leu)); 48.5 (d,
CH(α)(Ala)); 44.1 (t, CH2(Gly)); 39.8 (t, CH2(Leu)); 36.9, 35.7 (2t, 2 CH2CH2C(α)(Acp));
32.7, 30.3 (2t, 2 CH2CH2O(Thp)); 28.3 (d, CH(β)(Val)); 25.4, 24.5 (2q, 2 Me(Aib)); 24.1,
24.1, 24.0 (d, 2t, CH(γ)(Leu), 2 CH2CH2C(α)(Acp)); 23.0, 21.3 (2q, 2 Me(Leu)); 19.4, 19.3
(2q, 2 Me(Val)); 16.7 (q, Me(Ala)). ESI-MS: 682 (100, [M + H]+).
(S)-2-{[(4-{[(S)-2-({[({(S)-2-[(2-{[(S)-2-Amino-1-oxopropyl]amino}-2-methyl-1-oxo-
propyl)amino]-3-methyl-1-oxobutyl}amino)cyclopentyl]carbonyl}amino)-3-phenyl-1-oxo-
propyl]amino}-3,4,5,6-tetrahydro-2H-pyran-4-yl)carbonyl]amino}-4-methylpentanoic Acid
(H-Ala-Aib-Val-Acp-Phe-Thp-Leu-OH; 18). PAM resin (200 mg, 0.124 mmol) was treated as
described in GP 1, 2, 3, 4, 5, 2, 3, 4, 5, 2, 3, 4, 5 and 6 to yield 18 (14.2 mg, 13%) as a
colorless powder after prep. HPLC purification and lyophilization. HPLC-MS (method B): tR
= 11.4 min, m/z = 772 (100, [M + H]+). IR (KBr): 3431s, 3319s, 3062m, 3032m, 2962s,
2874m, 1726sh, 1662vs, 1532vs, 1469m, 1454m, 1445m, 1389w, 1367w, 1326w, 1293sh,
1266m, 1244m, 1202s, 1140s, 1108w, 1029w, 978w, 927w, 838w, 800w, 722w, 700w. 1H-
NMR ((D6)DMSO, 600 MHz): ca. 12.8–12.2 (br. s, COOH); 8.78 (br. s, NH(Aib)); 8.15 (br.
s, NH3(Ala)); 8.04 (br. s, NH(Val), NH(Acp)); 7.72 (br. s, NH(Phe)); 7.61 (s, NH(Thp));
7.26–7.24 (m, 2 arom. CH); 7.21–7.17 (m , NH(Leu), 3 arom. CH); 4.34–4.30 (m ,
CH(α)(Leu)); 4.23 (br. s, CH(α)(Phe)); 3.87 (br. s, CH(α)(Ala)); 3.83–3.81 (m, CH(α)(Val));
3.68–3.65 (m, 3 H of 2 CH2O(Thp)); 3.34–3.31 (m, 1 H of CH2(Phe)); 3.26–3.22 (m, 1 H of 2
CH2O(Thp)); 2.92–2.87 (m, 1 H of CH2(Phe)); 2.16–2.15 (m, 2 H of 2 CH2CH2O(Thp));
2.08–2.04 (m, CH(β)(Val), 1 H of 4 CH2(Acp)); 1.99–1.94 (m, 1 H of 2 CH2CH2O(Thp), 1 H
of 4 CH2(Acp)); 1.79–1.71 (m, CH(γ)(Leu), 1 H of 2 CH2CH2O(Thp), 2 H of 4 CH2(Acp));
1.69–1.58 (m, 1 H of CH2(Leu), 4 H of 4 CH2(Acp)); 1.49–1.44 (m, 1 H of CH2(Leu)); 1.49 (s,
1 Me of 2 Me(Aib)); 1.37 (d, J = 6.9, Me(Ala)); 1.36 (s, 1 Me of 2 Me(Aib)); 0.91 (d, J = 6.8,
1 Me of 2 Me(Val)); 0.88 (d, J = 6.7, 1 Me of 2 Me(Leu)); 0.85 (d, J = 6.7, 1 Me of 2
Me(Val), 1 Me of 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 175.9 (s, CO(Aib)); 174.2
(s, CO(Acp)); 173.9 (s, CO(Leu)); 172.9 (s, CO(Thp)); 172.6 (s, CO(Val)); 170.3 (s,
CO(Phe)); 169.4 (s, CO(Ala)); 138.4 (s, arom. C); 129.0, 128.2, 126.1 (3d, 5 arom. CH); 66.3
Chapter 5
76
(s, C(α)(Acp)); 62.5, 62.3 (2t, 2 CH2O(Thp)); 60.8 (d, CH(α)(Val)); 57.1 (s, C(α)(Thp)); 56.2
(s, C(α)(Aib)); 54.9 (d, CH(α)(Phe)); 49.8 (d, CH(α)(Leu)); 48.4 (d, CH(α)(Ala)); 40.2 (t,
CH2(Leu)); 36.1, 36.0 (2t, 2 CH2CH2C(α)(Acp)); 35.5 (t, CH2(Phe)); 33.7, 28.7 (2t, 2
CH2CH2O(Thp));  28.5 (d, CH(β)(Val)); 25.3, 24.3 (2q, 2 Me(Aib)); 24.1, 24.0 (2t, 2
CH2CH2C(α)(Acp)); 23.7 (d, CH(γ)(Leu)); 23.1, 21.1 (2q, 2 Me(Leu)); 19.3, 18.4 (2q, 2
Me(Val)); 16.7 (q, Me(Ala)). ESI-MS: 772 (100, [M + H]+).
2-({2-[(2-Amino-2-methyl-1-oxopropyl)amino]-2-methyl-1-oxopropyl}amino)-2-methyl-
propanoic Acid (H-Aib-Aib-Aib-OH; 19). PAM resin (200 mg, 0.124 mmol) was treated as
described in GP 1, 2, 3, 4, 3 and 6 to yield 19 (15.9 mg, 33%) as a colorless powder after
prep. HPLC purification and lyophilization. HPLC-MS (method A): tR = 1.3 min, m/z = 274
(100, [M + H]+). IR (KBr): 3508m, 3359s, 3262m, 3119s, 3064s, 2994s, 2947s, 2604w,
1719vs, 1667vs, 1519vs, 1472m, 1440m, 1406w, 1390w, 1367w, 1258s, 1203vs, 1179vs,
1144vs, 947w, 925w, 911w, 839w, 801w, 773w, 723m. 1H-NMR ((D6)DMSO, 300 MHz): ca.
9.0–7.0 (br. s, NH3); 8.00, 7.38 (2s, 2 NH); 1.49, 1.41, 1.38 (3s , 6 Me). 13C-NMR
((D6)DMSO, 75 MHz): 175.8, 172.6, 170.7 (3s, 3 CO); 56.6, 56.5, 55.2 (3s, 3 C(α)); 24.5,
24.4, 23.3 (3q, 6 Me). ESI-MS: 274 (100, [M + H]+), 170 (4, [M – Aib]+).
2-[(2-{[(S)-2-Amino-1-oxopropyl]amino}-2-methyl-1-oxopropyl)amino]-2-methylpropan-
oic Acid (H-Ala-Aib-Aib-OH; 20). PAM resin (200 mg, 0.124 mmol) was treated as described
in GP 1, 2, 3, 4, 3 and 6 to yield 20 (19.0 mg, 41%) as a colorless powder after prep. HPLC
purification and lyophilization. HPLC-MS (method A): tR = 1.3 min, m/z = 260 (100, [M +
H]+). IR (KBr): 3284s, 3072s, 2993s, 2945s, 2631w, 1726vs, 1673vs, 1530vs, 1471m, 1458m,
1441m, 1389m, 1368m, 1264s, 1204vs, 1141vs, 1005w, 930w, 880w, 838m, 801m, 768w,
723m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 8.8–7.5 (br. s, NH3(Ala));  8.38 (s, NH(Aib2));
7.46 (s, NH(Aib3)); 3.85 (q, J = 6.9, CH(α)(Ala)); 1.41–1.34 (m, 4 Me(Aib), Me(Ala)). 13C-
NMR ((D6)DMSO, 150 MHz): 175.7 (s, CO(Aib3)); 172.5 (s, CO(Aib2)); 168.9 (s, CO(Ala));
56.3 (s, C(α)(Aib2)); 55.2 (s, C(α)(Aib3)); 48.3 (d, CH(α)(Ala)); 24.8, 24.5, 24.5, 24.4 (4q, 4
Me(Aib)); 17.1 (q, Me(Ala)). ESI-MS: 519 (36, [2M + H]+), 260 (100, [M + H]+).
2-({2-[(2-{[(S)-2-Amino-1-oxopropyl]amino}-2-methyl-1-oxopropyl)amino]-2-methyl-1-
oxopropyl}amino)-2-methylpropanoic Acid (H-Ala-Aib-Aib-Aib-OH; 21). PAM resin (200
mg, 0.124 mmol) was treated as described in GP 1, 2, 3, 4, 3, 4, 3 and 6 to yield 21 (7 mg,
12%) as a colorless powder after prep. HPLC purification and lyophilization. Additional 20
was isolated as a colorless powder (16 mg, 35%). HPLC-MS (method A): tR = 1.5 min, m/z =
345 (100, [M  + H]+). IR(KBr): 3432vs, 3262vs, 3120vs, 2992vs, 2939s, 1670vs, 1543vs,
1535vs, 1469s, 1460s, 1399vs, 1367m, 1261m, 1204vs, 1182s, 1141s, 1089w, 1048w, 1025w,
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1005w, 722w. 1H-NMR ((D6)DMSO, 600 MHz): ca. 12.2–11.8 (br. s, COOH); 8.61 (s,
NH(Aib)); 8.04 (br. s, NH3(Ala)); 7.44, 7.31 (2s, 2 NH(Aib)); 3.87 (br. s, CH(α)(Ala));
1.39–1.34 (m, 6 Me(Aib), Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 174.4, 172.2, 171.1,
168.1 (4s, 4 CO); 55.2, 54.6, 53.8 (3s, 3 C(α)(Aib)); 47.1 (d, CH(α)(Ala)); 23.9, 23.6, 23.5,
23.3, 23.3, 23.2 (6q, 6 Me(Aib)); 15.8 (q, Me(Ala)). ESI-MS: 345 (100, [M + H]+).
2-{[2-({2-[((S)-2-{[(S)-2-Amino-1-oxopropyl]amino}-3-methyl-1-oxobutyl)amino]-2-
methyl-1-oxopropyl}amino)-2-methyl-1-oxopropyl]amino}-2-methylpropanoic Acid (H-Ala-
Val-Aib-Aib-Aib-OH; 22). PAM resin (200 mg, 0.124 mmol) was treated as described in GP
1, 2, 5, 2, 3, 4, 3, 4, 3 and 6 to yield 22 (11.0 mg, 16%) as a colorless powder after prep.
HPLC purification and lyophilization. HPLC-MS (method A): tR = 8.4 min, m/z = 444 (100,
[M + H]+). IR (KBr): 3431s, 3304s, 3063s, 2987s, 2942s, 2883m, 2629w, 1720sh, 1667vs,
1534vs, 1469m, 1389m, 1366m, 1203vs, 1181vs, 1140s, 1010w, 935w, 837w, 800w, 776w,
722m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 9.5–7.5 (br. s, NH3(Ala));  8.40 (s, NH(Aib3));
8.33 (d, J = 7.6, NH(Val)); 7.34 (s, NH(Aib5)); 7.13 (s, NH(Aib4)); 4.11 (dd, J = 7.2, 7.2,
CH(α)(Val)); 3.95 (q, J = 6.9, CH(α)(Ala)); 2.05 (dsept., J = 6.8, 6.8, CH(β)(Val)); 1.33–1.29
(m, 6 Me(Aib), Me(Ala)); 0.93, 0.91 (2d, J = 7.0, 2 Me(Val)). 13C-NMR ((D6)DMSO, 150
MHz): 175.6 (s, CO(Aib5)); 173.3 (s, CO(Aib4)); 172.6 (s, CO(Aib3)); 170.9 (s, CO(Val));
169.8 (s, CO(Ala)); 58.3 (d, CH(α)(Val)); 56.1 (s, C(α)(Aib3)); 55.7 (s, C(α)(Aib4)); 54.8 (s,
C(α)(Aib5)); 47.9 (d, CH(α)(Ala)); 30.0 (d, CH(β)(Val)); 25.0 (q, 1 Me of 2 Me(Aib3)); 24.9
(q, 1 Me of 2 Me(Aib4)); 24.8, 24.5 (2q, 2 Me(Aib5)); 24.4 (q, 1 Me of 2 Me(Aib4)); 24.2 (q, 1
Me of 2 Me(Aib3)); 19.2, 18.2 (2q, 2 Me(Val)); 17.4 (q, Me(Ala)). ESI-MS: 444 (100, [M +
H]+).
(S)-2-[(2-{[2-({(S)-2-[((S)-2-{[(S)-2-Amino-1-oxopropyl]amino}-3-methyl-1-oxobutyl)-
amino]-3-phenyl-1-oxopropyl}amino)-2-methyl-1-oxopropyl]amino}-2-methyl-1-oxopropyl)-
amino]-4-methylpentanoic Acid (H-Ala-Val-Phe-Aib-Aib-Leu-OH; 23). PAM resin (200 mg,
0.124 mmol) was treated as described in GP 1, 2, 5, 2, 5, 2, 3, 4, 3, 4, 5 and 6 to yield 23 (5.3
mg, 6%) as a colorless powder after prep. HPLC purification and lyophilization. HPLC-MS
(method B): tR = 11.1 min, m/z = 619 (100, [M + H]+). IR (KBr): 3421s, 3312s, 3065m,
3034m, 2964s, 2939m, 2876m, 1668vs, 1534vs, 1468m, 1460m, 1442m, 1388m, 1367w,
1203vs, 1190sh, 1140s, 837w, 800w, 745w, 722w, 700w. 1H-NMR ((D6)DMSO, 600 MHz):
ca. 12.4–12.1 (br. s, COOH); 8.32 (d, J = 5.7, NH(Phe)); 8.26 (d, J = 8.6, NH(Val)); 8.19 (s,
NH(Aib4)); 8.04 (br. s, NH3(Ala)); 7.32 (s, NH(Aib5)); 7.30–7.18 (m, 5 arom. H, NH(Leu));
4.41 (ddd, J = 8.1, 6.3, 6.3, CH(α)(Phe)); 4.15 (dd, J = 8.2, 8.2, CH(α)(Val)); 4.13–4.10 (m,
CH(α)(Leu)); 3.93–3.90 (m, CH(α)(Ala)); 2.95 (dd, J = 13.9, 6.5, 1 H of CH2(Phe)); 2.88 (dd,
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J = 13.9, 8.5, 1 H of CH2(Phe)); 1.92 (dsept., J = 7.0, 7.0, CH(β)(Val)); 1.72–1.63 (m,
CH(γ)(Leu), 1 H of CH2(Leu)); 1.47–1.42 (m, 1 H of CH2(Leu)); 1.34, 1.31 (2s, 2 Me(Aib5));
1.26 (d, J = 7.0, Me(Ala)); 1.19, 1.12 (2s, 2 Me(Aib4)); 0.90 (d, J = 6.7, 1 Me of 2 Me(Val));
0.87 (d, J = 6.5, 1 Me of 2 Me(Leu)); 0.84 (d, J = 6.7, 1 Me of 2 Me(Val)); 0.81 (d, J = 6.5, 1
Me of 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 174.1 (s, CO(Aib5)); 173.8 (s,
CO(Leu)); 172.6 (s, CO(Aib4)); 171.0 (s, CO(Phe)); 170.7 (s, CO(Val)); 169.2 (s, CO(Ala));
137.0 (s, arom. C); 129.1, 127.9, 126.2 (3d, 5 arom. CH); 57.8 (d, CH(α)(Val)); 55.9 (s, C
(α)(Aib4)); 55.6 (s, C(α )(Aib5)); 54.5 (d, CH(α)(Phe)); 50.3 (d, CH(α)(Leu)); 47.8 (d,
CH(α)(Ala)); 39.6 (t, CH2(Leu)); 36.9 (t, CH2(Phe)); 30.3 (d, CH(β)(Val)); 25.9 (q, 1 Me of 2
Me(Aib5)); 25.8 (q, 1 Me of 2 Me(Aib4)); 23.8 (d, CH(γ)(Leu)); 23.5 (q, 1 Me of 2 Me(Aib5));
23.4 (q, 1 Me of 2 Me(Aib4)); 23.0, 21.0 (2q, 2 Me(Leu)); 19.2, 18.5 (2q, 2 Me(Val)); 17.3 (q,
Me(Ala)). ESI-MS: 619 (100, [M + H]+), 488 (21, [M – Leu]+), 403 (10, [M – (Aib–Leu)]+).
(S)-2-({2-[(2-{[2-({(S)-2-[((S)-2-{[(S)-2-Amino-1-oxopropyl]amino}-3-methyl-1-oxobut-
yl)amino]-3-phenyl-1-oxopropyl}amino)-2-methyl-1-oxopropyl]amino}-2-methyl-1-oxoprop-
yl)amino]-2-methyl-1-oxomethyl}amino)-4-methylpentanoic Acid (H-Ala-Val-Phe-Aib-Aib-
Aib-Leu-OH; 24). PAM resin (200 mg, 0.124 mmol) was treated as described in GP 1, 2, 5, 2,
5, 2, 3, 4, 3, 4, 3, 4, 5 and 6 to yield 24 (8.6 mg, 9%) as a colorless powder after prep. HPLC
purification and lyophilization. HPLC-MS (method B): tR = 11.1 min, m/z = 704 (100, [M +
H]+). IR (KBr): 3422s, 3307s, 3065s, 3033s, 2964s, 2941s, 2875m, 1667vs, 1532vs, 1468m,
1458m, 1442m, 1387m, 1366m, 1276m, 1203vs, 1188s, 1140s, 945w, 923w, 837w, 800w,
722w, 700w. 1H-NMR ((D6)DMSO, 600 MHz): ca. 12.3–12.1 (br. s, COOH); 8.44 (s,
NH(Aib4)); 8.42 (d, J = 4.9, NH(Phe)); 8.26 (d, J = 8.6, NH(Val)); 8.04 (br. s, NH3(Ala));
7.53, 7.41 (2s, NH(Aib5), NH(Aib6)); 7.40 (d, J = 7.9, NH(Leu)); 7.28–7.20 (m, 5 arom. H);
4.41 (td, J = 7.6, 5.1, CH(α)(Phe)); 4.20 (dd, J =8.1, 8.1, CH(α)(Val)); 4.18–4.14 (m,
CH(α)(Leu)); 3.91 (br. s, CH(α)(Ala)); 2.96–2.89 (m, CH2(Phe)); 1.93 (dsept., J = 7.0, 7.0,
CH(β)(Val)); 1.78–1.75 (m, CH(γ)(Leu)); 1.73–1.69, 1.44–1.39 (2m, CH2(Leu)); 1.34, 1.33,
1.30, 1.26 (4s, 4 Me of 6 Me(Aib)); 1.26 (d, J = 6.5, Me(Ala)); 1.20, 1.14 (2s, 2 Me of 6
Me(Aib)); 0.94, 0.88 (2d, J = 6.8, 2 Me(Val)); 0.83, 0.81 (2d, J = 6.6, 2 Me(Leu)). 13C-NMR
((D6)DMSO, 150 MHz): 174.3, 174.1 (2s, 2 CO of 3 CO(Aib)); 174.0 (s, CO(Leu)); 173.0 (s,
1 CO of 3 CO(Aib)); 171.7 (s, CO(Phe)); 170.8 (s, CO(Val)); 169.2 (s, CO(Ala)); 136.8 (s,
arom. C); 129.2, 127.9, 126.3 (3d, 5 arom. CH); 57.6 (d, CH(α)(Val)); 56.1, 55.8, 55.7 (3s, 3
C(α)(Aib)); 54.5 (d, CH(α)(Phe)); 50.2 (d, CH(α)(Leu)); 47.8 (d, CH(α)(Ala)); 39.8 (t,
CH2(Leu)); 36.7 (t, CH2(Phe)); 30.3 (d, CH(β)(Val)); 26.7, 26.1, 25.9 (3q, 3 Me of 6
Me(Aib)); 23.6 (d, CH(γ)(Leu)); 23.4, 23.2 (2q, 2 Me of 6 Me(Aib)); 23.0 (q, 1 Me of 2
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Me(Leu)); 22.9 (q, 1 Me of 6 Me(Aib)); 21.0 (q, 1 Me of 2 Me(Leu)); 19.2, 18.5 (2q, 2
Me(Val)); 17.3 (q, Me(Ala)). ESI-MS: 704 (100, [M + H]+), 573 (21, [M – Leu]+).
5. Derivatization of ( S ,S ,S ) - 1 3  a n d  (S,R,S ) - 1 3 . (S)-2-{[(S)-2-({(S)-2-[4-
(Bromobenzoyl)amino]-1-oxopropyl}amino)-2-benzyl-1-oxopropyl]amino}-4-methylpentanoic
Acid (p-BrBz-Ala-Phe(2Me)-Leu-OH; (S ,S ,S ) - 1 4 ) and (S )-2-{[(R)-2-({(S)-2-[4-
(Bromobenzoyl)amino]-1-oxopropyl}amino)-2-benzyl-1-oxopropyl]amino}-4-methylpentanoic
Acid (p-BrBz-Ala-Phe(2Me)-Leu-OH; (S,R,S)-14). At 0° 4-bromobenzoylchloride (8 mg,
0.036 mmol) was added to a mixture of (S,S,S)-13 (ca. 12 mg, 0.025 mmol) and K2CO3 (12
mg, 0.087 mmol) and (S,R,S)-13 (ca. 12 mg, 0.025 mmol) and K2CO3 (12 mg, 0.087 mmol),
resp., in acetone (5 ml) and H2O (1 ml), then stirred at r.t. for 2 h. The org. solvent was
removed under reduced pressure and the residue acidified with diluted aq. HCl. The resulting
precipitation was filtered and purified by prep. TLC (CH2Cl2/MeOH 10:1; 2 × dev.) yielding
colorless powders (8 mg (59%) and 6 mg (44%), resp.). Suitable crystals for the X-ray
crystal-structure determination of (S,S,S)-14 were grown from MeOH/CHCl3/Et2O. Data of
(S,S,S)-14. ESI-MS: 593 (10), 592 (30, [M(81Br) – H + 2 Na]+), 591 (10), 590 (33, [M(79Br) –
H + 2 Na]+), 571 (42), 570 (100, [M(81Br) + Na]+), 569 (34), 568 (86, [M(79Br) + Na]+).
Data of (S,R,S)-14. ESI-MS: 593 (5), 592 (11, [M(81Br) – H + 2 Na]+), 591 (5), 590 (11,
[M(79Br) – H + 2 Na]+), 571 (29), 570 (100, [M(81Br) + Na]+), 569 (26), 568 (72, [M(79Br) +
Na]+).
6. X-Ray Crystal-Structure Determination of (S,S,S)-14, (see Table 3 and Fig. 1)2). A
crystal of C26H32BrN3O5·MeOH, obtained from MeOH/CHCl3/Et2O, was used for a low-
temperature X-ray structure determination. All measurements were made on a Nonius
KappaCCD area-detector diffractometer [27] using graphite-monochromated MoKα radiation
(λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700 cooler. The data collection and
refinement parameters are given in Table 3 and a view of the molecule is shown in the Fig.
Data reduction was performed with HKL Denzo and Scalepack [28]. The intensities were
corrected for Lorentz and polarization effects, and an absorption correction based on the
multi-scan method [29] was applied. Equivalent reflections, other than Friedel pairs, were
merged.
                                                 
2) CCDC-287054 contains the supplementary crystallographic data for this paper. These
data can be obtained free of charge from the Cambridge Crystallographic Data Center
via http://www.ccdc.cam.ac.uk/data_request/cif.
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The structure was solved by direct methods using SHELXS97 [30], which revealed the
positions of all non-H-atoms. There are two symmetry-independent peptide and two MeOH
molecules in the asymmetric unit. The atomic coordinates were tested carefully for a
relationship from a higher symmetry space group by using the program PLATON [31], but
none could be found. The non-hydrogen atoms were refined anisotropically. The hydroxy H-
atoms of the peptide and MeOH molecules were placed in the positions indicated by a
difference electron density map and their positions were allowed to refine together with
individual isotropic displacement parameters. All remaining H-atoms were placed in
geometrically calculated positions and refined using a riding model where each H-atom was
assigned a fixed isotropic displacement parameter with a value equal to 1.2Ueq of its parent
C-atom (1.5Ueq for the methyl groups). The refinement of the structure was carried out on F2
using full-matrix least-squares procedures, which minimised the function Σw(Fo2 – Fc2)2. A
correction for secondary extinction was not applied. Eleven reflections, whose intensities
were considered to be extreme outliers, were omitted from the final refinement. Refinement of
the absolute structure parameter [32] yielded a value of 0.00(1), which confidently confirms
that the refined model represents the true enantiomorph. Neutral atom scattering factors for
non-H-atoms were taken from [33a], and the scattering factors for H-atoms were taken from
[34]. Anomalous dispersion effects were included in Fc [35]; the values for f ' and f " were
those of [33b]. The values of the mass attenuation coefficients are those of [33c]. All
calculations were performed using the SHELXL97 [36] program.
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Table 3. Crystallographic Data of Compound (S,S,S)-14.
Crystallized from MeOH/CHCl3/Et2O
Empirical formula C27H36BrN3O6
Formula weight [g mol–1] 578.50
Crystal color, habit colorless, plate
Crystal dimensions [mm] 0.03 × 0.15 × 0.22
Temperature [K] 160(1)
Crystal system monoclinic
Space group P21
Z 4
Reflections for cell determination 84590
2θ range for cell determination [°] 4 – 50
Unit cell parameters a [Å] 15.2292(6)
b [Å] 10.1998(4)
c [Å] 18.6076(8)
β [°] 91.810(2)
V [Å3] 2889.0(2)
Dx [g cm–3] 1.330
µ(MoKα) [mm–1] 1.470
Scan type ω
2θ (max) [°] 50
Transmission factors (min; max) 0.737; 0.982
Total reflections measured 43528
Symmetry independent reflections 10174
Reflections with I > 2σ (I) 6247
Reflections used in refinement 10163
Parameters refined; restraints 693; 1
Final R(F)  [I > 2σ (I) reflections] 0.0646
wR(F2)  (all data) 0.1480
Weights:             w = [σ 2(Fo2) + (0.0518P)2 + 1.5382P]-1 where P = (Fo2 + 2Fc2) / 3
Goodness of fit 1.036
Final Δ max /σ 0.001
Δρ (max; min) [e Å–3] 0.49; -0.44
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6. Novel N -(2,2-Dimethyl-2H -azirin-3-yl)-L-prolinates as Aib-Pro
Synthons 1
The syntheses of phenacyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate and allyl N-(2,2-
dimethyl-2H-azirin-3-yl)-L-prolinate are reported. Reactions of these 2H-azirin-3-amines with
Z-protected amino acids have shown them to be suitable synthons for the Aib-Pro unit in
peptide synthesis. After incorporation into the peptide by means of the ‘azirine/oxazolone
method’, the C-termini of the resulting peptides were deprotected selectively with Zn in
AcOH or with a mild Pd0-promoted procedure, respectively.
1. Introduction
Peptides that contain α,α-disubstituted α-amino acids are of interest because the rigidity
of their peptide backbones leads to a stabilization or even a promotion of secondary
structures, such as β-turns or helices [1–4]. Moreover, a group of peptide antibiotics, the
peptaibols, contain a high proportion of α,α-disubstituted α-amino acids, in particular α-
aminoisobutyric acid (Aib) [5]. A valuable and convenient method for the introduction of
these sterically demanding α,α-disubstituted α-amino acids is the ‘azirine/oxazolone method’
[6–8]. Thus, the reaction of 2H-azirin-3-amines 1, which represent the amino acid synthons,
with amino or peptide acids leads to peptide amides, the terminal amide bonds of which can
be hydrolyzed selectively to give the extended peptide acids. This method has been applied
successfully in the introduction of a variety of α,α-disubstituted α-amino acids into peptides,
and it has found application in the synthesis of some peptaibols or segments thereof [9–18].
Recently, we adapted the ‘azirine/oxazolone method’ to solid-phase conditions, in order
to additionally profit from their benefits [19]. Moreover, it was shown that also on solid phase
the method is not limited to the Aib synthon 1a, and it was extended successfully to the 1-
aminocyclopentane-1-carboxylic acid synthon (1b), the 4-amino-3,4,5,6-tetrahydro-2H-
pyran-4-carboxylic acid synthon (1c), and the α-methylphenylalanine synthon (1d) [20].
                                                 
1 S. Stamm, H. Heimgartner, Helv. Chim. Acta, submitted.
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Since the Aib-Pro motif is widespread in peptaibols – in fact, 266 out of the 309 so far
known peptaibol sequences contain the Aib-Pro unit [21] – it was of great interest to
introduce this unit directly. In solution-phase chemistry, the introduction of the Aib-Pro unit
was accomplished with the use of dipeptide synthon 2 [22]. Unexpectedly, its use on solid
phase was not successful due to the incompatibility of the linker and the strong basic media
which is required for the saponification of the methyl ester [23]. In the course of working out
a new strategy for the introduction of the Aib-Pro motif on solid phase, a 2H-azirin-3-amine
with an easily removable carboxy-protecting group was required.
R1 N
N
Ph
1a   R1 = R2 = Me
1b   R1 – R2 = –(CH2)4–
1c   R1 – R2 = –(CH2)2O(CH2)2–
1d   R1 = Me, R2 = PhCH2
N
N
2
O OMe
R2
N
N
O OR
3a   R = PhCOCH2
3b   R = CH2CHCH2
Herein, we present the synthesis, chemical characterization, and briefly, the use in
solution-phase peptide synthesis of the novel Aib-Pro synthons 3a and 3b. After introduction
into the peptide, the carboxy termini of the resulting extended peptides can be deprotected
with Zn in AcOH or with a mild Pd0-promoted procedure, respectively.
2. Results and Discussion.
Since the synthesis of 2H-azirin-3-amines 1 is performed under acidic conditions, the
range of carboxy-protecting groups is limited to those which are base labile, which can be
removed by reduction, or which are labile towards transition metal complexes, but feature a
good stability towards acids. The fluorenylmethyl (Fm) [24][25] and 2-(4-
nitrophenylsulfonyl)ethyl [26] protecting groups, which can be cleaved by treatment with
secondary amines, should fulfill these prerequisites. Hence, we aimed at the synthesis of the
2H-azirin-3-amines 4a and 4b as outlined in Scheme 1. After saponification of methyl
prolinate 5 with LiOH and subsequent carbodiimide induced coupling of acid 6 with the
corresponding alcohols, the obtained amides 7a and 7b were converted to the thioamides 8a
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and 8b, respectively, by thionation with Lawesson reagent. A slightly modified2) procedure
compared to that of Wipf [27] did not lead to the desired 2H-azirin-3-amines 4a and 4b.
Consequently, we headed for 4b via the 2-(4-nitrophenylsulfanyl)ethyl protected 2H-azirin-3-
amine 4c. This route comprises the ‘safety catch principle’ since the activation for the β-
elimination is realized after the azirine synthesis by an oxidation of the sulfanyl group3).
However, the synthesis of 4c failed too.
N
N
O OR
O
N
O
OR
O
N
O
OR
S
N
O
OR
O2S NO2
S NO2
5   R = Me
6   R = H
7a   R = R1 
7b   R = R2
7c   R = R3
8a   R = R1
8b   R = R2
8c   R = R3
R1
R2
R3
b)
c)
d)
a)
4a   R = R1
4b   R = R2
4c   R = R3
Scheme 1. a) LiOH · H2O, THF, MeOH, H2O, r.t.; b) for 7a: 9H-fluoren-9-ylmethanol, DCC,
PPY, CH2Cl2, r.t.; for 7b: 2-(4-nitrophenylsulfonyl)ethanol, EDCI, DMAP, CH2Cl2, r.t.; for
7c: 2-(4-nitrophenylsulfanyl)ethanol, DCC, PPY, CH2Cl2, r.t.; c) Lawesson reagent, MePh,
ca. 90°; d) 1. COCl2, MePh, CH2Cl2, DMF (cat.), 0°; 2. for 4a and 4b: EtN(iPr)2, THF, r.t.; for
4c: DABCO, THF, r.t.; 3. NaN3, THF, (DMF), r.t. For abbreviations see Experimental Part,
General.
                                                 
2) In order to prevent early β-elimination, EtN(iPr)2 was used instead of DABCO.
3) A preliminary test showed that 2 is stable under mild oxidative conditions (TPAP, NMO).
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The phenacyl and allyl ester protecting groups, which can be removed by treatment with
Zn/AcOH [28] and Pd(Ph3P)4/PhSiH3 [29], respectively, were the next promising candidates
for proline protection. The synthesis of the phenacyl and allyl ester protected dipeptide
synthons 3a and 3b started with the preparation of the esters 9a and 9b by alkylation of 6 with
phenacyl bromide and allyl bromide, respectively (Scheme 2). A direct access from L-proline
was accomplished for 9b. For this purpose, L-proline was esterified with allyl alcohol and
then acylated with isobutyryl chloride. After thionation of the amides 9a and 9b  with
Lawesson reagent, the synthesis of 3a and 3b was achieved by consecutive treatment of the
obtained thioamides 10a and 10b and catalytic amounts of DMF in CH2Cl2 with COCl2,
evaporation of the solvent, addition of THF and 1,4-diazabicyclo[2.2.2]octane (DABCO),
filtration, and treatment with NaN3 (cf. [27]). After chromatographic workup, the 2H-azirin-3-
amines 3a and 3b were obtained in 58 and 62% yield, respectively, as pale yellow oils.
N
N
O OR
O
N
O
OH
O
N
O
OR
S
N
O
OR
6 9a   R = PhCOCH2
9b   R = CH2CHCH2
a)
c)
d)
L-Proline
HN
CO2H
b)
10a   R = PhCOCH2
10b   R = CH2CHCH2
3a   R = PhCOCH2
3b   R = CH2CHCH2
Scheme 2. a) for 9a: phenacyl bromide, Et3N, AcOEt, r.t.; for 9b: allyl bromide, aliquat 336,
CH2Cl2, NaHCO3, H2O, 0°→r.t.; b) 1. SOCl2, allyl alcohol, –20°→65°; 2. isobutyryl chloride,
Et3N, AcOEt, 0°→r.t.; c) Lawesson reagent, MePh, ca. 90°; d) 1. COCl2, MePh, CH2Cl2,
DMF (cat.), 0°; 2. DABCO, THF, r.t.; 3. NaN3, THF, r.t. For abbreviations see Experimental
Part, General.
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For a chemical characterization and for the examination of the reactivity of the novel 2H-
azirin-3-amines 3a and 3b, they were treated with thiobenzoic acid (Scheme 3). The reactions
proceeded smoothly and the thiopeptides 11 were obtained in high yield (93 and 94%, resp.).
In the case of 11a, crystals suitable for an X-ray crystal-structure determination were obtained
(Figure). Compound 11a  in the crystal is enantiomerically pure and the absolute
configuration of the molecule has been determined independently by the diffraction
experiment. The molecule has the expected S-configuration. The amide group forms an
intermolecular H-bond with the S-atom of an adjacent molecule and thereby links the
molecules into extended chains, which run parallel to the [0 1 0] direction and can be
described by the graph set motif [30] of C(5).
N
N
O OR
3a   R = PhCOCH2
3b   R = CH2CHCH2
Ph N
H
O
N
S
O OR
11a   R = PhCOCH2
11b   R = CH2CHCH2
PhCOSH, CH2Cl2, r.t.
Scheme 3
Fig. ORTEP Plot [31] of the molecular structure of 11a (50% probability ellipsoids; arbitrary
numbering of atoms).
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In order to examine the use of 3a and 3b in peptide synthesis, reactions with N-protected
amino acids were performed. The Aib-Pro synthon 3a was reacted with Z-Ile-OH and Z-Phe-
OH to give the tripeptides 12a and 13, respectively, while the reaction of 3b with Z-Ile-OH
yielded the tripeptide 12b (Scheme 4). All reactions gave the products in high purity and in
very good yields (90–94%, after chromatographic workup). Then, the selective deprotection
of the C-terminus of 13 was accomplished with Zn-powder in AcOH, and yielded peptide
acid 14. Deprotection of the phenacyl esters with Bu4N+F¯ in DMF [32] would possibly be
transferable to solid-phase conditions, which is the ultimate use of the new azirine. Therefore,
12a and 13 were subjected to Bu4N+F¯ (3 equiv.) in DMF and THF, respectively, but in none
of the experiments a peptide acid 14 or 15, respectively, could be isolated.
N
N
O OR
3a   R = PhCOCH2
3b   R = CH2CHCH2
O
N
O
OR
H
N
O
ZHN
12a   R = PhCOCH2
12b   R = CH2CHCH2
O
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O
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N
O
ZHN
O
N
O
OCH2COPh
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N
O
ZHN
Ph
O
N
O
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H
N
O
ZHN
Ph
13
14
15
Z-Ile-OH, CH2Cl2,
0° → r.t.
Z-Phe-OH, CH2Cl2,
0° → r.t.
Zn, AcOH, r.t.
Pd(Ph3P)4, PhSiH3,
CH2Cl2, r.t.
Scheme 4
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The deprotection of the C-terminus can be performed under milder conditions if synthon
3b is used in the peptide chain extension. This was illustrated with the model peptide 12b, in
which the allyl ester group was smoothly removed by treatment with Pd(Ph3P)4 and PhSiH3 in
CH2Cl2 to give peptide acid 15. Moreover, these deprotecting conditions should be applicable
on solid phase.
3. Conclusions
The novel 2H-azirin-3-amines 3a and 3b, which contain a phenacyl ester and an allyl
ester, respectively, as carboxy-protecting group, have been synthesized. These azirines
represent Aib-Pro synthons, and this dipeptide unit can be introduced conveniently into
peptides by the ‘azirine/oxazolone method’. The C-terminus of the resulting peptide esters
can be deprotected under non-basic conditions, i.e. by treatment with Zn/AcOH and
Pd(Ph3P)4/PhSiH3. The use of 3a and 3b as building blocks for the ‘azirine/oxazolone method’
on solid phase are in progress.
Experimental Part
1. General. – Reagents were obtained from commercial suppliers and were used without
further purification. Solvents were purified by standard procedures. Compound 5 was
prepared according to [22]. TLC: Merck TLC aluminum sheets, silica gel 60 F254. Prep. TLC:
Merck PLC plates (glass), silica gel 60 F254. Column chromatography (CC): Uetikon-Chemie,
silica gel C-560. M.p.: Büchi Melting Point B-450 apparatus, uncorrected. IR Spectra: Perkin-
Elmer, Spectrum One FT-IR spectrophotometer; unless otherwise stated in KBr, absorptions
in cm–1. NMR Spectra: Bruker ARX-300, Bruker AV-600, or Bruker AV-700 instruments; in
CDCl3, δ  in ppm, TMS as internal standard, coupling constants J in Hz. 2D-NMR
experiments were performed for assignment of the signals. In 1H- and 13C-NMR spectra where
two conformers were observed, only the signals of the major conformer are shown. The ratio
of the two conformers is given in parentheses. MS (m/z (rel.%)): Bruker ESQUIRE-LC
quadrupole ion trap instrument. Abbreviations: Aib: α-aminoisobutyric acid; DABCO: 1,4-
diazabicyclo[2.2.2]octane; DCC: N,N’-dicyclohexylcarbodiimid; DMAP: 4-(N,N-dimethyl-
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amino)pyridine; EDCI: N-ethyl-N’-[3-(dimethylamino)propyl]carbodiimide hydrochloride;
PPY: 4-pyrrolidinopyridine.
2. Synthesis of 2H-Azirin-3-amines 3a and 3b. N-(2-Methylpropanoyl)-L-proline (6). A
soln. of methyl N-(2-methylpropanoyl)-L-prolinate (5) (2.000 g, 10.04 mmol) and LiOH . H2O
(0.843 g, 20.11 mmol) in THF/MeOH/H2O (3:1:1; 100 ml) was stirred at r.t. overnight. The
org. solvents were removed under reduced pressure and the residue was washed with Et2O. At
0°, the aq. phase was acidified with 1M HCl and saturated with NaCl. After extraction with
CH2Cl2, the combined org. layers were washed with brine, dried (MgSO4), and concentrated
i.v. to give 6 (1.775 g, 96%). Colorless powder. M.p. 122.6–123.7°. IR: 2969s, 2942s, 2879s,
2771m, 2606m, 1721vs, 1600vs, 1509w, 1478s, 1446vs, 1332m, 1266m, 1254s, 1228vs,
1191s, 1167m, 1154m, 1092s, 1042w, 968w, 914m, 838w, 808w, 752w. 1H-NMR (300 MHz,
conformers (95:5)): 10.9–9.6 (br. s, CO2H); 4.61–4.57 (m, CH(α)(Pro)); 3.66–3.61, 3.58–3.50
(2m, CH2(δ)(Pro)); 2.72 (sept., J = 6.8, Me2CH); 2.44–2.40, 2.10–1.99 (2m, CH2(β)(Pro),
CH2(γ)(Pro)); 1.53, 1.16 (2d, J = 6.8, 2 Me). 13C-NMR (75 MHz): 179.1, 172.8 (2s, 2 CO);
60.0 (d, CH(α)(Pro)); 47.6 (t, CH2(δ)(Pro)); 32.5 (d, Me2CH); 27.4, 24.9 (2t, CH2(β)(Pro),
CH2(γ)(Pro)); 19.0, 18.5 (2q, 2 Me). ESI-MS (MeOH): 208 (100, [M+Na]+). Anal. calc. for
C9H15NO3 (185.22): C 58.36, H 8.16, N 7.56; found: C 58.51, H 8.06, N 7.77.
Phenacyl N-(2-Methylpropanoyl)-L-prolinate (9a). A mixture of 6 (0.801 g, 4.32 mmol),
Et3N (601 µl, 4.32 mmol) and phenacyl bromide (0.860g, 4.32 mmol) in AcOEt (20 ml) was
stirred at r.t. overnight. The mixture was filtered, and the soln. was concentrated i.v. CC
(SiO2, AcOEt/hexane 6:4) yielded 9a (1.280 g, 98%). Colorless oil. IR (film): 3488m, 3391w,
3270w, 3063s, 2974vs, 2935vs, 2876vs, 1755vs, 1701vs, 1644vs, 1598vs, 1582vs, 1470vs,
1449vs, 1426vs, 1376vs, 1364vs, 1318vs, 1279vs, 1230vs, 1173vs, 1092vs, 1043s, 1001vs,
973vs, 953vs, 921m, 886m, 851m, 810s, 753vs, 735vs. 1H-NMR (300 MHz, conformers
(85:15)): 7.90–7.87, 7.63–7.57, 7.52–7.45 (3m, 5 arom. H); 5.55, 5.21 (AB, J = 16.5, CH2CO);
4.68–4.62 (m, CH(α)(Pro)); 3.76–3.67, 3.62–3.54 (2m, CH2(δ)(Pro)); 2.69 (sept., J = 6.8,
Me2CH); 2.42–2.13, 2.10–1.97 (2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.15, 1.14 (2d, J = 6.8, 2
Me). 13C-NMR (75 MHz): 192.2 (s, CO(carbonyl)); 175.9 (s, CO(amide)); 171.8 (s,
CO(ester)); 134.1 (s, arom. C); 133.8, 128.8, 127.6 (3d, 5 arom. CH); 60.0 (t, CH2CO); 58.5
(d, CH(α)(Pro)); 46.7 (t, CH2(δ)(Pro)); 32.2 (d, Me2CH); 29.1, 24.8 (2t, CH2(β)(Pro),
CH2(γ)(Pro)); 18.7, 18.6 (2q, 2 Me). ESI-MS (MeOH, NaI): 326 (100, [M+Na]+). Anal. calc.
for C17H21NO4 (303.35): C 67.31, H 6.98, N 4.62; found: C 67.11, H 6.61, N 4.62.
Allyl N-(2-Methylpropanoyl)-L-prolinate (9b). From 6. A soln. of allyl bromide (22.8 ml,
269.50 mmol) and aliquat 336 (21.6 g) in CH2Cl2 (75 ml) was added to a soln. of 6 (10.004 g,
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54.01 mmol) and NaHCO3 (4.539 g, 54.03 mmol) in H2O (75 ml) at 0°. The mixture was
vigorously stirred at r.t. for 3 d, then H2O (50 ml) was added and the suspension was extracted
with CH2Cl2. The combined org. layers were dried (MgSO4) and concentrated i.v. CC (SiO2,
AcOEt/hexane 4:6 → 1:1) yielded 9b (11.328 g, 93%). Colorless liquid.
From L-Proline. At –20°, SOCl2 (1.70 ml, 23.36 mmol) was added to allyl alcohol (12
ml, 176.45 mmol), then L-proline (2.000 g, 17.37 mmol) was added, and the mixture was
slowly heated to 65° and stirred at 65° for 1 h. The mixture was concentrated i.v., the residue
was dissolved in AcOEt (60 ml), and Et3N (5.05 ml, 36.23 mmol) and isobutyryl chloride
(1.85 ml, 17.52 mmol) were added at 0°. The mixture was stirred at r.t. overnight, H2O (20
ml) was added, and the mixture was extracted with AcOEt. The combined org. layers were
dried (MgSO4) and concentrated i.v. CC (AcOEt/hexane 1:1) yielded 9b (3.164 g, 81%).
Colorless liquid. IR (film): 3568w, 3479w, 3085w, 2973vs, 2935s, 2877s, 1745vs, 1650vs,
1741vs, 1426vs, 1377s, 1362s, 1318vs, 1274s, 1242s, 1177vs, 1091s, 1044m, 990s, 954m,
930s, 882w, 819w, 754m. 1H-NMR (300 MHz, conformers (85:15)): 5.97–5.84 (m, CH2=CH);
5.37–5.20 (m, CH2=CH); 4.68–4.60 (m , CH2O); 4.53–4.48 (m , CH(α)(Pro)); 3.73–3.64,
3.62–3.53 (2m, CH2(δ)(Pro)); 2.68 (sept., J  = 6.8, Me2CH); 2.29–1.90 (m, CH2(β)(Pro),
CH2(γ)(Pro)); 1.16, 1.13 (2d , J = 6.8, 2 Me). 13C-NMR (75 MHz): 176.0 (s, CO(amide));
172.3 (s, CO(ester)); 132.2 (d, CH2=CH); 118.4 (t, CH2=CH); 65.7 (t, CH2O); 58.9 (d,
CH(α)(Pro)); 46.9 (t, CH2(δ)(Pro)); 32.4 (d , Me2C H); 29.3, 25.1 (2t, CH2(β)(Pro),
CH2(γ)(Pro)); 19.0, 18.8 (2q, 2 Me). ESI-MS (MeOH): 298 (13, [M+Na+MeOH+H2O]+), 248
(100, [M+Na]+). Anal. calc. for C12H19NO3 (225.28): C 63.98, H 8.50, N 6.22; found: C 63.71,
H 8.45, N 6.13.
Phenacyl N-(2-Methylpropanthioyl)-L-prolinate (10a). A suspension of Lawesson
reagent (dried i.v., 444 mg, 1.10 mmol) and 9a (600 mg, 1.98 mmol) in toluene (20 ml) was
heated at 90° (oilbath) for 1 h. After cooling to r.t., the mixture was filtered, and the solvent
was evaporated. CC (SiO2, CH2Cl2/MeOH 200:1 →  100:1) yielded 10a (571 mg, 90%).
Colorless solid. M.p. 83.9–84.9°. IR: 2976m, 2946w, 2928w, 2868w, 1749vs, 1701vs, 1596m,
1579w, 1468s, 1445vs, 1419m, 1373m, 1356m, 1345m, 1309w, 1263m, 1255m, 1237v,
1192vs, 1173s, 1156s, 1130m, 1013s, 1000w, 967m, 910w, 815w, 757m, 735w, 690s. 1H-
NMR (600 MHz, conformers (87:13)): 7.90–7.88, 7.65–7.59, 7.52–7.47 (3m, 5 arom. H);
5.54, 5.25 (AB, J = 16.4, CH2CO); 5.27–5.25 (m, CH(α)(Pro)); 3.97–3.93, 3.79–3.75 (2m,
CH2(δ)(Pro)); 3.07 (sept ., J  = 6.6, Me2CH); 2.56–2.50, 2.40–2.31, 2.21–2.14 (3m,
CH2(β)(Pro), CH2(γ)(Pro)); 1.26, 1.23 (2d, J = 6.6, 2 Me). 13C-NMR (150 MHz): 209.9 (s,
CS); 192.2 (s, CO(carbonyl)); 170.0 (s, CO(ester)); 134.1 (s, 1 arom. C); 134.0, 128.9, 127.7
Chapter 6
93
(3d, 5 arom. CH); 66.3 (t, CH2CO); 65.2 (d, CH(α)(Pro)); 50.4 (t, CH2(δ)(Pro)); 38.7 (d,
Me2CH); 29.0, 24.7 (2t, CH2(β)(Pro), CH2(γ)(Pro)); 22.7, 22.4 (2q, 2 Me). ESI-MS (MeOH,
NaI): 342 (100, [M+Na]+). Anal. calc. for C17H21NO3S  (319.42): C 63.92, H 6.63, N 4.39, S
10.04; found: C 64.07, H 6.37, N 4.30, S 10.08.
Allyl N-(2-Methylpropanthioyl)-L-prolinate (10b). A suspension of Lawesson reagent
(dried i.v., 5.584 g, 13.81 mmol) and 9b (5.618 g, 24.94 mmol) in toluene (70 ml) was heated
at 95° (oilbath) for 1 h. After cooling to r.t., the mixture was filtered, and the solvent was
evaporated. CC (SiO2, CH2Cl2/MeOH 400:1 →  100:1) yielded 10b (5.439 g, 90%). Pale
yellow oil. IR (film): 3084w, 2973vs, 2931s, 2878s, 1742vs, 1648w, 1440vs, 1381s, 1360s,
1333vs, 1268vs, 1227vs, 1191vs, 1170vs, 1126s, 1088m, 1046m, 1016vs, 989s, 969s, 930s,
874m, 784w. 1H-NMR (700 MHz, conformers (83:17)): 5.94–5.88 (m, CH2=CH); 5.37–5.23
(m, CH2=CH); 5.13–5.11 (m, CH(α)(Pro)); 4.67–4.60 (m, CH2O); 3.93–3.88, 3.78–3.74 (2m,
CH2(δ)(Pro)); 3.05 (sept., J  = 6.6, Me2CH); 2.30–2.25, 2.23–2.17, 2.14–2.09  (3m ,
CH2(β)(Pro), CH2(γ)(Pro)); 1.25, 1.24 (2d, J = 6.6, 2 Me). 13C-NMR (175 MHz): 209.9 (s,
CS); 170.5 (s, CO); 132.1 (d, CH2=CH); 118.7 (t, CH2=CH); 66.0 (t, CH2O); 65.4 (d,
CH(α)(Pro)); 50.4 (t, CH2(δ)(Pro)); 38.9 (d , Me2C H); 29.0, 24.9 (2t, CH2(β)(Pro),
CH2(γ)(Pro)); 22.9, 22.5 (2q, 2 Me). ESI-MS (MeOH): 264 (100, [M+Na]+). Anal. calc. for
C12H19NO2S (241.35): C 59.72, H 7.93, N 5.80, S 13.29; found: C 59.80, H 7.65, N 5.58, S
13.07.
Phenacyl N-(2,2-Dimethyl-2H-azirin-3-yl)-L-prolinate (3a). A soln. of COCl2 in toluene
(20%, 1.8 ml, 3.47 mmol) was added to a soln. of 10a (1.001 g, 3.13 mmol) and 3 drops of
DMF in CH2Cl2 (10 ml) at 0°, the mixture was stirred for 30 min at 0°, and the volatiles were
removed i.v. THF (15 ml) and DABCO (0.351 g, 3.13 mmol) were added under vigorous
stirring to the residue, and the mixture was stirred at r.t. for 30 min. The solid was removed
by filtration under N2 and washed with THF. To the filtrate, NaN3 (0.617 g, 9.49 mmol) was
added, and the resulting mixture was stirred at r.t. for 4 d. After addition of Et2O, the resulting
suspension was filtered over a Celite pad, and the solvent was removed i.v. CC (SiO2,
AcOEt/hexane 6:4, Et3N (1%)) yielded 3a (0.542 g, 58%). Pale yellow oil. IR (film): 3434w,
3388w, 3063w, 2976s, 2942s, 2879m, 1771vs, 1703vs, 1598m, 1581w, 1450s, 1417m, 1369s,
1345m, 1277s, 1233vs, 1174vs, 1095m, 1001w, 964s, 911w, 846w, 819w, 758m, 690s. 1H-
NMR (300 MHz): 7.91–7.88, 7.65–7.59, 7.52–7.47 (3m, 5 arom. H); 5.47–5.32 (m, CH2CO);
4.50 (br. s, CH(α)(Pro)); 3.74–3.67, 3.62–3.54 (2m, CH2(δ)(Pro)); 2.50–2.04 (m, CH2(β)(Pro),
CH2(γ)(Pro)); 1.35, 1.31 (2s, 2 Me). 13C-NMR (75 MHz): 191.5 (s, CO(carbonyl)); 171.7 (s,
CO(ester)); 165.5 (s, C(3)); 134.1 (d, 1 arom. CH); 134.0 (s, 1 arom. C); 129.0, 127.7 (2d, 4
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arom. CH); 66.4 (t, CH2CO); ca. 60.9 (br. d, CH(α)(Pro)); ca. 46.9 (br. t, CH2(δ)(Pro)); 39.2
(s, C(2)); 30.6 (t, CH2(β)(Pro)); 25.2 (q, 2 Me); 24.0 (t, CH2(γ)(Pro)). ESI-MS (MeOH): 323
(100, [M+Na]+). Anal. calc. for C17H20N2O3  (300.35): C 67.98, H 6.71, N 9.33; found: C
67.73, H 6.53, N 9.35.
Allyl N-(2,2-Dimethyl-2H-azirin-3-yl)-L-prolinate (3b). A soln. of COCl2 in toluene
(20%, 2.6 ml, 5.02 mmol) was added to a soln. of 10b (1.008 g, 4.14 mmol) and 3 drops of
DMF in CH2Cl2 (10 ml) at 0°, the mixture was stirred for 30 min at 0°, and the volatiles were
removed i.v. The residue was dissolved in THF (15 ml), DABCO (0.465 g, 4.15 mmol) was
added, and the mixture was stirred at r.t. for 30 min. The solid was removed by filtration
under N2 and washed with THF. To the filtrate, NaN3 (0.810 g, 12.46 mmol) was added, and
the resulting mixture was stirred at r.t. for 4 d. After addition of Et2O, the resulting suspension
was filtered over a Celite pad, and the solvent was removed i.v. CC (SiO2, AcOEt/hexane 6:4,
Et3N (1%)) yielded 3b (0.575 g, 63%). Pale yellow oil. IR (film): 3458w, 3087w, 2976s,
2943s, 2879s, 1770vs, 1745vs, 1649w, 1454s, 1413m, 1368s, 1352m, 1272s, 1235s, 1177vs,
1093m, 1043w, 1015m , 987s, 933m . 1H-NMR (300 MHz): 5.97–5.84 (m , CH2=CH);
5.36–5.24 (m, CH2=CH); 4.67–4.61 (m, CH2O); 4.35–4.34 (m, CH(α)(Pro)); 3.70–3.52 (m,
CH2(δ)(Pro)); 2.39–1.99 (m, CH2(β)(Pro), CH2(γ)(Pro)); 1.32, 1.29 (2s, 2 Me). 13C-NMR (75
MHz): 171.6 (s, CO); 165.2 (s, C(3)); 131.4 (d, CH2=CH); 118.8 (t, CH2=CH); 65.8 (t,
CH2O); ca. 60.8 (br. d, CH2(δ)(Pro)); ca. 46.9 (br. t, CH2(δ)(Pro)); 39.0 (s, C(2)); 30.2 (t,
CH2(β )(Pro)); 25.0 (q , 2 Me); 23.9 (t, CH2(γ)(Pro)). ESI-MS (MeOH): 255 (23,
[M+H+MeOH]+), 245 (100, [M+Na]+), 223 (29, [M +H]+), 196 (25). Anal. calc. for
C12H18N2O2⋅0.2 H2O (225.88): C 63.81, H 8.21, N 12.40; found: C 63.85, H 8.12, N 12.32.
3. Reactions of 2H -Azirin-3-amines 3a  and  3 b  with PhCOSH. Phenacyl N-[2-
(Benzoylamino)-2-methyl-1-thioxopropyl]-L-prolinate (11a). A soln. of PhCOSH (20 mg,
0.145 mmol) in CH2Cl2 (2 ml) was added to a soln. of 3a (40 mg, 0.133 mmol) in CH2Cl2 (2.5
ml) at 0°. The mixture was stirred at r.t. overnight, the solvent was evaporated, and the crude
product was purified by prep. TLC (CH2Cl2/MeOH 50:1, 2 × dev.; CH2Cl2/MeOH 30:1, 1 ×
dev.) to give 11a (54 mg, 93%). Colorless crystals. M.p. 189.1–190.2°. IR: 3361m, 3301m,
3059w, 2984m, 2932m, 2881w, 1749vs, 1702vs, 1642vs, 1598s, 1579s, 1524vs, 1486s,
1449vs, 1419vs, 1385s, 1362s, 1341m, 1301s, 1288s, 1264s, 1226vs, 1186vs, 1160vs, 1092m,
1074m, 1043s, 1028m, 1001m, 965s, 911w, 884w, 803w, 754s, 720s, 690vs. 1H-NMR (600
MHz): 8.51 (s, NH); 7.90–7.86, 7.63–7.60, 7.51–7.48, 7.45–7.43 (4m, 10 arom. H); 5.53, 5.27
(AB, J = 16.4, CH2CO); 5.38–5.36 (m, CH(α)(Pro)); 4.12–4.08, 3.96–3.92 (2m, CH2(δ)(Pro));
2.51–2.48, 2.39–2.31, 2.14–2.10 (3m, CH2(β)(Pro), CH2(γ)(Pro)); 1.95, 1.89 (2s, 2 Me). 13C-
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NMR (150 MHz): 205.9 (s, CS); 192.1 (s, CO(carbonyl)); 169.8 (s, CO(ester)); 164.9 (s,
CO(amide)); 135.0 (s, 1 arom. C); 134.0 (d, 1 arom. CH); 134.0 (s, 1 arom. C); 131.4, 128.9,
128.5, 127.7, 127.0 (5d, 9 arom. CH); 69.1 (d, CH(α)(Pro)); 66.3 (t, CH2CO); 61.2 (s,
C(α)(Aib)); 53.6 (t, CH2(δ)(Pro)); 28.0 (t, CH2(β)(Pro)); 26.0 (t, CH2(γ)(Pro)); 25.8, 24.9 (2q,
2 Me). ESI-MS (MeOH): 461 (100, [M+Na]+). Anal. calc. for C24H26N2O4S  (438.54): C
65.73, H 5.98, N 6.39, S 7.31; found: C 65.33, H 5.72, N 6.24, S 7.02. Suitable crystals for
the X-ray crystal-structure determination were grown from CDCl3/Et2O.
Allyl N-[2-(Benzoylamino)-2-methyl-1-thioxopropyl]-L-prolinate (1 1 b ). A soln. of
PhCOSH (27 mg, 0.195 mmol) in CH2Cl2 (3 ml) was added to a soln. of 3b (40 mg, 0.180
mmol) in CH2Cl2 (2 ml) at 0°. The mixture was stirred at r.t. overnight, the solvent was
evaporated, and the crude product was purified by prep. TLC (CH2Cl2/MeOH 40:1, Et3N
(0.5%), 2 × dev.) to give 11b (61 mg, 94%). Colorless powder. M.p. 46.5–48.0°. IR: 3303m,
3059w, 2984m, 2925s, 2880m, 2853m, 1741vs, 1639vs, 1602m, 1578m, 1530vs, 1488s,
1461s, 1419vs, 1385s, 1362s, 1340m, 1301s, 1292s, 1271s, 1245m, 1187vs, 1160vs, 1086w,
1075w, 1046s, 1028w, 988m, 969m, 931m, 885w, 803w, 717s, 694m. 1H-NMR (300 MHz):
8.66 (br. s, NH); 7.89–7.85, 7.52–7.40 (2m, 5 arom. H); 5.99–5.86 (m, CH2=CH); 5.39–5.20
(m, CH2=CH, CH(α)(Pro)); 4.65–4.63 (m, CH2O); 4.08–3.91 (m, CH2(δ)(Pro)); 2.34–2.15,
2.10–2.00 (2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.95, 1.89 (2s, 2 Me). 13C-NMR (75 MHz): 205.8
(s, CS); 170.0, 164.7 (2s, 2 CO); 135.1 (s, 1 arom. C); 131.7, 131.2, 128.4, 126.9 (4d, 5 arom.
CH, CH2=CH); 118.6 (t, CH2=CH); 68.9 (d, CH(α)(Pro)); 65.8 (t, CH2O); 61.0 (s, C(α)(Aib));
53.4 (t, CH2(δ)(Pro)); 27.8 (t, CH2(β)(Pro)); 25.8 (t, CH2(γ)(Pro)); 25.5, 24.7 (2q, 2 Me(Aib)).
ESI-MS (MeOH): 383 (100, [M+Na]+), 367 (17, [M(S→O)+Na]+). Anal. calc. for
C19H24N2O3S (360.47): C 63.31, H 6.71, N 7.77, S 8.90; found: C 63.25, H 6.45, N 7.68, S
8.67.
4. Synthesis of Model Peptides. Phenacyl N-{2-[(2(S),3(S)-2-{[(Benzyloxy)carbon-
yl]amino}-3-methyl-1-oxopentyl)amino]-2-methyl-1-oxopropyl}-L-prolinate (12a). A soln. of
3a (65 mg, 0.216 mmol) in CH2Cl2 (2.5 ml) was added to a soln. of Z-Ile-OH (57 mg, 0.215
mmol) in CH2Cl2 (2.5 ml) at 0°. The mixture was stirred at r.t. overnight, the solvent was
evaporated, and the crude product was purified by CC (SiO2, CH2Cl2/MeOH 60:1) to give 12a
(105 mg, 86%). Colorless solid. M.p. 70.1–71.5°. IR: 3318s, 3064w, 3034w, 2966s, 2936m,
2877m, 1753vs, 1702vs, 1660vs, 1633vs, 1599m, 1531vs, 1468s, 1451s, 1409vs, 1378s,
1363s, 1286s, 1230vs, 1167vs, 1096m, 1042m, 1028m, 1001w, 977m, 754s, 693s. 1H-NMR
(600 MHz): 7.89–7.88, 7.62–7.59, 7.50–7.47, 7.37–7.31 (4m, 10 arom. H); 6.97 (s, NH(Aib));
5.57, 5.21 (AB, J = 16.4, CH2CO); 5.41 (d, J = 8.8, NH(Ile)); 5.12, 5.08 (AB, J = 12.3,
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CH2(carbamate)); 4.72–4.69 (m , CH(α)(Pro)); 4.00–3.97 (m , CH(α )(Ile)); 3.77–3.73,
3.57–3.54 (2m, CH2(δ)(Pro)); 2.32–2.30 (m, 1 H of CH2(β)(Pro)); 2.19–2.10 (m, 1 H of
CH2(β)(Pro), 1 H of CH2(γ)(Pro)); 1.90–1.88 (m , 1 H of CH2(γ)(Pro)); 1.83–1.82 (m,
CH(β)(Ile)); 1.65, 1.61 (2s, 2 Me(Aib)); 1.53–1.48, 1.16–1.11 (2m, CH2(γ)(Ile)); 0.92 (d, J =
6.8, MeCH(β)(Ile)); 0.89 (t , J  = 7.4, MeCH2(γ)(Ile)). 13C-NMR (150 MHz): 192.2 (s,
CO(carbonyl)); 172.2 (s, CO(Aib)); 171.8 (s, CO(Pro)); 169.6 (s, CO(Ile)); 156.2 (s,
CO(carbamate)); 136.3, 134.1 (2s, 2 arom. C); 134.0, 128.9, 128.5, 128.2, 128.0, 127.7 (6d,
10 arom. CH); 66.9 (t, PhCH2); 66.2 (t, CH2CO); 60.9 (d, CH(α)(Pro)); 59.7 (d, CH(α)(Ile));
57.1 (s, C(α)(Aib)); 48.2 (t, CH2(δ)(Pro)); 37.8 (d, CH(β)(Ile)); 27.9 (t, CH2(β)(Pro)); 25.8 (t,
CH2(γ)(Pro)); 24.9 (t, CH2(γ)(Ile)); 23.6, 23.2 (2q, 2 Me(Aib)); 15.4 (q, MeCH(β)(Ile)); 11.4
(q, MeCH2(γ)(Ile)). ESI-MS (MeOH): 588 (100, [M+Na]+). Anal. calc. for C31H39N3O7
(565.66): C 65.82, H 6.95, N 7.43; found: C 65.53, H 7.06, N 7.27.
Allyl N-{2-[(2(S),3(S)-2-{[(Benzyloxy)carbonyl]amino}-3-methyl-1-oxopentyl)amino]-2-
methyl-1-oxopropyl}-L-prolinate (12b). A soln. of 3b (60 mg, 0.270 mmol) in CH2Cl2 (3 ml)
was added to a soln. of Z-Ile-OH (79 mg, 0.297 mmol) in CH2Cl2 (2 ml) at 0°. The mixture
was stirred at r.t. overnight, the solvent was evaporated, and the crude product was purified by
CC (SiO2, CH2Cl2/MeOH 20:1) to give 12b (123 mg, 93%). Colorless powder. M.p.
135.0–136.1°. IR: 3287s, 3256s, 3065m, 2964s, 2937m, 2876w, 1751vs, 1715vs, 1666vs,
1619vs, 1547vs, 1497m, 1453s, 1419s, 1383s, 1366m, 1355m, 1285s, 1272s, 1243vs, 1208m,
1174vs, 1162vs, 1126m, 1095w, 1047m, 1028m, 987m, 949w, 923w, 877w, 853w, 778w,
751w, 738m, 700m. 1H-NMR (600 MHz): 7.37–7.29 (m, 5 arom. H); 6.97 (br. s, NH(Aib));
5.94–5.87 (m, CH2=CH); 5.40 (d, J = 8.5, NH(Ile)); 5.35–5.31, 5.25–5.23 (2m, CH2=CH);
5.11, 5.08 (AB, J = 12.3, CH2(carbamate)); 4.66–4.58 (m, CH2O); 4.58–4.55 (m, CH(α)(Pro));
4.00–3.97 (m, CH(α)(Ile)); 3.72–3.69, 3.58–3.55 (2m, CH2(δ)(Pro)); 2.11–2.07 (m , 1 H of
CH2(β)(Pro)); 2.04–1.97 (m, 1 H of CH2(γ)(Pro)); 1.91–1.82 (m, 1 H of CH2(β)(Pro), 1 H of
CH2(γ)(Pro), CH(β)(Ile)); 1.65, 1.62 (2s, 2 Me(Aib)); 1.53–1.49, 1.16–1.10 (2m, CH2(γ)(Ile));
0.92 (d, J = 7.0, MeCH(β)(Ile)); 0.90 (t, J = 7.4, MeCH2(γ)(Ile)). 13C-NMR (150 MHz): 172.0
(s, CO(Aib)); 172.0 (s, CO(Pro)); 169.6 (s, CO(Ile)); 156.2 (s, CO(carbamate)); 136.4 (s, 1
arom. C); 131.9 (d, CH2=CH); 128.5, 128.2, 128.0 (3d, 5 arom. CH); 118.5 (t, CH2=CH); 66.9
(t, CH2(carbamate)); 65.7 (t, CH2O); 61.0 (d, CH(α)(Pro)); 59.7 (d, CH(α)(Ile)); 57.1 (s,
C(α)(Aib)); 48.1 (t, CH2(δ)(Pro)); 37.8 (d, CH(β)(Ile)); 27.8 (t, CH2(β)(Pro)); 25.8 (t,
CH2(γ)(Pro)); 24.9 (t, CH2(γ)(Ile)); 23.5, 23.1 (2q, 2 Me(Aib)); 15.4 (q, MeCH(β)(Ile)); 11.4
(q, MeCH2(γ)(Ile)). ESI-MS (MeOH): 510 (100, [M+Na]+). Anal. calc. for C26H37N3O6
(487.59): C 64.05, H 7.65, N 8.62; found: C 63.89, H 7.40, N 8.58.
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Phenacyl N-{2-[((S)-2-{[(Benzyloxy)carbonyl]amino}-3-phenyl-1-oxopropyl)amino]-2-
methyl-1-oxopropyl}-L-prolinate (13). A soln. of 3a (120 mg, 0.380 mmol) in CH2Cl2 (3 ml)
was added to a soln. of Z-Phe-OH (120 mg, 0.401 mmol) in CH2Cl2 (3 ml) at 0°. The mixture
was stirred at r.t. overnight, the solvent was evaporated, and the crude product was purified by
CC (SiO2, CH2Cl2/MeOH 80:1 → 60:1) to give 13 (213 mg, 94%). Colorless powder. M.p.
76.7–78.4°. IR: 3311s, 3062m, 3031w, 2983m, 2940m, 2880w, 1752vs, 1703vs, 1670vs,
1625vs, 1532vs, 1498s, 1469s, 1451s, 1412vs, 1377s, 1364s, 1341m, 1286s, 1232vs, 1166vs,
1097w, 1084w, 1052m, 1028m, 1001w, 977m, 913w, 848w, 752s, 698s. 1H-NMR (600 MHz):
7.88–7.87, 7.61–7.59, 7.49–7.46, 7.37–7.20 (4m, 15 arom. H); 6.57 (s, NH(Aib)); 5.55, 5.18
(A B , J  = 16.5, CH2CO); 5.39 (d , J  = 7.2, NH(Phe)); 5.10, 5.08 (A B , J  = 12.0,
CH2(carbamate)); 4.68–4.66 (m , CH(α)(Pro)); 4.38–4.37 (m , CH(α)(Phe)); 3.66–3.59,
3.46–3.42 (2m, CH2(δ)(Pro)); 3.11–3.08, 3.03–3.00 (2m, CH2(Phe)); 2.32–2.26, 2.19–2.13
(2m, CH2(β)(Pro)); 2.10–2.06, 1.92–1.84 (2m, CH2(γ)(Pro)); 1.50, 1.42 (2s, 2 Me(Aib)). 13C-
NMR (150 MHz): 192.2 (s, CO(carbonyl)); 171.8 (s, CO(Aib), CO(Pro)); 169.1 (s, CO(Phe));
155.9 (s, CO(carbamate)); 136.3, 136.2, 134.1 (3s, 3 arom. C); 134.0, 129.5, 128.9, 128.7,
128.6, 128.2, 128.0, 127.7, 127.1 (9d, 15 arom. CH); 67.0 (t, CH2(carbamate)); 66.1 (t,
CH2CO); 60.8 (d , CH(α )(Pro)); 56.9 (s, C(α)(Aib)); 56.4 (d, CH(α)(Phe)); 48.1 (t,
CH2(δ)(Pro)); 38.7 (t, CH2(Phe)); 27.8 (t, CH2(β)(Pro)); 25.8 (t, CH2(γ)(Pro)); 23.7, 23.4 (2q,
2 Me(Aib)). ESI-MS (MeOH): 622 (100, [M+Na]+). Anal. calc. for C34H37N3O7 (599.67): C
68.10, H 6.22, N 7.01; found: C 68.13, H 6.27, N 6.90.
N-{2-[((S)-2-{[(Benzyloxy)carbonyl]amino}-3-phenyl-1-oxopropyl)amino]-2-methyl-1-
oxopropyl}-L-proline (14). Zn-powder (274 mg, 4.190 mmol) was added to a soln. of 13 (50
mg, 0.083 mmol) in AcOH (100%, 2 ml) and the mixture was stirred at r.t. for 45 min.
Additional Zn-powder (136 mg, 2.080 mmol) and AcOH (100%, 0.5 ml) were added and the
mixture was stirred for further 45 min. The mixture was filtered, the residue washed with
AcOH, and the filtrate was concentrated under reduced pressure. Prep. TLC (CH2Cl2/MeOH
10:1, 2 × dev.) yielded 14 (30 mg, 75%). Colorless powder. M.p. 94.4–96.3°. IR: 3305vs,
3063s, 3032s, 2984s, 2945s, 2879m, 1720vs, 1666vs, 1620vs, 1537vs, 1498vs, 1469s, 1454vs,
1419vs, 1383s, 1366s, 1341s, 1294sh, 1245vs, 1217s, 1178s, 1152s, 1084w, 1053s, 1028m,
912w, 744s, 699vs. 1H-NMR (600 MHz): 7.37–7.21 (m, 10 arom. H); 6.58 (br. s, NH(Aib));
5.43 (br. s, NH(Phe)); 5.12, 5.07 (AB, J = 12.1, CH2(carbamate)); 4.57–4.54 (m, CH(α)(Pro));
4.41 (q-like, J ≈ 7.4, CH(α)(Phe)); 3.39–3.35 (m , 1 H of CH2(δ)(Pro)); 3.07–3.05 (m,
CH2(Phe)); 2.96–2.94 (m, 1 H of CH2(δ)(Pro)); 2.09–1.95 (m, CH2(β)(Pro)); 1.78–1.68 (m,
CH2(γ)(Pro)); 1.37 (s, 2 Me(Aib)); COOH could not be detected. 13C-NMR (150 MHz): 173.0
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(s, CO(Pro)); 172.7 (s, CO(Aib)); 170.4 (s, CO(Phe)); 156.3 (s, CO(carbamate)); 136.0, 135.9
(2s, 2 arom. C); 129.5, 128.8, 128.6, 128.4, 128.1, 127.2 (6d, 10 arom. CH); 67.4 (t,
CH2(carbamate)); 61.6 (d, CH(α)(Pro)); 56.9 (s, C(α)(Aib)); 56.1 (d, CH(α)(Phe)); 48.2 (t,
CH2(δ)(Pro)); 37.4 (t, CH2(Phe)); 27.3 (t, CH2(β)(Pro)); 25.9 (t, CH2(γ)(Pro)); 24.8, 24.3 (2q,
2 Me(Aib)). ESI-MS (MeOH): 504 (100, [M+Na]+). Anal. calc. for C26H31N3O6⋅H2O (499.56):
C 62.51, H 6.66, N 8.41; found: C 62.80, H 6.47, N 8.27.
N-{2-[(2(S),3(S)-2-{[(Benzyloxy)carbonyl]amino}-3-methyl-1-oxopentyl)amino]-2-meth-
yl-1-oxopropyl}-L-proline (15). A soln. of Pd(Ph3P)4 (ca. 4 mg, ca. 0.004 mmol) and PhSiH3
(70 µl, 0.567 mmol) in CH2Cl2 (1 ml) was added to a soln. of 12b (70 mg, 0.144 mmol) in
CH2Cl2 (1 ml) and the mixture was stirred at r.t. under Ar and exclusion of light for 50 min.
The mixture was concentrated i.v. and purified by prep. TLC (CH2Cl2/MeOH 10:1, 3 × dev.)
to give 15 (54 mg, 84%). Colorless powder. M.p. 101.5–103.2°. IR: 3426s, 3306vs, 3063s,
3035s, 2966vs, 2936s, 2878s, 1705vs, 1659vs, 1622vs, 1535vs, 1469s, 1454vs, 1416vs,
1384s, 1365s, 1342s, 1309s, 1288s, 1245vs, 1178s, 1128m, 1094m, 1042s, 1028m, 983w,
914w, 882w, 778w, 739m, 698s. 1H-NMR (600 MHz): 7.34–7.31 (m, 5 arom. H); 7.10 (br. s,
NH(Aib)); 5.69 (br. s, NH(Ile)); 5.11, 5.07 (AB , J = 11.8, CH2(carbamate)); 4.55 (br. s,
CH(α)(Pro)); 3.97 (br. s, CH(α)(Ile)); 3.49 (br. s, CH2(δ)(Pro)); 2.08–1.83 (m, CH2(β)(Pro), 1
H of CH2(γ)(Pro), CH(β)(Ile)); 1.75–1.67 (m, 1 H of CH2(γ)(Pro)); 1.53, 1.51 (2s, 2 Me(Aib));
ca. 1.50, 1.67–1.09 (2m, CH2(γ)(Ile)); 0.92 (d , J  = 7.1, MeCH(β)(Ile)); 0.88 (t, J  = 7.1,
MeCH2(γ)(Ile)); COOH could not be detected. 13C-NMR (150 MHz): 173.9, 173.0, 171.1 (3s,
3 CO); 156.6 (s, CO(carbamate)); 136.2 (s, 1 arom. C); 128.6, 128.3, 128.0 (3d, 5 arom. CH);
67.1 (t, CH2(carbamate)); 61.7 (d, CH(α)(Pro)); 59.8 (d, CH(α)(Ile)); 57.0 (s, C(α)(Aib));
48.2 (t, CH2(δ)(Pro)); 36.8 (d, CH(β)(Ile)); 27.4 (t, CH2(β)(Pro)); 25.9 (t, CH2(γ)(Pro)); 24.8
(t, CH2(γ)(Ile)); 24.5, 24.4 (2q, 2 Me(Aib)); 15.5 (q, MeCH(β)(Ile)); 11.2 (q, MeCH2(γ)(Ile)).
ESI-MS (MeOH): 486 (19, [M+K]+), 470 (100, [M+Na]+), 305 (57, [M–Pro–CO]+). Anal.
calc. for C23H33N3O6⋅H2O (465.54): C 59.34, H 7.58, N 9.03; found: C 59.46, H 7.41, N 8.69.
5. Synthesis of Thioamides 8a–c. (9H-Fluoren-9-yl)methyl N-(2-Methylpropanoyl)-L-
prolinate (7a). At 0°, DCC (1.227 g, 5.95 mmol) was added to a soln. of 6 (1.000 g, 5.40
mmol), 9H-fluoren-9-ylmethanol (1.166 g, 5.94 mmol) and PPY (42 mg, 0.283 mmol) in
CH2Cl2 (50 ml). After stirring at r.t. for 4 h, the mixture was filtered, and the solvent was
evaporated. CC (SiO2, AcOEt/hexane: 4:6 →  6:4) yielded 7a (1.786 g, 91%). Colorless
powder. M.p. 104.4–107.3°. IR: 2971m, 2951m, 2932m, 2892w, 2873m, 1750vs, 1707w,
1629vs, 1536w, 1471s, 1446s, 1432vs, 1381m, 1329s, 1320m, 1270m, 1196s, 1167vs, 1088m,
1035m, 1024w, 1003w, 955w, 945w, 903w, 752s, 741s. 1H-NMR (300 MHz, conformers
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(86:14)): 7.78–7.73, 7.64–7.54, 7.42–7.27 (3m, 8 arom. H); 4.64–4.59 (m, CH(α)(Pro));
4.53–4.43 (m, CH2(Fm)); 4.21 (t, J = 6.3, CH(Fm)); 3.52–3.46 (m, CH2(δ)(Pro)); 2.60 (sept., J
= 6.8, Me2CH); 2.11–2.01, 1.91–1.65 (2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.10, 1.06 (2d, J = 6.8,
2 Me). 13C-NMR (75 MHz): 175.9, 172.4 (2s, 2 CO); 144.1, 143.7, 141.4, 141.4 (4s, 4 arom.
C); 127.8, 127.2, 125.1, 125.0, 119.9 (5d, 8 arom. CH); 66.2 (t, CH2(Fm)); 58.8 (d,
CH(α)(Pro)); 47.1 (d, CH(Fm)); 46.7 (t, CH2(δ)(Pro)); 32.3 (d, Me2CH); 29.0, 24.7 (2t,
CH2(β)(Pro), CH2(γ)(Pro)); 18.8, 18.7 (2q , 2 Me). ESI-MS (MeOH): 414 (19,
[M+H+H2O+MeOH]+), 386 (100, [M+Na]+).
2-[(4-Nitrophenyl)sulfonyl]ethyl N-(2-Methylpropanoyl)-L-prolinate (7b). A soln. of 2-
(4-nitrophenylsulfonyl)ethanol (433 mg, 1.873 mmol), EDCI (474 mg, 2.473 mmol), DMAP
(24 mg, 0.196 mmol) and 6 (381 mg, 2.057 mmol) in CH2Cl2 (30 ml) was stirred under N2 at
r.t. for 1 d. Aq. AcOH (5%, ca. 40 ml) was added, and the mixture was extracted with CH2Cl2.
The combined org. layers were dried (Na2SO4) and concentrated i.v. CC (SiO2, CH2Cl2/MeOH
50:1) yielded 7b (683 mg, 92%). Colorless powder. M.p. 89.8–91.9°. IR: 3463w, 3119w,
2975s, 2931m, 2879w, 1740vs, 1642vs, 1608m, 1530vs, 1467m, 1428vs, 1391m, 1351vs,
1330vs, 1312vs, 1302vs, 1270w, 1248m, 1210m, 1179vs, 1146vs, 1104m, 1089s, 1046w,
1010m, 994w, 919w, 857m, 840w, 805w, 757s, 739s, 703s. 1H-NMR (300 MHz, conformers
(96:4)): 8.44–8.40, 8.20–8.15 (2m, 4 arom. H); 4.51–4.46 (m, CH2CH2O); 4.16–4.12 (m,
CH(α)(Pro)); 3.67–3.49 (m, CH2CH2O, CH2(δ)(Pro)); 2.64 (sept., J = 6.8, Me2CH); 2.11–1.86
(m, CH2(β)(Pro), CH2(γ)(Pro)); 1.12, 1.10 (2d, J = 6.8, 2 Me). 13C-NMR (75 MHz): 176.0 (s,
CO(amide)); 171.8 (s, CO(ester)); 151.0, 144.8 (2s, 2 arom. C); 129.9, 124.6 (2d, 4 arom.
CH); 58.5 (d, CH(α)(Pro)); 57.5 (t, CH2CH2O); 55.1 (t, CH2CH2O); 46.8 (t, CH(δ)(Pro)); 32.2
(d, Me2CH); 28.8, 25.0 (2t, CH2(β)(Pro), CH2(γ)(Pro)); 18.8, 18.7 (2q, 2 Me). ESI-MS
(MeOH, NaI): 421 (100, [M+Na]+).
2-[(4-Nitrophenyl)sulfanyl]ethyl N-(2-Methylpropanoyl)-L-prolinate (7c). At 0°, DCC
(513 mg, 2.486 mmol) was added to a soln. of 6  (420 mg, 2.268 mmol), 2-(4-
nitrophenylsulfanyl)ethanol (470 mg, 2.359 mmol) and PPY (38 mg, 0.256 mmol) in CH2Cl2
(20 ml). After stirring at r.t. for 5.5 h, the mixture was filtered, and the solvent was
evaporated. CC (SiO2, AcOEt/hexane: 6:4) yielded 7c (807 mg, 97%). Yellow oil. IR (film):
3469w, 3327w, 3100m, 3069w, 2972vs, 2933vs, 2876s, 1745vs, 1643vs, 1594vs, 1578vs,
1512vs, 1471vs, 1427vs, 1381vs, 1338vs, 1322sh, 1274vs, 1243s, 1171vs, 1090vs, 1046s,
1009s, 966m, 953m, 916w, 886w, 853vs, 742vs. 1H-NMR (600 MHz, conformers (92:8)):
8.18–8.13, 7.44–7.40 (2m, 4 arom. H); 4.45–4.43 (m, CH(α)(Pro)); 4.39–4.30 (m, CH2CH2O);
3.71–3.67, 3.60–3.56 (2m, CH2(δ)(Pro)); 3.31–3.27 (m , CH2CH2O); 2.69 (sept., J = 6.8,
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Me2CH); 2.21–2.16, 2.11–2.07, 2.02–1.93 (3m, CH2(β)(Pro), CH2(γ)(Pro)); 1.16, 1.13 (2d, J =
6.8, 2 Me). 13C-NMR (150 MHz): 176.0 (s, CO(amide)); 172.3 (s, CO(ester)); 146.0, 145.4
(2s, 2 arom. C); 126.7, 124.1 (2d, 4 arom. CH); 62.5 (t, CH2CH2O); 58.8 (d, CH(α)(Pro));
46.8 (t, CH2(δ)(Pro)); 32.3 (d, Me2CH); 30.3 (t, CH2CH2O); 29.1 (t, CH2(β)(Pro)); 25.0 (t,
CH2(γ)(Pro)); 18.9, 18.7 (2q, 2 Me). ESI-MS (CH2Cl2,MeOH, NaI): 389 (100, [M+Na]+).
(9H-Fluoren-9-yl)methyl N-(2-Methylpropanthioyl)-L-prolinate (8a). A suspension of
Lawesson reagent (dried i.v., 307 mg, 0.759 mmol) and 7a (499 mg, 1.373 mmol) in toluene
(15 ml) was heated at 95° (oilbath) for 1 h. After cooling to r.t., the mixture was filtered, and
the solvent was evaporated. CC (SiO2, AcOEt/hexane 2:8) yielded 8a (369 mg, 71%).
Colorless powder. M.p. 174.1–176.3°. IR: 2974m, 2964m, 2927m, 2873w, 1743vs, 1595w,
1554w, 1503w, 1461s, 1440vs, 1383s, 1359m, 1345s, 1336s, 1300w, 1270s, 1255m, 1229m,
1194vs, 1171vs, 1156vs, 1123s, 1020m, 1006s, 975m, 939m, 761s, 742vs, 716w. 1H-NMR
(300 MHz, conformers (88:12)): 7.78–7.58, 7.42–7.27 (2m, 8 arom. H); 5.10–5.06 (m,
CH(α)(Pro)); 4.73 (dd, J = 10.8, 5.6, 1 H of CH2(Fm)); 4.42 (dd, J = 10.8, 6.4, 1 H of
CH2(Fm)); 4.24 (t-like, J ≈ 6.0, CH(Fm)); 3.68–3.63 (m, CH2(δ)(Pro)); 2.94 (sept., J = 6.6,
Me2CH); 2.17–2.07, 1.96–1.73 (2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.21, 1.11 (2d, J = 6.5, 2
Me)). 13C-NMR (CDCl3, 75 MHz): 209.7 (s, CS); 170.5 (s, CO); 144.0, 143.6, 141.4, 141.4
(4s, 4 arom. C); 127.8, 127.2, 125.2, 125.0, 119.9 (5d, 8 arom. H); 66.2 (t, CH2(Fm)); 65.3 (d,
CH(α)(Pro)); 50.1 (t, CH2(δ)(Pro)); 47.1 (d, CH(Fm)); 38.7 (d, Me2CH); 28.7, 24.5 (2t,
CH2(β)(Pro), CH2(γ)(Pro)); 22.6, 22.4 (2q, 2 Me). ESI-MS (MeOH): 402 (100, [M+Na]+).
2-[(4-Nitrophenyl)sulfonyl]ethyl N-(2-Methylpropanthioyl)-L -prolinate  (8 b) .  A
suspension of Lawesson reagent (dried i.v., 374 mg, 0.925 mmol) and 7b (662 mg, 1.662
mmol) in toluene (20 ml) was heated at 90° (oilbath) for 1 h. After cooling to r.t., the mixture
was filtered, and the solvent was evaporated. CC (SiO2, CH2Cl2/MeOH 70:1) yielded 8b (509
mg, 74%). Yellow powder. M.p. 174.1–176.3°. IR: 3470w, 3109w, 3062w, 3033w, 2966s,
2924s, 2887m, 2864w, 1742vs, 1606m, 1524vs, 1475vs, 1458vs, 1402m, 1377s, 1350vs,
1327vs, 1303vs, 1264s, 1253s, 1226s, 1196vs, 1174vs, 1152vs, 1124s, 1106m, 1086s, 1070s,
1013s, 999m, 977m, 921w, 881w, 851s, 828w, 789w, 756vs, 738vs, 702vs. 1H-NMR (300
MHz, conformers (95:5)): 8.47–8.41, 8.20–8.14 (2m, 4 arom. H); 4.77–4.73 (m, CH(α)(Pro));
4.61–4.44 (m , CH2CH2O); 4.13–3.85, 3.78–3.69 (2m , CH2(δ)(Pro)); 3.63–3.46 (m ,
CH2CH2O); 3.02 (sept., J = 6.6, Me2CH); 2.24–1.98 (m, CH2(β)(Pro), CH2(γ)(Pro)); 1.21, 1.21
(2d, J = 6.5, 2 Me). 13C-NMR (75 MHz): 209.9 (s, CS); 169.8 (s, CO); 151.0, 144.8 (2s, 2
arom. C); 129.9, 124.6 (2d, 4 arom. CH); 65.0 (d, CH(α)(Pro)); 57.6 (t, CH2CH2O); 55.1 (t,
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CH2CH2O); 50.3 (t, CH2(δ)(Pro)); 38.7 (d, Me2CH); 28.5, 24.8 (2t, CH2(β)(Pro), CH2(γ)(Pro));
22.7, 22.4 (2q, 2 Me). ESI-MS (MeOH, NaI): 437 (100, [M+Na]+), 206 (25).
2-[(4-Nitrophenyl)sulfanyl]ethyl N-(2-Methylpropanthioyl)-L - p r o l i n a t e  (8 c ). A
suspension of Lawesson reagent (dried i.v., 473 mg, 1.170 mmol) and 7c (773 mg, 2.110
mmol) in toluene (20 ml) was heated at 90° (oilbath) for 1 h. After cooling to r.t., the mixture
was filtered, and the solvent was evaporated. CC (SiO2, CH2Cl2/MeOH 300:1 → 100:1)
yielded 8c (599 mg, 74%). Yellow oil. IR (film): 3098w, 3067w, 2971vs, 2929s, 2878s,
1743vs, 1594vs, 1578vs, 1513vs, 1479vs, 1462vs, 1441vs, 1381vs, 1338vs, 1300s, 1268vs,
1257vs, 1227vs, 1188vs, 1166vs, 1125s, 1090vs, 1049m, 1016vs, 970s, 922w, 912w, 877w,
853vs, 841s, 779w, 742vs. 1H-NMR (300 MHz, conformers (93:7)): 8.16–8.13, 7.45–7.41
(2m, 4 arom. H); 5.05–5.01 (m, CH(α)(Pro)); 4.41–4.30 (m, CH2CH2O); 3.91–3.89, 3.82–3.76
(2m, CH2(δ)(Pro)); 3.31 (t, J = 7.1, CH2CH2O); 3.06 (sept., J = 6.6, Me2CH); 2.29–2.07 (m,
CH2(β)(Pro), CH2(γ)(Pro)); 1.25, 1.25 (2d, J = 6.6, 2 Me). 13C-NMR (75 MHz): 210.1 (s, CS);
170.5 (s, CO); 146.1, 145.6 (2s, 2 arom. C); 126.8, 124.3 (2d, 4 arom. CH); 65.4 (d,
CH(α)(Pro)); 62.8 (t, CH2CH2O); 50.5 (t, CH2(δ)(Pro)); 38.9 (d, Me2CH); 30.3 (t, CH2CH2O);
29.0, 25.0 (2t, CH2(β)(Pro), CH2(γ)(Pro)); 22.9, 22.5 (2q, 2 Me). ESI-MS (MeOH, NaI): 405
(100, [M+Na]+).
6. X-Ray Crystal-Structure Determination of 11a (Table and Fig.)4). A crystal of
C24H26N2O4S, obtained from CDCl3/Et2O, was used for a low-temp. X-ray crystal-structure
determination. All measurements were made on a Nonius KappaCCD area-detector
diffractometer [33] using graphite-monochromated MoKα radiation (λ 0.71073 Å) and an
Oxford Cryosystems Cryostream 700 cooler. The data collection and refinement parameters
are given in the Table, and a view of the molecule is shown in the Figure. Data reduction was
performed with HKL Denzo and Scalepack [34]. The intensities were corrected for Lorentz
and polarization effects, and an absorption correction based on the multi-scan method [35]
was applied. Equivalent reflections, other than Friedel pairs, were merged. The structure was
solved by direct methods using SIR92 [36], which revealed the positions of all non-H-atoms.
The non-H-atoms were refined anisotropically. The amide H-atom was placed in the position
indicated by a difference electron density map and its position was allowed to refine together
with an isotropic displacement parameter. All remaining H-atoms were placed in
                                                 
4 ) CCDC 602724 contains the supplementary crystallographic data for this paper. These data
can be obtained free of charge from the Cambridge Crystallographic Data Center via
http://www.ccdc.cam.ac.uk/data_request/cif.
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geometrically calculated positions and refined using a riding model where each H-atom was
assigned a fixed isotropic displacement parameter with a value equal to 1.2Ueq of its parent
C-atom (1.5Ueq for the Me groups). Refinement of the structure was carried out on F2 using
full-matrix least-squares procedures, which minimised the function Σw(Fo2 – Fc2)2. A
correction for secondary extinction was applied. Refinement of the absolute structure
parameter [37] yielded a value of -0.08(6), which confidently confirms that the refined
coordinates, represent the true enantiomorph. Neutral atom scattering factors for non-H atoms
were taken from [38a], and the scattering factors for H-atoms were taken from [39].
Anomalous dispersion effects were included in Fc [40]; the values for f ' and f " were those of
[38b]. The values of the mass attenuation coefficients are those of [38c]. All calculations were
performed using the SHELXL97 [41] program.
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Table. Crystallographic Data for Compound 11a
Crystallised from CDCl3/Et2O
Empirical formula C24H26N2O4S
Formula weight [g mol–1] 438.54
Crystal color, habit colorless, needle
Crystal dimensions [mm] 0.08 × 0.10 × 0.30
Temp. [K] 160(1)
Crystal system monoclinic
Space group P21
Z 2
Reflections for cell determination 30655
2θ range for cell determination [°] 4 – 55
Unit cell parameters a [Å] 9.2417(3)
b [Å] 11.1230(4)
c [Å] 11.4726(4)
β [°] 110.418(2)
V [Å3] 1105.24(7)
Dx [g cm–3] 1.318
µ(MoKα) [mm–1] 0.180
Scan type φ and ω
2θ (max) [°] 55
Transmission factors (min; max) 0.799; 0.994
Total reflections measured 24199
Symmetry independent reflections 5044
Reflections with I > 2σ (I) 4212
Reflections used in refinement 5044
Parameters refined; restraints 287; 1
Final R(F)  [I > 2σ (I) reflections] 0.0391
wR(F2)  (all data) 0.0862
Weights: w = [σ 2(Fo2) + (0.0369P)2 + 0.2109P]–1 where P = (Fo2 + 2Fc2) / 3
Goodness of fit 1.030
Final Δ max /σ 0.001
Δρ (max; min) [e Å–3] 0.19; -0.22
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7. Introduction of the Aib-Pro Unit into Peptides by means of the ‘Azirine/
Oxazolone Method’ on Solid Phase1
A method for the direct introduction of Aib-Pro into peptides on solid phase was
developed. The Aib-Pro unit was introduced by means of the ‘azirine/oxazolone method’
using allyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate as the synthon. After the reaction of
the resin-bound peptide acid with allyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate, the allyl
protecting group of the resulting extended peptide could be removed by a mild Pd0-promoted
procedure. Cleavage of the peptide from the resin was performed with UV-light at 352 nm
and yielded C-terminal protected peptides. The method found a successful application in the
syntheses of different Aib-Pro containing peptaibol segments. Furthermore, a protected
derivative of the peptide antibiotic Trichovirin I 1B was prepared by segment condensation.
1. Introduction
2H-Azirin-3-amines are highly-strained systems with versatile reactivity.1 One very
interesting and useful reaction is their application in peptide synthesis. In the
‘azirine/oxazolone method’, 2H-azirin-3-amines such as 1 or 2, are used as synthons for the
introduction of sterically demanding α,α-disubstituted α-amino acids into peptides.1–3 Thus,
the reaction of 2H-azirin-3-amines, e.g., the α-aminoisobutyric acid (Aib) synthon 1a, with
amino or peptide acids leads to peptide amides, the terminal amide bonds of which can be
hydrolyzed selectively to give extended peptide acids. In solution-phase chemistry, the
‘azirine/oxazolone method’ has proven to be successful for the introduction of a variety of
sterically demanding α,α -disubstituted α -amino acids into oligopeptides,4–13
endothiopeptides,14–16 cyclic peptides,17–18 and cyclic depsipeptides.19–23
                                                 
1 S. Stamm, H. Heimgartner, Tetrahedron, submitted.
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Recently, we adapted the ‘azirine/oxazolone method’ to solid-phase conditions, in order to
additionally benefit from their advantages.24 In this method, the growing peptide was attached
through a carbamate linker to a [4-(hydroxymethyl)phenyl]acetamidomethyl (PAM)
polystyrene resin (3) (Scheme 1). After deprotection of tBu ester 4, resin 5 was treated with a
solution of 1a. It is worth mentioning that unconsumed 1a could easily be recovered and re-
used. The terminal amide 6 was selectively hydrolyzed with 3M HCl in THF/H2O to provide
peptide acid resin 7. Further extension of the peptide chain could be achieved either with a tBu
protected amino acid and a coupling reagent or with 1a. Cleavage of the peptide from the
resin was achieved with HBr (33%) in acetic acid, and yielded the tripeptide 8. In a recent
paper, we showed that the method is not restricted to the Aib synthon 1a, and that it was
successfully extended  to the 1-aminocyclopentane-1-carboxylic acid synthon 1b, the 4-
amino-3,4,5,6-tetrahydro-2H -pyran-4-carboxylic acid synthon 1 c , and the α-
methylphenylalanine synthon 1d.25
R1 N
N
Ph
1a   R1 = R2 = Me
1b   R1 – R2 = –(CH2)4–
1c   R1 – R2 = –(CH2)2O(CH2)2–
1d   R1 = Me, R2 = PhCH2
R2
N
N
O OR
2a   R = Me
2b   R = CH2CHCH2
2c   R = PhCOCH2
Peptaibols are linear, amphiphilic oligopeptides from fungal sources with a high proportion
of α,α-disubstituted α-amino acids, primarily, Aib.26–27 Peptaibols show antibiotic properties
due to self-association in lipid membranes forming ion channels.28 Several peptaibols, or
segments thereof, were synthesized by means of the ‘azirine/oxazolone method’.4,8–13 The 2H-
azirine-3-amine 2a played an important role in these syntheses, since 2a allowed the direct
introduction of the frequently present, but relatively acid labile, Aib-Pro unit.9 Unexpectedly,
the use of 2a on solid phase was not successful (vide infra).
Herein we report a method for the introduction of the Aib-Pro unit into peptides on solid
phase, using a photolabile linker and a new Aib-Pro synthon (2b), which was especially
developed for this purpose.29
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O O N
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O
H
N
O
R
6  R = N(Me)Ph
1
7  R = OH
1) COCl2 (1.9M in PhMe), THF
2) H-Ala-OtBu · HCl, DIPEA, CH2Cl2
4  R = OtBu
1
5  R = OH
 1a
CH2Cl2
3
TFA, CH2Cl2, TIPS
HCl (3M),
THF/ H2O
N
N
Ph
1. H-Phe-OtBu . HCl, HOBt,
1. PyBOP, DIPEA, DMF
2. 33% HBr/AcOH
H2N
O
H
N
O
N
H
Ph
OH
O
8
Scheme 1
2. Results and Discussion
The most obvious approach to the introduction of the Aib-Pro unit was the use of synthon
2a in analogy to the method outlined in Scheme 1. In doing so, resin 5 was treated with a
solution of 2a, and the resulting resin-bound tripeptide methyl ester was saponified with
LiOH in a mixture of THF, MeOH, and H2O. After coupling H-Val-OtBu and using PyBOP as
the coupling reagent, the peptide was cleaved from the resin with HBr (33%) in acetic acid to
give H-Ala-Aib-Pro-Val-OH (9) in 20% yield. In order to guarantee proper swelling of the
resin during the saponification, the experiment was repeated with a Tentagel resin. However,
the yield (21%) was still conspicuously lower, in comparison with the 37–50% obtained when
introducing the synthons 1a–d. The problem was recognized, when attempting to prepare the
model peptide H-Ala-Aib-Pro-Leu-Aib-Val-OH (on Tentagel resin) and the peptaibol
segment (A8–A14 of Trichovirin Ia) H-Val-Aib-Gly-Aib-Aib-Pro-Leu-OH (on polystyrene
resin), whose syntheses failed completely. Only peptide fragments, which are caused by Aib-
Pro fissions, were detected. The analysis of the fragments revealed that the cleavage of the
Aib-Pro amide bond occurred during the HBr-promoted cleavage of the peptide from the
resin, and not during the hydrolysis of the terminal amide, which was necessary after the
incorporation of 1a.
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Thus, a linker was required which can be cleaved under milder conditions, but is still stable
in TFA (50%) and HCl (3M). Some years ago, Kunz introduced a Pd0-labile allyl linker for
the synthesis of peptide acids.30 Therefore, we synthesized 2-{[(Z)-4-(triisopropylsilyloxy)but-
2-enyl]oxy}ethanoic acid31 and attached its carboxy group via an alanine spacer to an
aminomethyl polystyrene resin.32 Additionally, (E)-7-hydroxyhept-5-enoic acid was
prepared,33 and its carboxy group was attached to an aminomethyl polystyrene resin. In both
cases, the N-terminus of the first amino acid was immobilized through a carbamate group to
the resin (in the first case after removing the TIPS-protecting group with TFA), and the resin
bound peptides 8 and 9 were synthesized analogously to the ‘PAM/HBr-strategy’. Cleavage
from the resin was performed with Pd(Ph3P)4 and PhSiH3 in DMSO/CH2Cl2, but the desired
peptides could only be obtained in low yield and after a painstaking purification of the Pd-
containing crude product.
In 1995, Holmes introduced a photolabile nitroveratryl linker and immobilized peptides by
coupling their C-terminus to the resin.34–36 This photolinker is among the most effective ever
described – it is stable to various chemical reactions, but can easily be cleaved with UV-light
with λ = 365 nm, a wavelength that does not affect aromatic amino acids such as Trp or Tyr.
The corresponding photocleavable resin 10 (Scheme 2) is commercially available from
Novabiochem.
With the aim of testing the stability under acidic conditions, N-(4,5-dimethoxy-2-
nitrobenzyloxy)carbonyl-L-alanine tert-butyl ester (NVOC-Ala-OtBu) was prepared by
reaction of 4,5-dimethoxy-2-nitrobenzyl alcohol and COCl2 in THF, and subsequently with
H-Ala-OtBu · HCl under Schotten-Baumann conditions to give NVOC-Ala-OtBu, which was
then subjected to acidic conditions. Apart from tBu hydrolysis, neither in TFA (50%), nor in
HCl (3M) was cleavage or decomposition of the linker observed. Hence, the chloroformate of
the photocleavable resin 10 was reacted with H-Ala-OtBu. Deprotection of the tBu ester 11
with TFA afforded resin 12, which was treated with a solution of 1a. Selective hydrolysis of
the terminal amide of resin 13 with 3M HCl afforded peptide-acid resin 14, which was
coupled to H-Phe-OtBu. Cleavage of the peptide from the resin was performed with UV-light
(16 × 8 W, λmax = 352 nm) in MeCN/H2O, but the initial yields were disappointing. Most
probably, the remaining nitrosoaldehyde functionalized resin captured the peptide (15) via its
amino group.37 This assumption was supported by 1H-NMR experiments: the formyl signal of
methyl 4-[(4-formyl-2-methoxy-2-nitrophenyl)oxy]butanoate disappeared within 20 min on
reaction with isopropylamine, and a new signal at 8.65 ppm, typical for imines, appeared. To
overcome the peptide-capture, the cleavage from the resin was performed in a solution of
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semicarbazide hydrochloride in THF/MeOH.37 Although 15 was now obtained in much better
yield (ca. 30–40%), its purity was unsatisfactory. Therefore, the general procedures had to be
slightly modified again. The reaction time for the tBu ester hydrolysis was extended to 60 min
to avoid the previously detected H-Ala-Phe-OtBu side product. Moreover, the synthesis was
carried out on a polystyrene  instead of a Tentagel resin. The use of Tentagel resin suffered
from (poly)ethylene glycol loss. Finally, model peptide 15 was prepared in high purity and in
33% yield (after prep. HPLC, based on resin loading).
13  R = N(Me)Ph
14  R = OH
1) COCl2 (1.9M in PhMe), THF
2) H-Ala-OtBu · HCl, DIPEA, CH2Cl2
11  R = OtBu
12  R = OH
10
TFA, CH2Cl2, TIPS
HCl (3M), THF/ H2O
1. H-Phe-OtBu . HCl, HOBt,
1. PyBOP, DIPEA, DMF
2. hν (352 nm), MeOH, THF,
2. H2NCONHNH2 . HCl
H2N
O
H
N
O
N
H
Ph
OtBu
O
15
H
N
O
O
OH
NO2
MeO O
NO2
MeO
N
H
O
R
O
O
NO2
MeO
N
H
O
H
N
O
R
O
16  R = OMe
17  R = OH
LiOH, THF/MeOH/H2O
O
NO2
MeO
N
H
O
H
N
O
N
O
R
O
H2N
O
H
N
O
18 NHO
N Ph
O
OtBu
1. H-Phe-OtBu . HCl, HOBt,
1. PyBOP, DIPEA, DMF
2. hν (352 nm), MeOH, THF,
2. H2NCONHNH2 . HCl
3
H
N
O
O3
H
N
O
O3
H
N
O
O3
 1a, CH2Cl2 2a, CH2Cl2
N
N
O OMe
N
N
Ph
Scheme 2
Chapter 7
111
After having established the protocol for the use of Aib synthon 1a, the preparation of Aib-
Pro containing peptides was attempted. But when dipeptide synthon 2a  was used to
incorporate the Aib-Pro unit, the experiment failed again (Scheme 2). During the
saponification of resin-bound methyl ester 16 to give 17, we observed a considerable
darkening of the resin. Hence, quenching prevented the subsequent photo-induced cleavage of
the peptide from the resin.
This issue was addressed by the synthesis of the new Aib-Pro synthons allyl N-(2,2-
dimethyl-2H-azirin-3-yl)-L-prolinate (2b) and phenacyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-
prolinate (2c), which contain easily removable carboxy-protecting groups.29 Resin 12 was
reacted with a solution of 2c, and the resulting phenacyl ester resin was treated with
tetrabutylammonium fluoride. Again, considerable darkening of the resin was observed. On
the other hand, the allyl protecting group of resin 19, obtained from the reaction of resin 12
and 2b, was smoothly removed with Pd(Ph3P)4 and PhSiH338 in CH2Cl2 to give resin 1 7
(Scheme 3). The latter was then coupled with H-Phe-OtBu and PyBOP as the coupling
reagent affording the corresponding resin bound tetrapeptide. Cleavage from the resin was
achieved with UV-light (16 ×  8 W, λmax = 352 nm) in a solution of semicarbazide
hydrochloride in THF/MeOH and gave H-Ala-Aib-Pro-Phe-OtBu (18) in high purity and in
35% yield (after prep. HPLC, based on resin loading).
1) COCl2 (1.9M in PhMe), THF
2) H-Ala-OtBu · HCl, DIPEA, CH2Cl2
 2b
CH2Cl2
N
1. H-Phe-OtBu . HCl, HOBt,
1. PyBOP, DIPEA, DMF
2. hν (352 nm), MeOH, THF,
2. H2NCONHNH2 . HCl
N
OO
H2N
O
H
N
O
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N Ph
O
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1
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To evaluate the described protocol for the introduction of the Aib-Pro motif into peptides,
the preparation of some peptaibol segments was attempted. The heptapeptide H-Val-Aib-Gly-
Aib-Aib-Pro-Leu-OtBu (20, A8–A14 of Trichovirin Ia; Table 1), whose synthesis failed with
the ‘PAM/HBr-strategy’ (see above), was prepared in 42% yield using the photocleavable
resin 10, the Aib synthon 1a, and the allyl-protected Aib-Pro synthon 2b. Gly and Leu were
introduced with PyBOP as the coupling reagent. Analogously, the syntheses of the hexa- and
octapeptides H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (21, A1–A6 of Trichovirin I 1B) and
H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (22, A7–A14 of Trichovirin I 1B) were carried
out. Sequence 21 was chosen to evaluate the introduction of non-aliphatic amino acids, while
in the synthesis of 22, an Aib-Pro unit had to be installed prior to an Aib-residue and another
Aib-Pro unit. Both peptides were prepared on the photocleavable resin 10 using the Aib
synthon 1a and the allyl protected Aib-Pro synthon 2b. All other amino acids were introduced
with PyBOP as the coupling reagent. The side chain of Asn was not protected, while the
hydroxy group of the serine side chain was masked as benzyl ether, a protecting group which
is orthogonal to the tBu protecting group. The peptides were obtained in each 34% yield (after
prep. HPLC, based on resin loading), which is comparable to that of tetrapeptide 18 and
therefore indicating a good linker stability.
Table 1. Peptides synthesized by means of the ‘azirine/oxazolone method’ on solid phase.
Sequence Description Yield [%] a)
H-Ala-Aib-Phe-OtBu (15) model peptide 33
H-Ala-Aib-Pro-Phe-OtBu (18) model peptide 35
H-Val-Aib-Gly-Aib-Aib-Pro-Leu-OtBu (20) A8–A14 of Trichovirin Ia 42
H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (21) A1–A6 of Trichovirin I 1B 34
H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (22) A7–A14 of Trichovirin I 1B 34
a) based on resin loading, after prep. HPLC.
In contrast to the ‘PAM/HBr-strategy’ (Scheme 1), the use of the photolinker allows the
preparation of tBu-protected peptides, which, in turn, offers the possibility of segment
condensations. For that purpose, the C-terminal tBu-protected peptides had to be turned into
N-terminal protected peptides. tBu-protected peptide 1 8  was reacted with N -
(benzyloxycarbonyloxy)succinimid (Z-ONSu), and the corresponding tBu protecting group
was hydrolyzed to give the N-protected peptide 23 (Scheme 4).
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Analogously, the heptapeptide 21 (A1–A6 of Trichovirin I 1B) was turned into the N-
protected peptide 24 (Scheme 5). Due to steric hindrance of Aib, the reaction time for the
introduction of the Z-protecting group was extended to 8 h. However, the transformation was
not complete, and 21 (20%) was partially recovered. The hydrolysis of the corresponding tBu
ester with TFA was accompanied by partial cleavage of the Aib-Pro amide bond. Most
probably, the extent of this side reaction could be reduced by shortening the reaction time
(HPLC/MS indicates complete deprotection already after 20 min). Finally, 24 was coupled
with 22 (A7–A14 of Trichovirin I 1B) and TBTU as the coupling reagent, and protected
Trichovirin I 1B (Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-
OtBu; 25) was obtained in 73% yield (Scheme 5).39
H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OH
1. Z-ONSu, DIPEA,
1. dioxane, rt
2. TFA, CH2Cl2,
2. TIPS, H2O, rt21 24
Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu
25
22, TBTU, HOBt,
DIPEA, CH2Cl2,
DMF, rt
Scheme 5
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3. Conclusions
A method for the direct introduction of Aib-Pro into peptides via ‘azirine coupling’ on
solid phase was developed. The protocol is based on a photocleavable resin (10) and the Aib-
Pro synthon 2b. After the coupling of the resin-bound peptide acid with 2b, the allyl
protecting group of the extended peptide was removed by a mild Pd0-promoted procedure. In
contrast to the previously described ‘PAM/HBr-strategy’, this protocol allows the isolation of
peptides with a protected C-terminus. The method found a successful application in the
syntheses of different Aib-Pro containing peptaibol segments. A subsequent segment
condensation led to the Trichovirin I 1B derivative 25, an oligopeptide containing three Aib-
Pro units and two additional Aib residues.
4. Experimental Part
4.1. General
Unless otherwise noted, materials were obtained from commercial suppliers and were used
without further purification. Aminomethyl polystyrene resin (1% divinylbenzene, 100–200
mesh, loading 1.14 mmol/g) and aminomethyl Tentagel resin (90 µm, loading 0.28 mmol/g)
from Rapp Polymere (Rapp Polymere, Tübingen, Germany). Hydroxymethyl-photolinker AM
resin (10) (polystyrene, 1% divinylbenzene, 100–200 mesh, loading 0.75 mmol/g) from
Novabiochem (Calbiochem-Novabiochem, Läufelfingen, Switzerland). N,2,2-Trimethyl-N-
phenyl-2H-azirin-3-amine (1a) was synthesized according to the method of Villalgordo and
Heimgartner.40,41 Methyl N -(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate (2a), allyl N-(2,2-
dimethyl-2H-azirin-3-yl)-L-prolinate (2b) and phenacyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-
prolinate (2c) were synthesized according to Ref. 9 (2a) and Ref. 29 (2b, 2c), respectively. H-
Ser(OBn)-OtBu was prepared by treatment of Fmoc-Ser(OBn)-OH with tert-butyl
trichloroacetamidate and removal of Fmoc with Et2NH. The 1H-NMR spectra of H-Ser(OBn)-
OtBu was in accordance with the data given in Ref. 42. Reaction vessels for solid phase
synthesis: Single fritted (20 µm) PE reservoir (15 ml) (Separtis, Grenzach-Wyhlen, Germany)
were wrapped with aluminum foil and used on an Advanced ChemTech PLS 4 × 6 Shaker
(Advanced ChemTech, Inc., Louisville, KY, USA) with a selfmade adapter. The original
Advanced ChemTech reaction vessels were used for reactions with COCl2. Photolysis was
performed in a quartz tube (13.5 cm, 13 mm i.d.). Irradiation with circulary arranged sterilAir
BLB8  lamps (16 × 8 W, λmax = 352 nm) (sterilAir AG, Weinfelden, Switzerland). High-
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performance liquid chromatography (HPLC): instrument: Waters 600E multisolvent delivery
system equipped with a Waters 996 PDA (Waters, Milford, CA, USA); column: Interchim
Uptisphere WOD C18, 300 Å, 10 µm, 250 × 21.2 mm (Interchim, Montluçon, France);
eluents: A = H2O/TFA (0.1%), B = MeCN/TFA (0.1%); flow rate: 10 ml/min; various
gradients. Column chromatography (CC): Silica gel C-560 from Chemie Uetikon (CU Chemie
Uetikon GmbH, Uetikon, Switzerland). IR Spectra: Perkin-Elmer, Spectrum one FT-IR
spectrophotometer (Perkin-Elmer, Wellesley, MA, USA), absorptions in cm–1. NMR Spectra:
Bruker AV-600 (Bruker Biospin, Karlsruhe, Germany). Chemical shifts in ppm relative to
tetramethylsilane as internal standard. 2D-NMR experiments were performed for assignment
of the signals. The integer n in Xaan corresponds to the position of the amino acid within the
peptide, but is only given if the amino acid was present more than once in the peptide and if
the NMR signal could be assigned unambigously. HPLC/MS: The system consists of a Rheos
2000 pump, a Rheos CPS-LC degasser (Flux Instruments, Basel, Switzerland) and a Thermo
Finnigan Surveyor photo-diode array detector (Thermo Finnigan, San Jose, CA, USA). The
HPLC-system is equipped with a HTS PAL autosampler (CTC Analytics, Zwingen,
Switzerland) and connected to a Thermo Finnigan MSQ linear quadrupole instrument.
Interchim Uptisphere C18-ODB, 120 Å, 3 µm, 50 × 2.0 mm column; eluents: A = H2O, B =
MeCN, C = HCOOH (1%) in H2O; flow rate: 0.2 ml/min, gradient (A:B:C): 0.0–15.0 min:
87:3:10–40:50:10. MS: Bruker ESQUIRE-LC quadrupole instrument (Bruker Daltonik
GmbH, Bremen, Germany) or Finnigan TSQ-700 triple quadrupole instrument (Finnigan
MAT, San Jose, CA, USA). Direct infusion ESI-MS were performed with a syringe infusion
pump at a flow rate of 5 µl/min.
4.2. Abbreviations
Aib: α -aminoisobutyric acid; DIPEA: N ,N-diisopropylethylamine; HOBt: 1-
hydroxybenzotriazole; PyBOP: (1H-benzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate; TBTU: O-(1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
tetrafluoroborat; TFA: trifluoroacetic acid; TIPS: triisopropylsilane; Z: benzyloxycarbonyl; Z-
ONSu: N-[(benzyloxycarbonyl)oxy]succinimid.
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4.3. General Procedures 1–7 (GP 1 – GP 7)
GP 1: Attachment of the First Amino Acid. All manipulations were carried out under N2.
Hydroxymethyl-photolinker AM resin was swollen in THF. After filtration, a solution of
COCl2 (CAUTION) in toluene (ca. 20%, 10 equiv.) and THF (ca. 0.7 ml/100 mg resin) were
added to the resin, which was agitated at rt for 2 h, then washed with THF (2×) and CH2Cl2
(2×). In a separate vial, H-Xaa-OtBu · HCl (4 equiv.) was dissolved in DIPEA (8 equiv.) and
CH2Cl2 (conc. of H-Xaa-OtBu · HCl = ca. 0.2M). This mixture was added to the resin and any
ammonium salt that occured was removed by filtration. The resin was agitated at rt overnight,
then washed with DMF (3×) and CH2Cl2 (3×).
GP2: Removing the tBu Protecting Group. The resin was swollen in CH2Cl2. TFA in
CH2Cl2 (2 ml, 1×15 s, 25%; 2 ml, 1×60 min, 50%) and TIPS (5%, in each case) were added,
and the resin was agitated at rt. Then, the resin was washed with CH2Cl2 (3×), DMF (2×) and
CH2Cl2 (3×).
GP3: Coupling with 2H-Azirin-3-amines 1a, 2a and 2b. The corresponding resin was
swollen in CH2Cl2. A solution of 2H-azirin-3-amine (4 equiv.) in CH2Cl2 (conc. of 2H-azirin-
3-amine = ca. 0.2M) was added, the resin was agitated at rt overnight, and then washed with
CH2Cl2 (3×). Unconsumed 2H-azirin-3-amine could easily be recovered.
GP 4: Hydrolysis of the Terminal Amide. The resin was swollen in THF. Aq. HCl (ca. 2
ml/100 mg resin, 3M in THF/H2O, prepared from conc. HCl and THF) was added, and the
resin was agitated at rt overnight, then washed with THF (3×), DMF (3×) and CH2Cl2 (3×).
GP 5: Coupling with H-Xaa-OtBu · HCl. The resin was swollen in DMF. HOBt (6 equiv.)
in DMF, PyBOP (4 equiv.) in DMF, H-Xaa-OtBu · HCl (4 equiv.) in DMF and DIPEA (12
equiv.) were added (conc. of H-Xaa-OtBu . HCl = ca. 0.2M), the resin was agitated at rt, and
then washed with DMF (3×) and CH2Cl2 (3×).
GP 6: Removal of the Allyl Protecting Group. The resin was dried i.v. All manipulations
were carried out under Ar. The resin was swollen in CH2Cl2. A mixture of Pd(Ph3P)4 (0.3
equiv.) and PhSiH3 (20 equiv.) in CH2Cl2 (ca. 2 ml/100 mg resin) was added, the resin was
agitated at rt for 1.5 h, and then washed with CH2Cl2 (3×), DMF, CH2Cl2 (2×), THF (1% H2O)
(2×), THF (1×), MeOH and CH2Cl2 (2×).
GP 7: Cleavage. The resin (ca. 0.075 mmol) was swollen in a solution of semicarbazide
hydrochloride (24 mg) in MeOH/THF (2:1, 6 ml), and the mixture was degassed by bubbling
Ar into the mixture. Under vigorous stirring, the resin was irradiated with 16 × 8 W (λmax =
352 nm) for 2 h, then the supernatant solution was removed, and the irradiation process was
repeated two times. Afterwards, the resin was washed with MeOH/THF (2:1, 3×). All
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solutions were combined, concentrated under reduced pressure, and the crude product was
purified by means of HPLC. The purified product was lyophilized.
4.4. Synthesis of Peptides
4.4.1. H-Ala-Aib-Pro-Val-OH (9)
Aminomethyl Tentagel resin (350 mg, 0.098 mmol) was swollen in DMF. 4-
(hydroxymethyl)phenylacetic acid (33 mg, 0.199 mmol), DIPEA (103 µl, 0.602 mmol) and
PyBOP (104 mg, 0.200 mmol) in DMF (1.5 ml) were added, and the resin was agitated at rt
for 30 min (negative Kaiser test), then washed with DMF (3×), CH2Cl2 (3×) and THF (3×).
The resin was treated as described in GP 1, 2, and 3. Then, the resin was swollen in a mixture
of THF (1 ml) and MeOH (0.7 ml), and LiOH · H2O (33 mg, 0.787 mmol) in H2O (0.3 ml)
was added. The resin was agitated at rt overnight, washed with THF/MeOH/H2O (4:3:1, 3×),
and DMF (3×). The resin was treated as described in GP 5 (2 h), then swollen in CH2Cl2. HBr
in AcOH (33%, 3 ml) and two drops of H2O were added, and the resin was agitated at rt for
4h. The resin was separated by filtration and washed with AcOH/CH2Cl2 (1:1, 3×) and
MeCN/CH2Cl2 (1:1, 3×). The solvents were evaporated under reduced pressure and the crude
product was purified by means of HPLC. The purified product was lyophilized and yielded 9
(10 mg, 21%) as a colorless powder. IR (KBr): 3435s, 3271s, 3068s, 2969s, 2882s, 1674vs,
1630vs, 1548s, 1472m, 1422s, 1369m, 1338w, 1310w, 1269m, 1202vs, 1183vs, 1138vs,
1005w, 979w, 929w, 837w, 800w, 722m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 10.0–7.0 (br
s, NH3(Ala)); 8.61 (s, NH(Aib)); 7.73 (d, J = 8.2 Hz, NH(Val)); 4.42–4.41 (m, CH(α)(Pro));
4.06–4.04 (m, CH(α)(Val)); 3.88–3.87 (m, CH(α)(Ala)); 3.57–3.54, 3.38–3.34 (2m,
CH2(δ)(Pro)); 2.04 (dsept., J  = 6.6, 6.6 Hz, CH(β)(Val)); 1.88–1.83, 1.81–1.76 (2m,
CH2(β)(Pro), CH2(γ)(Pro)); 1.37, 1.34 (2s, 2 Me(Aib)); 1.36 (d, J = 7.6 Hz, Me(Ala)); 0.90,
0.89 (2d, J = 6.8 Hz, 2 Me(Val)). 13C-NMR ((D6)DMSO, 150 MHz): 173.0 (s, CO(Val));
171.9 (s, CO(Pro)); 170.4 (s, CO(Aib)); 168.4 (s, CO(Ala)); 60.6 (d, CH(α)(Pro)); 57.2 (d,
CH(α)(Val)); 56.0 (s, C(α)(Aib)); 47.9 (d, CH(α)(Ala)); 47.6 (t, CH2(δ)(Pro)); 29.9 (d,
CH(β)(Val)); 27.9, 25.2 (2t, CH2(β)(Pro), CH2(γ)(Pro)); 24.9, 24.5 (2q, 2 Me(Aib)); 19.1, 18.1
(2q, 2 Me(Val)); 17.3 (q, Me(Ala)). ESI-MS: 371 (100, [M+H]+), 215 (34, [Pro-Val]+).
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4.4.2. H-Ala-Aib-Phe-OtBu (15)
Aminomethyl polystyrene resin (62 mg, 0.071 mmol) was swollen in DMF. 4-[(4-
Hydroxymethyl-2-methoxy-5-nitrophenyl)oxy]butanoic acid (40 mg, 0.140 mmol), PyBOP
(72 mg, 0.138 mmol) and DIPEA (72 µl, 0.421 mmol) in DMF (1.5 ml) were added, and the
resin was agitated at rt for 30 min, then washed with DMF (3×), CH2Cl2 (2×) and THF (2×).
The resin was treated as described in GP 1, 2, 3, 4, 5 (overnight), and 7 to yield 15 (11.4 mg,
33%) as a colorless powder after prep. HPLC purification and lyophilization. IR (KBr):
3426s, 3399s, 3288s, 3065m, 3032m, 2983s, 2939s, 1724s, 1674vs, 1549s, 1516s, 1457m,
1440m, 1393m, 1368s, 1324w, 1259s, 1204vs, 1180vs, 1156vs, 1139vs, 1079w, 1030w,
1015w, 1003w, 948w, 929w, 881w, 839m, 800w, 754w, 739w, 722m, 700m. 1H-NMR
((D6)DMSO, 600 MHz): 8.31 (s, NH(Aib)); 8.01 (br s, NH3(Ala)); 7.67 (d, J = 7.8 Hz,
NH(Phe)); 7.29–7.19 (m, 5 arom. H); 4.34 (ddd, J = 8.2, 7.8, 6.4 Hz, CH(α)(Phe)); 3.84 (q, J
= 6.9 Hz, CH(α)(Ala)); 3.02 (dd, J = 13.8, 6.4 Hz, 1 H of CH2(Phe)); 2.95 (dd, J = 13.8, 8.2
Hz, 1 H of CH2(Phe)); 1.38, 1.37 (2s, 2 Me(Aib)); 1.33 (s, Me3C); 1.32 (d, J = 7.3 Hz,
Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 172.9 (s, CO(Aib)); 170.4 (s, CO(Phe)); 168.8
(s, CO(Ala)); 137.4 (s, arom. C); 129.2, 128.1, 126.4 (3d, 5 arom. CH); 80.7 (s, Me3C); 56.3
(s, C(α)(Aib)); 54.2 (d, CH(α)(Phe)); 48.3 (d, CH(α)(Ala)); 36.8 (t, CH2(Phe)); 27.5 (q,
Me3C); 24.7, 24.6 (2q, 2 Me(Aib)); 17.1 (q, Me(Ala)). ESI-MS: 378 (53, [M+H]+), 322 (100,
[M–tBu]+). HPLC/MS: tR 10.3 min, m/z 378 (16, [M+H]+), 322 (100, [M–tBu]+), 157 (27,
[M–(Phe-OtBu)]+).
4.4.3. H-Ala-Aib-Pro-Phe-OtBu (18)
Hydroxymethyl-photolinker AM resin (101 mg, 0.075 mmol) was treated as described in
GP 1, 2, 3, 6, 5 (2 h), and 7 to yield 18 (15.6 mg, 35%) as a colorless powder after prep.
HPLC purification and lyophilization. IR (KBr): 3428s, 3293s, 3065s, 3032s, 2983s, 2940s,
1728s, 1674vs, 1548s, 1536s, 1499m, 1472m, 1456m, 1422m, 1415m, 1395m, 1369m,
1258m, 1203vs, 1177vs, 1156vs, 1135vs, 1052w, 1029w, 1004w, 928w, 879w, 836w, 800w,
740w, 721m, 701m. 1H-NMR ((D6)DMSO, 600 MHz): 8.65 (s, NH(Aib)); 8.08 (br s,
NH3(Ala)); 7.91 (d, J = 7.4 Hz, NH(Phe)); 7.29–7.20 (m, 5 arom. H); 4.33–4.31 (m,
CH(α)(Pro)); 4.26 (ddd, J = 7.3, 7.3, 7.3 Hz, CH(α)(Phe)); 3.88–3.87 (m, CH(α)(Ala));
3.52–3.50, 3.38–3.35 (2m, CH2(δ)(Pro)); 2.97–2.95 (m, CH2(Phe)); 1.86–1.76, 1.69–1.67
(2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.36 (d, J = 7.1 Hz, Me(Ala)); 1.35, 1.34 (2s, 2 Me(Aib));
1.30 (s, Me3C). 13C-NMR ((D6)DMSO, 150 MHz): 171.7 (s, CO(Pro)); 170.4 (s, CO(Phe));
170.3 (s, CO(Aib)); 168.3 (s, CO(Ala)); 137.3 (s, arom. C); 129.2, 128.0, 126.3 (3d, 5 arom.
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CH); 80.3 (s, Me3C); 60.7 (d, CH(α)(Pro)); 55.9 (s, C(α)(Aib)); 54.2 (d, CH(α)(Phe)); 47.8
(d, CH(α)(Ala)); 47.5 (t, CH2(δ)(Pro)); 36.6 (t, CH2(Phe)); 27.9 (t, CH2(β)(Pro)); 27.4 (s,
Me3C); 25.0 (t, CH2(γ)(Pro)); 24.7, 24.6 (2q, 2 Me(Aib)); 17.1 (q, Me(Ala)). ESI-MS: 497
(10, [M+Na]+), 475 (100, [M+H]+), 419 (17, [M–tBu]+), 319 (7, [M–(Ala-Aib)]+). HPLC/MS:
tR 9.9 min, m/z 497 (10, [M+Na]+), 475 (30, [M+H]+), 419 (24, [M–tBu]+), 319 (32, [M–(Ala-
Aib)]+), 263 (100, [M–(Ala-Aib)–tBu]+).
4.4.4. H-Val-Aib-Gly-Aib-Aib-Pro-Leu-OtBu (20)
Hydroxymethyl-photolinker AM resin (100 mg, 0.075 mmol) was treated as described in
GP 1, 2, 3, 4, 5 (overnight), 2, 3, 4, 3, 6, 5 (2 h), and 7 to yield 20 (25.7 mg, 42%) as a
colorless powder after prep. HPLC purification and lyophilization. IR (KBr): 3433vs, 3317vs,
3063m, 2978s, 2939s, 2877m, 1725m, 1671vs, 1543vs, 1537vs, 1469m, 1440m, 1416m,
1397m, 1384m, 1368m, 1333w, 1282m, 1248m, 1203vs, 1178vs, 1146s, 1018w, 947w, 878w,
837w, 801w, 722w. 1H-NMR ((D6)DMSO, 600 MHz): 8.82 (s, NH(Aib2)); 8.20 (s, NH(Gly));
8.08 (br s, NH3(Val)); 7.81 (d, J = 8.1 Hz, NH(Leu)); 7.72 (s, NH(Aib4)); 7.43 (s, NH(Aib5));
4.37–4.35 (m, CH(α)(Pro)); 4.11–4.07 (m, CH(α)(Leu)); 3.61–3.59 (m, CH(α)(Val), 1 H of
CH2(Gly), 1 H of CH2(δ)(Pro)); 3.55–3.51 (m, 1 H of CH2(Gly)); 3.43–3.39 (m, 1 H of
CH2(δ)(Pro)); 2.12 (dsept., J = 6.7, 6.7 Hz, CH(β)(Val)); 2.02–1.98 (m, 1 H of CH2(β)(Pro));
1.74–1.69 (m, 1 H of CH2(β)(Pro), CH2(γ)(Pro)); 1.63–1.57 (m, CH(γ)(Leu), 1 H of
CH2(β)(Leu)); 1.51–1.45 (m, 1 H of CH2(β)(Leu)); 1.403, 1.398 (2s, 2 Me(Aib2), 2 Me(Aib4));
1.38 (s, Me3C); 1.35, 1.33 (2s, 2 Me(Aib5)); 0.96, 0.94 (2d, J = 7.0 Hz, 2 Me(Val)); 0.89, 0.82
(2d, J = 6.3 Hz, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 174.6 (s, CO(Aib2)); 174.3 (s,
CO(Aib4)); 171.7 (s, CO(Pro)); 171.1 (s, CO(Leu)); 171.0 (s, CO(Aib5)); 168.4 (s, CO(Gly));
168.0 (s, CO(Val)); 79.9 (s, Me3C); 60.8 (d, CH(α)(Pro)); 57.5 (d, CH(α)(Val)); 56.13 (s,
C(α)(Aib4)); 56.09 (s, C(α)(Aib2)); 56.0 (s, C(α)(Aib5)); 50.9 (d, CH(α)(Leu)); 47.2 (t,
CH2(δ)(Pro)); 43.8 (t, CH2(Gly)); 39.3 (t, CH2(β)(Leu)); 29.5 (d, CH(β)(Val)); 28.4 (t,
CH2(β)(Pro)); 27.5 (q, Me3C); 25.8 (q, 1 Me of 2 Me(Aib4)); 25.6 (q, 1 Me of 2 Me(Aib2));
25.2 (q, 1 Me of 2 Me(Aib5)); 25.0 (t, CH2(γ)(Pro)); 24.5 (q, 1 Me of 2 Me(Aib4)); 24.2 (d,
CH(γ)(Leu)); 24.0 (q, 1 Me of 2 Me(Aib5)); 23.7 (q, 1 Me of 2 Me(Aib2)); 22.7, 21.2 (2q, 2
Me(Leu)); 18.4, 17.5 (2q, 2 Me(Val)). ESI-MS: 718 (17, [M+Na]+), 696 (100, [M+H]+).
HPLC/MS: tR 11.5 min, m/z 696 (100, [M+H]+), 640 (27, [M–tBu]+), 412 (24, [M–(Pro-Leu-
OtBu)]+), 339 (16).
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4.4.5. H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (21)
Hydroxymethyl-photolinker AM resin (100 mg, 0.075 mmol) was treated as described in
GP 1, 2, 5 (overnight), 2, 5 (90 min), 2, 3, 6, 5 (90 min), and 7 to yield 21 (21.7 mg, 34%) as
a colorless powder after prep. HPLC purification and lyophilization. IR (KBr): 3427s, 3301s,
3066m, 2979m, 2961m, 2938m, 2875m, 1673vs, 1535s, 1470m, 1453m, 1424m, 1412m,
1369m, 1247m, 1203vs, 1182vs, 1138vs, 837w, 800w, 742w, 722m, 700w. 1H-NMR
((D6)DMSO, 600 MHz): 8.39–8.37 (m, NH(Asn)); 8.17–8.13 (m, NH(Leu), NH3(Aib1),
NH(Aib4)); 7.99 (d, J = 8.0 Hz, NH(Ser)); 7.42–7.41 (m, 1 H of CONH2(Asn)); 7.36–7.32,
7.29–7.27 (2m, 5 arom. H); 6.98 (s, 1 H of CONH2(Asn)); 4.70 (ddd, J = 7.5, 7.5, 7.5 Hz,
CH(α)(Asn)); 4.49, 4.53 (AB, J = 12.1 Hz, OCH 2Ph(Ser)); 4.42–4.40 (m, CH(α)(Pro));
4.36–4.33 (m, CH(α)(Ser)); 4.29–4.25 (m, CH(α)(Leu)); 3.72 (dd, J = 9.7, 5.8 Hz, 1 H of
CH2(β)(Ser)); 3.65 (dd, J = 9.7, 4.4 Hz, 1 H of CH2(β)(Ser)); 3.46–3.44, 3.42–3.38 (2m,
CH2(δ)(Pro)); 2.64–2.60, 2.43–2.39 (2m, CH2(β)(Asn)); 1.90–1.87, 1.77–1.72 (2m,
CH2(β)(Pro), CH2(γ)(Pro)); 1.60–1.55 (m, CH(γ)(Leu)); 1.49–1.43 (m, CH2(β)(Leu)); 1.45,
1.43 (2s, 2 Me(Aib1)); 1.37 (s, Me3C); 1.34, 1.30 (2s, 2 Me(Aib4)); 0.86, 0.80 (2d, J = 6.6 Hz,
2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 171.9 (s, CO(Pro)); 171.2 (s, CO(Leu),
CONH2(Asn)); 171.1 (s, CO(Aib1)); 170.8 (s, CO(Aib4)); 170.3 (s, CO(Asn)); 169.0 (s,
CO(Ser)); 137.9 (s, arom. C); 128.1, 127.5, 127.4 (3d, 5 arom. CH); 80.5 (s, Me3C); 72.1 (t,
OCH2Ph(Ser)); 69.3 (t, CH2(β)(Ser)); 60.5 (d, CH(α)(Pro)); 56.2 (s, C(α)(Aib1)); 55.6 (s,
C(α)(Aib4)); 52.8 (d, CH(α)(Ser)); 50.8 (d, CH(α)(Leu)); 49.8 (d, CH(α)(Asn)); 47.3 (t,
CH2(δ)(Pro)); 40.3 (t, CH2(β)(Leu)); 36.8 (t, CH2(β)(Asn)); 28.0 (t, CH2(β)(Pro)); 27.5 (q,
Me3C); 25.0 (t, CH2(γ)(Pro)); 24.9, 24.7 (2q, 2 Me(Aib4)); 24.1 (d, CH(γ)(Leu)); 23.3, 23.1
(2q, 2 Me(Aib1)); 22.9, 21.3 (2q, 2 Me(Leu)). ESI-MS: 768 (100, [M+Na]+), 746 (48,
[M+H]+), 712 (28, [M–tBu+Na]+), 622 (17). HPLC/MS: tR 12.4 min, m/z 746 (100, [M+H]+),
398 (34, [M–(Pro-Ser(OBn)-tBu)]+).
4.4.6. H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (22)
Hydroxymethyl-photolinker AM resin (100 mg, 0.075 mmol) was treated as described in
GP 1, 2, 3, 6, 3, 4, 5 (overnight), 2, 3, 6, 5 (2 h), and 7 to yield 22 (24.8 mg, 34%) as a
colorless powder after prep. HPLC purification and lyophilization. IR (KBr): 3440vs, 3330sh,
3058m, 2961s, 2874m, 1724sh, 1653vs, 1627vs, 1536vs, 1471s, 1451m, 1440m, 1416s,
1385m, 1368m, 1344w, 1249m, 1241m, 1203vs, 1178vs, 1146s, 839w, 833w, 800w, 722w.
1H-NMR ((D6)DMSO, 600 MHz): 9.00 (s, NH(Aib2)); 8.13 (br s, NH3(Val)); 7.77 (d, J = 7.8
Hz, NH(Leu8)); 7.72 (s, NH(Aib4)); 7.69 (s, NH(Aib6)); 7.38 (d, J = 8.5 Hz, NH(Leu5));
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4.37–4.35 (m, CH(α)(Pro7)); 4.17–4.12 (m, CH(α)(Leu5), CH(α)(Pro3)); 4.04–4.00 (m,
CH(α)(Leu8)); 3.76–3.73 (m, CH(α)(Val)); 3.60–3.55 (m, 3 H of 2 CH2(δ)(Pro)); 3.40–3.36
(m, 1 H of 2 CH2(δ)(Pro)); 2.21–2.18 (m, CH(β)(Val)); 2.12–2.08 (m, 1 H of 2 CH2(β)(Pro));
2.00–1.95 (m, 1 H of 2 CH2(β)(Pro), 1 H of 2 CH2(γ)(Pro)); 1.89–1.85 (m, 1 H of 2
CH2(γ)(Pro)); 1.74–1.68 (m, 2 H of 2 CH2(β)(Pro), 2 H of 2 CH2(γ)(Pro)); 1.66–1.57 (m, 3 H
of 2 CH2(β)(Leu), 2 CH(γ)(Leu)); 1.48–1.44 (m, 1 H of 2 CH2(β)(Leu)); 1.42, 1.40 (2s, 2 Me
of 6 Me(Aib)); 1.38 (s, Me3C, 1 Me of 6 Me(Aib)); 1.36, 1.35 (2s, 3 Me of 6 Me(Aib)); 1.00,
0.94 (2d, J = 7.0 Hz, 2 Me(Val)); 0.91, 0.87, 0.82, 0.78 (4d, J = 6.2 Hz, 4 Me(Leu)). 13C-NMR
((D6)DMSO, 150 MHz): 173.9 (s, CO(Aib4)); 172.6 (s, CO(Pro3)); 172.2 (s, CO(Aib2)); 171.7
(s, CO(Leu5), CO(Pro7)); 171.3 (s, CO(Leu8)); 170.8 (s, CO(Aib6)); 167.5 (s, CO(Val)); 79.9
(s, Me3C); 63.2 (d, CH(α)(Pro3)); 60.8 (d, CH(α)(Pro7)); 56.9 (d, CH(α)(Val)); 56.2 (s,
C(α)(Aib4)); 56.1 (s, C(α)(Aib2)); 55.6 (s, C(α)(Aib6)); 51.1 (s, 2 CH(α)(Leu)); 48.0, 47.5 (2t,
2 CH2(δ)(Pro)); 39.6, 39.2 (2t, 2 CH2(β)(Leu)); 29.6 (d, CH(β)(Val)); 28.3, 27.6 (2t, 2
CH2(β)Pro)); 27.5 (q, Me3C); 26.4 (q, 1 Me of 6 Me(Aib)); 25.5 (t, 1 CH2 of 2 CH2(γ)(Pro));
25.4 (q, 1 Me of 6 Me(Aib)); 25.1 (t, 1 CH2 of 2 CH2(γ)(Pro)); 24.6, 24.32, 24.29 (3q, 3 Me of
6 Me(Aib)); 24.27, 24.2 (2d, 2 CH(γ)(Leu)); 23.9 (q, 1 Me of 6 Me(Aib)); 23.0, 22.9, 21.2,
20.6 (4q, 4 Me(Leu)); 18.6, 16.7 (2q, 2 Me(Val)). ESI-MS: 871 (19, [M+Na]+), 849 (100,
[M+H]+). HPLC/MS: tR 13.9 min, m/z 849 (100, [M+H]+), 565 (93, [M–(Pro-Leu-OtBu)]+).
4.4.7. Z-Ala-Aib-Pro-Phe-OH (23)
Z-ONSu (4.3 mg, 17.3 µmol) and DIPEA (8.1 µl, 47.3 µmol) were added to a solution of
18 (9.3 mg, 15.8 µmol) in dioxane (2.5 ml) at rt, and the solution was stirred at rt for 3 h. The
mixture was concentrated, and the crude product was purified by prep. HPLC. After
lyophilization, Z-Ala-Aib-Pro-Phe-OtBu (HPLC/MS: tR 16.5 min, m/z 631 (100, [M+Na]+))
(8.5 mg, 89%) was obtained as a colorless powder, which was dissolved in CH2Cl2/TFA (1:1,
2 ml) and TIPS (100 µl). The solution was stirred at rt for 1 h, then it was concentrated under
reduced pressure, and the crude product was purified by prep. HPLC. The purified product
was lyophilized and yielded 23 (7.5 mg, 97%) as a colorless powder. IR (KBr): 3412vs,
3292vs, 3063m, 3032m, 2984s, 2940m, 2876m, 1722vs, 1650vs, 1535vs, 1499s, 1469m,
1454s, 1411s, 1380m, 1366m, 1340m, 1328m, 1317m, 1282m, 1243vs, 1215s, 1203s, 1177s,
1116m, 1072m, 1040m, 1028m, 1002w, 977w, 911w, 824w, 743m, 700s. 1H-NMR
((D6)DMSO, 600 MHz): ca. 13.2–11.2 (br s, COOH); 8.20 (s, NH(Aib)); 7.77 (d, J = 8.0 Hz,
NH(Phe)); 7.44 (d, J = 7.6 Hz, NH(Ala)); 7.38–7.18 (m, 10 arom. H); 5.01, 5.06 (AB, J =
12.6 Hz, CH2(carbamate)); 4.37 (ddd, J = 8.4, 8.4, 5.3 Hz, CH(α)(Phe)); 4.29–4.27 (m,
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CH(α )(Pro)); 4.10 (dq, J  = 7.2, 7.2 Hz, CH(α )(Ala)); 3.54–3.50, 3.35–3.31 (2m,
CH2(δ)(Pro)); 3.05 (dd, J = 13.9, 5.1 Hz, 1 H of CH2(Phe)); 2.93 (dd, J = 13.9, 9.2 Hz, 1 H of
CH2(Phe)); 1.79–1.73 (m, 1 H of CH2(β)(Pro)); 1.61–1.58 (m, CH2(γ)(Pro)); 1.51–1.48 (m, 1
H of CH2(β)(Pro)); 1.30, 1.29 (2s, 2 Me(Aib)); 1.21 (d, J = 7.1 Hz, Me(Ala)). 13C-NMR
((D6)DMSO, 150 MHz): 172.6 (s, CO(Phe)); 171.9 (s, CO(Ala)); 171.7 (s, CO(Pro)); 170.9 (s,
CO(Aib)); 155.6 (s, CO(carbamate)); 137.6, 137.0 (2s, 2 arom. C); 129.1, 128.2, 128.0, 127.7,
127.6, 126.2 (6d, 10 arom. CH); 65.2 (t, CH2(carbamate)); 60.9 (d, CH(α)(Pro)); 55.5 (s,
C(α)(Aib)); 53.2 (d, CH(α)(Phe)); 49.9 (d, CH(α)(Ala)); 47.2 (t, CH2(δ)(Pro)); 36.6 (t,
CH2(Phe)); 27.8 (t, CH2(β)(Pro)); 25.0 (q, 1 Me of 2 Me(Aib)); 24.9 (t, CH2(γ)(Pro)); 24.6 (q,
1 Me of 2 Me(Aib)); 17.9 (q, Me(Ala)). ESI-MS: 591 (67, [M+K]+), 575 (100, [M+Na]+), 553
(44, [M+H]+), 263 (96, [M–(Pro-Phe)–CO]+, [Pro-Phe]+). HPLC/MS: tR 14.0 min, m/z 591
(51, [M+K]+), 263 (100, [M–(Pro-Phe)–CO]+, [Pro-Phe]+).
4.4.8. Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OH (24)
Z-ONSu (6.0 mg, 24.1 µmol) and DIPEA (11.6 µl, 67.8 µmol) were added to a solution of
21 (19.4 mg, 22.6 µmol) in MeCN (5 ml) at rt, and the solution was stirred at rt for 6 h.
Additional Z-ONSu (0.6 mg, 2.3 µmol) and DIPEA (3.9 µl, 22.6 µmol) were added, and the
solution was stirred at rt for further 2 h. Then, the mixture was concentrated, and the crude
product was purified by prep. HPLC. After lyophilization, Z-Aib-Asn-Leu-Aib-Pro-
Ser(OBn)-OtBu (HPLC/MS: tR 16.6 min, m/z 880 (62, [M+H]+)) (13.8 mg, 70%; additionally,
21 (3.8 mg, 20%) was isolated) was obtained as a colorless powder, which was dissolved in
CH2Cl2/TFA (1:1, 2 ml), H2O (1 drop) and TIPS (100 µl). The solution was stirred at rt for 45
min, then it was concentrated under reduced pressure, and the crude product was purified by
prep. HPLC. The purified product was lyophilized and yielded 24 (8.9 mg, 67%) as a
colorless powder. IR (KBr): 3418sh, 3308vs, 3063m, 3033m, 2957m, 2872m, 1660vs,
1532vs, 1469s, 1454s, 1412s, 1387m, 1366m, 1267s, 1203s, 1176s, 1094s, 1078m, 1028w,
740m, 698m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 13.2–11.3 (br s, COOH); 8.49 (d, J = 6.0
Hz, NH(Asn)); 8.06 (s, NH(Aib1)); 7.96 (d, J = 7.9 Hz, NH(Ser)); 7.74 (d, J = 8.5 Hz,
NH(Leu)); 7.49 (s, 1 H of CONH2(Asn)); 7.48 (s, NH(Aib4)); 7.40–7.26 (m, 10 arom. H);
7.04 (s, 1 H of CONH2(Asn)); 5.08, 5.00 (AB, J = 12.4 Hz, CH2(carbamate)); 4.51 (s,
OCH2Ph(Ser)); 4.43–4.38 (m, CH(α)(Ser), CH(α)(Pro)); 4.32–4.29 (m, CH(α)(Asn));
4.25–4.21 (m, CH(α)(Leu)); 3.75 (dd, J = 9.8, 5.9 Hz, 1 H of CH2(β)(Ser)); 3.68 (dd, J = 9.8,
4.2 Hz, 1 H of CH2(β)(Ser)); 3.45–3.42 (m, CH2(δ)(Pro)); 2.67–2.63, 2.57–2.54 (2m,
CH2(β )(Asn)); 1.90–1.86, 1.75–1.56 (2m, CH2(β)(Pro), CH2(γ)(Pro), CH2(β)(Leu),
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CH(γ)(Leu)); 1.36 (s, 1 Me of 2 Me(Aib1)); 1.35, 1.332 (2s, 2 Me(Aib4)); 1.325 (s, 1 Me of 2
Me(Aib1)); 0.81, 0.74 (2d, J = 6.3 Hz, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 175.3
(s, CO(Aib1)); 172.1 (s, CONH2(Asn)); 172.0 (s, CO(Pro)); 171.4 (s, CO(Ser)); 171.2 (s,
CO(Leu)); 170.9 (s, CO(Asn)); 170.8 (s, CO(Aib4)); 156.2 (s, CO(carbamate)); 138.1 (s,
arom. C(Bn)); 136.4 (s, arom. C(Z)); 128.4, 128.2, 128.0, 127.7, 127.5, 127.4 (6d, 10 arom.
CH); 72.2 (t, OCH2Ph(Ser)); 69.4 (t, CH2(β)(Ser)); 65.7 (t, CH2(carbamate)); 60.7 (d,
CH(α)(Pro)); 56.1 (s, C(α)(Aib1)); 55.8 (s, C(α)(Aib4)); 52.4 (d, CH(α)(Ser)); 51.6 (d,
CH(α)(Asn)); 50.9 (d, CH(α)(Leu)); 47.5 (t, CH2(δ)(Pro)); 39.4 (t, CH2(β)(Leu)); 35.1 (t,
CH2(β)(Asn)); 27.9 (t, CH2(β)(Pro)); 26.1 (q, 1 Me of 2 Me(Aib1)); 25.1 (q, 1 Me of 2
Me(Aib4)); 25.0 (t, CH2(γ)(Pro)); 24.8 (q, 1 Me of 2 Me(Aib4)); 24.0 (d, CH(γ)(Leu)); 23.9 (q,
1 Me of 2 Me(Aib1)); 23.1, 20.7 (2q, 2 Me(Leu)). ESI-MS: 868 (45, [M–H+2Na]+), 846 (100,
[M+Na]+). HPLC/MS: tR 15.6 min, m/z 824 (11, [M+H]+), 532 (100, [M–(Pro-Ser(OBn)-
OtBu)]+), 447 (40, [M–(Aib-Pro-Ser(OBn)-OtBu)]+).
4.4.9. Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (25).
HOBt, TBTU, and DIPEA were taken from stock-solutions. HOBt (1.7 mg, 11.1 µmol),
TBTU (3.5 mg, 11.0 µmol), DIPEA (5.4 µl, 31.3 µmol) and 22 (10.6 mg, 11.0 µmol) were
added to a solution of 24 (8.6 mg, 10.4 µmol) in CH2Cl2/DMF (1:1, 3 ml). The mixture was
stirred at rt for 4 h, the solvent was evaporated under reduced pressure, and the crude product
was purified by prep. HPLC. After lyophilization, 25 (12.5 mg, 73%) was obtained as a
colorless powder. IR (KBr): 3435sh, 3306s, 2958m, 2872w, 1648vs, 1623vs, 1536vs, 1470s,
1454m, 1412s, 1385m, 1366m, 1269m, 1203m, 1172s, 1152m, 1094w, 1028w, 740w, 698w.
1H-NMR ((D6)DMSO, 600 MHz): 8.57 (d, J = 5.5 Hz, NH(Asn)); 8.11 (s, 1 NH of 5
NH(Aib)); 7.90 (d, J = 6.7 Hz, NH(Ser)); 7.82 (d, J = 7.7 Hz, 1 NH of 3 NH(Leu)); 7.82, 7.79
(2s, 2 NH of 5 NH(Aib)); 7.74 (d, J = 7.7 Hz, 1 NH of 3 NH(Leu)); 7.55, 7.54 (2s, 2 NH of 5
NH(Aib)); 7.53 (s, 1 H of CONH2(Asn)); 7.39–7.30, 7.27–7.24 (2m, 10 arom. H, 1 NH of 3
NH(Leu), NH(Val)); 7.07 (s, 1 H of CONH2(Asn)); 5.07, 5.00 (AB, J  = 12.3 Hz,
CH2(carbamate)); 4.55, 4.51 (AB, J = 11.9 Hz, OCH2Ph(Ser)); 4.38–4.36 (m, 1 H of 3
CH(α)(Pro)); 4.33–4.26 (m, CH(α)(Ser), CH(α)(Asn), 1 H of 3 CH(α)(Leu), 1 H of 3
CH(α)(Pro)); 4.19–4.14 (m, 1 H of 3 CH(α)(Leu), CH(α)(Val)); 4.08 (dd, J = 8.4, 8.4 Hz, 1 H
of 3 CH(α)(Pro)); 4.04–4.00 (m, 1 H of 3 CH(α)(Leu)); 3.86–3.83 (m, 1 H of CH2(β)(Ser));
3.77–3.68 (m, 1 H of CH2(β)(Ser), 2 H of 3 CH2(δ)(Pro)); 3.65–3.61, 3.52–3.48, 3.38–3.34,
3.30–3.25 (4m, 4 H of 3 CH2(δ)(Pro)); 2.68–2.64, 2.60–2.56 (2m, CH2(β)(Asn)); 2.24–2.19
(m, 2 H of 3 CH2(β)(Pro)); 2.09 (dsept., J = 6.8, 6.8 Hz, CH(β)(Val)); 2.01–1.98 (m, 1 H of 3
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CH2(β)(Pro)); 1.93–1.83 (m, 4 H of 3 CH2(γ)(Pro)); 1.74–1.57 (m, 3 CH(γ)(Leu), 4 H of 3
CH2(β)(Leu), 3 H of 3 CH2(β)(Pro), 2 H of 3 CH2(γ)(Pro)); 1.54–1.51 (m, 1 H of 3
CH2(β)(Leu)); 1.48 (s, 1 Me of 10 Me(Aib)); ca. 1.44 (m, 1 H of 3 CH2(β)(Leu)); 1.43, 1.42,
1.38, 1.37, 1.364, 1.358, 1.34 (7s, 9 Me of 10 Me(Aib), Me3C); 0.91 (d, J = 6.4 Hz, 1 Me of 6
Me(Leu)); 0.87, 0.83 (2d, J = 6.8 Hz, 2 Me(Val)); 0.82 (d, J = 6.4 Hz, 2 Me of 6 Me(Leu));
0.749, 0.745 (2d, J = 6.0 Hz, 2 Me of 6 Me(Leu)); 0.63 (d, J = 6.2 Hz, 1 Me of 6 Me(Leu)).
13C-NMR ((D6)DMSO, 150 MHz): 175.7, 174.2, 173.0. 172.8, 172.74, 172.70, 172.6, 171.90,
171.86, 171.6, 171.3, 171.2, 171.1, 170.9, 169.6 (15s, 15 CO); 156.2 (s, CO(carbamate));
137.9 (s, arom. C of CH2Ph(Ser)); 136.2 (s, arom. C(Z)); 128.3, 128.1, 127.9, 127.6, 127.4,
127.2 (6d, 10 arom. CH); 79.8 (s, Me3C); 72.0 (t, OCH2Ph(Ser)); 68.6 (t, CH2(β)(Ser)); 65.8
(t, CH2(carbamate)); 63.9, 62.9, 60.8 (3d, 3 CH(α)(Pro)); 58.3 (d, CH(α)(Val)); 56.1, 56.0,
55.9, 55.8, 55.6 (5s, 5 C(α)(Aib)); 55.4, 51.9 (2d, CH(α)(Asn), CH(α)(Ser)); 51.1, 51.0 (2d, 3
CH(α)(Leu)); 48.3, 48.2, 47.6 (3t, 3 CH2(δ)(Pro)); 39.5, 39.1, 39.1 (3t, 3 CH2(β)(Leu)); 34.9
(t, CH2(β)(Asn)); 29.6 (d, CH(β)(Val)); 28.4, 28.3, 28.1 (3t, 3 CH2(β)(Pro)); 27.5 (q, Me3C);
26.5, 26.0, 25.7 (3q, 3 Me of 10 Me(Aib)); 25.6 (t, 1 CH2 of 3 CH2(γ)(Pro)); 25.5 (q, 1 Me of
10 Me(Aib)); 25.4 (t, 1 CH2 of 3 CH2(γ)(Pro)); 25.3 (q, 1 Me of 10 Me(Aib)); 25.1 (t, 1 CH2
of 3 CH2(γ)(Pro)); 24.2 (q,d, 1 Me of 10 Me(Aib), 2 CH of 3 CH(γ)(Leu)); 23.81 (q, 1 Me of
10 Me(Aib)); 23.76 (d, 1 CH of 3 CH(γ)(Leu)); 23.3 (q, 2 Me of 10 Me(Aib)); 23.1 (q, 1 Me
of 10 Me(Aib)); 23.0, 22.93, 22.89, 21.1, 20.3, 20.2 (6q, 6 Me(Leu)); 18.8, 17.9 (2q, 2
Me(Val)). ESI-MS: 1693 (17, [M+K]+), 1677 (85, [M+Na]+). HPLC/MS: tR 18.1 min, m/z
1676 (2, [M+H]+), 846 (100), 819 (35).
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